Pathway,Count
BMI (Adjusted For Smoking Behaviour),54
Body Mass Index (Joint Analysis Main Effects And Smoking Interaction),53
Height,6159
Itch Intensity From Mosquito Bite Adjusted By Bite Size,127
Low Density Lipoprotein Cholesterol Levels,754
Mosquito Bite Size,97
Waist-to-hip Ratio Adjusted For BMI (Joint Analysis For Main Effect And Physical Activity Interaction),29
Barrett's Esophagus,13
Esophageal Adenocarcinoma,10
Barrett's Esophagus Or Esophageal Adenocarcinoma,15
LDL Cholesterol Change In Response To Fenofibrate In Statin-Treated Type 2 Diabetes,6
Total Cholesterol Change In Response To Fenofibrate In Statin-Treated Type 2 Diabetes,20
Triglyceride Change In Response To Fenofibrate In Statin-Treated Type 2 Diabetes,15
Waist Circumference Adjusted For Body Mass Index,966
Body Mass Index,1912
Appendicular Lean Mass,836
Lean Body Mass,54
Alopecia Areata,26
Peak Insulin Response,8
Acute Insulin Response,6
Post Bronchodilator FEV1/FVC Ratio In COPD,63
Endometriosis,80
Subcutaneous Adipose Tissue,24
Visceral Adipose Tissue Adjusted For BMI,37
Visceral Adipose Tissue/Subcutaneous Adipose Tissue Ratio,23
Ankylosing Spondylitis,35
Intelligence,326
Gestational Age At Birth (Maternal Effect),7
Body Fat Mass,43
Nasopharyngeal Carcinoma,9
BMI In Non-Smokers,37
Waist Circumference Adjusted For BMI In Smokers,10
QRS Duration,121
Acute Graft Versus Host Disease In Bone Marrow Transplantation (Recipient Effect),10
Diastolic Blood Pressure,803
Systolic Blood Pressure,1073
Alcoholic Chronic Pancreatitis,38
Triglycerides,361
Total Cholesterol Levels,843
Waist-to-hip Ratio Adjusted For BMI (Joint Analysis Main Effects And Smoking Interaction),15
Dehydroepiandrosterone Sulphate Levels,6
Glycated Hemoglobin Levels,308
Alanine Transaminase Levels,20
Primary Sclerosing Cholangitis,23
Glomerular Filtration Rate,56
Breast Cancer,469
Breast Cancer (Estrogen-Receptor Positive),5
Breast Cancer (Estrogen-Receptor Negative),36
Cirrhosis (Alcohol Related),11
Type 1 Diabetes,119
Pulse Pressure,735
High Density Lipoprotein Cholesterol Levels,764
Waist-to-hip Ratio Adjusted For BMI In Non-Smokers,16
Multiple Sclerosis,271
Waist Circumference Adjusted For BMI In Non-Smokers,46
Plasma Trimethylamine N-oxide Levels,8
Psoriasis,105
Seborrheic Dermatitis,6
Rheumatic Heart Disease,9
Anorexia Nervosa,30
Hip Circumference Adjusted For BMI,900
BMI In Smokers,12
Psychosis Proneness (Hypomanic Personality Scale),5
Psychosis Proneness (Hypomanic Personality Scale And Revised Physical Anhedonia Scale),6
TB-LM Or TBLH-BMD (Pleiotropy),7
"Bone Mineral Density (Paediatric, Total Body Less Head)",7
Heel Bone Mineral Density,1034
General Risk Tolerance (MTAG),161
Lifetime Smoking Index,80
Male-pattern Baldness,328
LDL Cholesterol Levels,314
Two-hour Glucose,17
Triglyceride Levels,774
Left Ventricular Ejection Fraction,7
Risk-taking Tendency (4-Domain Principal Component Model),67
Brain Region Volumes,213
HDL Cholesterol Levels X Long Total Sleep Time Interaction (2Df Test),37
Ebbinghaus Illusion (Underestimation),19
HDL Cholesterol Levels X Short Total Sleep Time Interaction (2Df Test),39
LDL Cholesterol Levels X Long Total Sleep Time Interaction (2Df Test),35
Type 2 Diabetes,913
Ebbinghaus Illusion (Overestimation),48
Blood Pressure,56
Glucose Homeostasis Traits,50
Hormone Measurements,6
Iron Status Biomarkers,18
Lipid Traits,23
Hematology Traits,20
Liver Disease Biomarker,8
Anthropometric Traits,17
Asthma,304
"Number Of Decayed, Missing And Filled Tooth Surfaces Or Use Of Dentures",32
Dentures,32
Plasma Anti-Thyroid Peroxidase Levels,9
Plasma Anti-Thyroglobulin And Anti-Thyroid Peroxidase Levels (Bivariate Analysis),9
Plasma Anti-Thyroglobulin Levels,14
Uterine Fibroids And Heavy Menstrual Bleeding,5
Uterine Fibroids,81
Blood Protein Levels,890
Pancreatic Ductal Adenocarcinoma,10
Systemic Seropositive Rheumatic Diseases (Systemic Sclerosis Or Systemic Lupus Erythematosus Or Rheumatoid Arthritis Or Idiopathic Inflammatory Myopathies),16
Blond Vs. Brown/Black Hair Color,108
Brown Vs. Black Hair Color,31
Bitter Taste Perception (6-N-Propylthiouracil) In Obesity With Metabolic Syndrome,9
Fat-free Mass,124
Bitter Taste Perception (Phenylthiocarbamide) In Obesity With Metabolic Syndrome,6
Bipolar Disorder,217
Alcohol Consumption (Drinks Per Week),98
Smoking Status (Ever Vs Never Smokers),128
Birth Weight,179
HDL Cholesterol Levels,519
TPE Interval (Resting),21
Adiponectin Levels,53
Bone Mineral Density,39
Bipolar Disorder Or Body Mass Index,8
G Alloprevotella Abundance,6
Low HDL-cholesterol Levels,7
Hypertriglyceridemia,9
LDL Cholesterol Levels X Short Total Sleep Time Interaction (2Df Test),40
OTU97 56 (Ruminococcaceae) Abundance,5
Number Of Sexual Partners,59
Machado-Joseph Disease (Age At Onset),5
Thoracic Aortic Calcification Levels,5
Abdominal Aortic Calcification Levels,7
Glaucoma (Primary Open-Angle),92
Ischemic Stroke,51
Intracerebral Hemorrhage,7
Physiological Traits,10
Hematological And Biochemical Traits,24
Lung Function,7
Cholesterol,11
Metabolic Syndrome,85
G Bacteroidetes Abundance,6
Anxiety,43
Smoking Initiation (Ever Regular Vs Never Regular),249
Smoking Behaviour (Cigarettes Smoked Per Day),41
Age Of Smoking Initiation,32
Carotid Intima Media Thickness (Mean),28
Carotid Intima Media Thickness (Maximum),26
Carotid Intima Media Thickness (Mean-Maximum),6
OTU99 132 (Bacteroidales) Abundance,6
Type 2 Diabetes (Adjusted For BMI),67
Relative Fat Intake,8
Relative Protein Intake,7
Relative Carbohydrate Intake,8
Parkinson's Disease,115
Heel Bone Mineral Density (MTAG),19
Total Body Bone Mineral Density (MTAG),19
Depression,190
Post-traumatic Stress Disorder,26
Suicidal Or Self-Harm Ideation,6
OTU97 21 (Parasutterella) Abundance,7
Triglyceride Levels X Alcohol Consumption (Regular Vs Non-Regular Drinkers) Interaction (2Df),48
Asthma (Childhood Onset),183
Asthma And Major Depressive Disorder,5
Mosaic Loss Of Chromosome Y (Y Chromosome Dosage),45
Gout Vs. Hyperuricemia,8
Glaucoma,59
Glaucoma (Multi-Trait Analysis),15
Response To Antidepressants (Symptom Improvement),14
Response To SSRI (Symptom Remission),7
Response To Antidepressants (Symptom Remission),7
Phenylephrine Infusion Rate During Anesthesia,8
Alanine Aminotransferase Levels In Low Alcohol Consumption,7
Aspartate Aminotransferase Levels In Low Alcohol Consumption,28
Gamma Glutamyl Transferase Levels In Low Alcohol Consumption,17
Aspartate Aminotransferase Levels In Excessive Alcohol Consumption,17
Bipolar I Disorder,68
Schizoaffective Disorder-Bipolar Type,7
Prostate Cancer,257
Childhood Obesity,30
HDL Cholesterol Levels X Alcohol Consumption (Regular Vs Non-Regular Drinkers) Interaction (2Df),63
Epilepsy,13
Generalized Epilepsy,15
vWF Levels,20
Factor VIII Levels,25
Hepatitis C (Spontaneous Viral Clearance),5
Loneliness,25
Childhood Steroid-Sensitive Nephrotic Syndrome,16
Ulcerative Colitis,149
Cerebral Microbleeds,6
Antipsychotic Drug-Induced Weight Gain In Schizophrenia,9
Gamma Glutamyl Transferase Levels In Excessive Alcohol Consumption,11
Alanine Aminotransferase Levels In Excessive Alcohol Consumption,16
Cytokine Levels,5
Cytokine Network Levels (Multivariate Analysis),8
Early Spontaneous Preterm Birth,11
Gestational Age At Birth (Child Effect),20
Automobile Speeding Propensity,24
Adventurousness,97
Cancer,83
Platelet Count,949
Hematocrit,559
Hemoglobin Levels,368
White Blood Cell Count,1056
Serum Platinum Levels After Completion Of Cisplatin Chemotherapy,21
Regular Attendance At A Pub Or Social Club,6
Regular Attendance At A Religious Group,8
Loneliness (MTAG),8
Peripheral Artery Disease,19
Uveal Melanoma,14
Disease Severity In Uveal Melanoma (TNM Stage 3 Or 4 Vs TNM Stage 1 Or 2),5
Acne (Severe),14
Red Vs. Brown/Black Hair Color,21
Rate Of Ventricular Enlargement,7
Body Fat Percentage,227
Intraocular Pressure,241
3-Month Functional Outcome In Ischaemic Stroke (Modified Rankin Score),30
vWF And FVIII Levels,9
Amyotrophic Lateral Sclerosis,53
High Chromosomal Aberration Frequency (Chromosome Type),5
Schizophrenia,996
Moderate-to-late Spontaneous Preterm Birth,17
Spontaneous Preterm Birth With Premature Rupture Of Membranes,12
Spontaneous Preterm Birth (Preterm Birth),15
T Wave Morphology Restitution During Exercise (MTAG),6
T Wave Morphology Restitution During Exercise,5
T Wave Morphology Restitution During Recovery From Exercise,5
T Wave Morphology Restitution During Recovery From Exercise (MTAG),5
Vertical Cup-Disc Ratio (Multi-Trait Analysis),58
Age-related Cognitive Decline (Memory) (Slope Of Z-Scores),10
Age-related Cognitive Decline (Attention/Processing Speed) (Slope Of Z-Scores),6
Age-related Cognitive Decline (Language) (Slope Of Z-Scores),13
Voxel-wise Structural Brain Imaging Measurements In Alzheimerâ€™s Disease,12
Rapid Automised Naming Of Letters,16
Eosinophilic Esophagitis,33
Bilirubin Levels,50
Spontaneous Preterm Birth Without Premature Rupture Of Membranes,17
Corneal Resistance Factor,51
Corneal Hysteresis,7
Vertical Cup-Disc Ratio (Adjusted For Vertical Disc Diameter),55
Epigenetic Age Acceleration In Alcohol Use Disorder,6
Response To Ketamine In Bipolar Disorder Or Major Depression (Dissociation Effects),5
Erectile Dysfunction,15
Adult Asthma,30
Angioedema In Response To Angiotensin-Converting Enzyme Inhibitor And/Or Angiotensin Receptor Blocker,10
Age-related Hearing Impairment,59
Triglyceride Levels X Long Total Sleep Time Interaction (2Df Test),32
Triglyceride Levels X Short Total Sleep Time Interaction (2Df Test),34
Urinary Metabolite Levels In Chronic Kidney Disease,84
Fish- And Plant-Related Diet,48
Processed Meat Consumption,15
Apolipoprotein B Levels,413
Leisure Sedentary Behaviour (Television Watching),100
Hallux Valgus,23
TestASV 26 (Phascolarctobacterium) Abundance,9
TestASV 28 (Holdemanella) Abundance,5
Femoral Neck Bone Mineral Density And Trunk Fat Mass Adjusted By Trunk Lean Mass,12
G Ruminococcus Prevalence,5
Birth Weight (MTAG),31
Birth Length (MTAG),22
Infant Head Circumference (MTAG),8
Refractive Error,337
Cerebrospinal Fluid sTREM-2 Levels,118
Lung Function (Low FEV1 Vs High FEV1),11
Lung Function In Never Smokers (Low FEV1 Vs High FEV1),16
Lung Function In Never Smokers (Low FEV1 Vs Average FEV1),5
Smoking Status (Heavy Vs Never),10
Lung Function (Low FEV1 Vs High FEV1) X Smoking Interaction,7
Venous Thromboembolism,122
Skin Pigmentation (Conditioned On Rs1426654 And Rs35397),6
Skin Pigmentation,36
OTU99 1 (Bacteroides) Prevalence,5
Parkinson's Disease Or First Degree Relation To Individual With Parkinson's Disease,74
Corneal Astigmatism,45
Refractive Astigmatism,33
OTU99 137 (Ruminococcus) Prevalence,5
Kidney Stones,19
Idiopathic Pulmonary Fibrosis,36
Hemoglobin A1c Levels,301
Red Blood Cell Count,1001
Mean Corpuscular Hemoglobin,930
Alanine Aminotransferase Levels,386
Serum Albumin Levels,279
Serum Alkaline Phosphatase Levels,548
Gamma Glutamyl Transferase Levels,284
Hip Circumference,130
Mean Corpuscular Volume,864
Mean Corpuscular Hemoglobin Concentration,291
Red Cell Distribution Width,794
Mean Platelet Volume,613
Monocyte Count,645
Neutrophil Count,681
OTU97 19 (Bacteria) Prevalence,5
Blood Metabolite Levels,13
OTU97 8 (Ruminococcaceae) Prevalence,5
Facial Morphology,17
Panic Disorder,10
Heart Failure,37
Childhood Maltreatment,10
Pork Consumption,35
Raw Vegetable Consumption,17
Cooked Vegetable Consumption,5
Fruit Consumption,33
OTU99 47 (Prevotella) Prevalence,5
OTU99 8 (Ruminococcaceae) Abundance,5
Proportion Of Activated Microglia (Inferior Temporal Cortex),14
Femoral Neck Bone Mineral Density,43
Trunk Fat Mass Adjusted For Trunk Lean Mass,6
Waist Circumference,158
Weight,587
Cortical Surface Area (Visual PC2),11
Cortical Surface Area (Global PC1),8
Circulating Leptin Levels In High Cardiovascular Risk,14
Hospital Contact For Infections,10
Triglyceride Levels X Loop Diuretics Use Interaction,10
HDL Cholesterol Levels X Thiazide Or Thiazide-Like Diuretics Use Interaction,5
Circulating Leptin Levels X Sex Interaction In High Cardiovascular Risk,5
Protein Levels In Obesity,36
Apolipoprotein A1 Levels,432
Serum Metabolite Levels (CMS),58
Insomnia,816
Response To Levetiracetam In Genetic Generalized Epilepsy,5
Response To Lamotrigine And Valproic Acid In Genetic Generalized Epilepsy,6
Adipose Morphology,19
Opioid Use Disorder,5
Cutaneous Malignant Melanoma,58
Cerebral Amyloid Angiopathy,6
Microscopic Brain Infarct,6
Dementia With Lewy Bodies,13
Neurofibrillary Tangles,35
Neuritic Plaque,23
Youthful Appearance (Self-Reported),54
Smoking Initiation,1205
Spherical Equivalent,142
Estimated Glomerular Filtration Rate,518
Serum Creatinine Levels,342
QT Interval,247
Behcet's Disease,17
Smoking Cessation,126
Smoking Status (Current Vs Never),12
JT Interval,134
Circulating Leptin Levels Or Type 2 Diabetes,7
Brainstem Volume,15
Amygdala Volume,7
Caudate Nucleus Volume,19
Pallidum Volume,9
Putamen Volume,15
Thalamus Volume,8
Cataracts (Operation),11
Vascular Endothelial Growth Factor Levels,32
Nicotine Dependence,30
Severe Aplastic Anemia,7
Cutaneous Melanoma Or Hair Colour,38
Neuropathologic Traits (Pleiotropy),10
Glucagon Levels In Response To Oral Glucose Tolerance Test (Fasting),15
Glucagon Levels In Response To Oral Glucose Tolerance Test (30 Minutes),5
Glucagon Levels In Response To Oral Glucose Tolerance Test (120 Minutes),13
B-cell Acute Lymphoblastic Leukaemia,8
Retinal Detachment Or Retinal Break,22
High Myopia,90
Cortical Thickness,401
Primary Biliary Cirrhosis,18
Narcolepsy With Cataplexy,5
Nevus Count Or Cutaneous Melanoma,63
White Matter Hyperintensities,20
White Matter Integrity (Fractional Anisotropy),9
COVID-19 (Critical Illness Vs Population),21
Sleep (1/2-Day Periodicity),7
Sleep (1/3-Day Periodicity),12
Mastocytosis (KIT D816V Positive),5
Fasting Glucose,131
Fasting Insulin,45
Prostate Cancer (Early Onset),13
Body Fat Distribution (Arm Fat Ratio),48
Serum Metabolite Levels,294
Plasma Free Amino Acid Levels,19
Body Fat Distribution (Leg Fat Ratio),68
Body Fat Distribution (Trunk Fat Ratio),78
Triglycerides X Physical Activity Interaction (2Df Test),17
Blood Protein Levels In Cardiovascular Risk,54
Sleep Duration (> 10 Hours),5
Response To Serotonin-Norepinephrine Reuptake Inhibitors (Responders Vs Non-Responders),16
Response To Antidepressants (Non-Treatment-Resistant Vs Treatment-Resistant Depression),14
Response To SSRI (Responders Vs Non-Responders),11
Response To Norepinephrine-Dopamine Reuptake Inhibitors (Responders Vs Non-Responders),11
White Matter Hyperintensity Volume,47
Eye Color,30
Hair Color,277
Eye Color (Saturation),7
Eye Color (Brightness),7
"Skin, Hair And Eye Pigmentation (Multivariate Analysis)",8
Plasma Free Amino Acid Levels (Adjusted For Twenty Other PFAAs),18
Plasma Free Amino Acid Levels (Adjusted For One Other PFAA),6
Childhood Body Mass Index,38
Prostate Cancer (Advanced),10
Chronic Rhinosinusitis,6
Non-del(5q) Myelodysplastic Syndromes,6
Nicotine Metabolite Ratio In Current Smokers,6
Smoking Behaviour (Cigarette Pack-Years),11
LDL Cholesterol X Physical Activity Interaction (2Df Test),28
HDL Cholesterol X Physical Activity Interaction (2Df Test),31
Intrinsic Epigenetic Age Acceleration,31
Central Retinal Vein Equivalent,7
Colorectal Cancer,267
Fractures,13
Urinary Metabolite Modules (Eigenmetabolites) In Chronic Kidney Disease,23
Coronary Artery Disease In Type 1 Diabetes,15
Gastrointestinal Infection,10
TestASV 38 (Ruminococcus) Abundance,5
Parkinson's Disease (Age Of Onset),9
Meat-related Diet,25
OTU99 8 (Ruminococcaceae) Prevalence,5
Snoring,37
Chronic Obstructive Pulmonary Disease,138
TestASV 43 (Parasutterella) Abundance,5
Interleukin-6 Receptor Subunit Alpha Levels,7
MHC Class I Polypeptide-Related Sequence A Levels,27
Vascular Endothelial Growth Factor D Levels,7
E-selectin Levels,11
Melanoma-Derived Growth Regulatory Protein Levels,7
OTU99 19 (Bacteria) Prevalence,5
Oily Fish Consumption,42
Non-oily Fish Consumption,5
Lamb Consumption,8
Serum Immune Biomarker Levels,24
Cerebrospinal Fluid Immune Biomarker Levels,10
Leisure Sedentary Behaviour (Computer Use),23
Idiopathic Downbeat Nystagmus,11
Renal Underexcretion Gout,14
Renal Overload Gout,9
Gout (Combined Type),6
Gout (Normal Type),5
Gout,74
OTU97 117 (Ruminococcus) Prevalence,5
C-reactive Protein Levels,464
Cirrhosis,8
Bone Mineral Content,14
Fasting Plasma Glucose,76
Multiple Myeloma,37
Longitudinal Brain Connectivity Change (Louvain Modularity),6
Longitudinal Brain Connectivity Change (Transitivity),6
Longitudinal Brain Connectivity Change (Global Efficiency),6
Cognitive Decline (Age-Related),12
Maternal Nondisjunction Of Chromosome 21 (MII Error Vs Fathers),11
Maternal Nondisjunction Of Chromosome 21 (MI Error Vs MII Error),5
Hip Bone Size,28
Bone Mineral Density (Hip) And Hip Bone Size,25
Urate Levels,421
Bone Mineral Density (Hip),43
Blood Glucose Levels,72
Serum Docosahexaenoic Fatty Acid Concentration In Metabolic Syndrome,8
Serum Omega-3 Polyunsaturated Fatty Acid Concentration In Metabolic Syndrome,9
Serum Omega-6 To Omega-3 Polyunsaturated Fatty Acid Ratio In Metabolic Syndrome,7
Serum Polyunsaturated Fatty Acid Concentration X Sex Interaction In Metabolic Syndrome,5
Myocardial Infarction,180
Alcohol Consumption (Heavy Vs. Light/Non-Drinkers),11
Uterine Fibroids (MTAG),21
Coffee Consumption,80
Alcohol Consumption (Drinkers Vs Non-Drinkers),8
Endometriosis (MTAG),50
Ovarian Cancer,43
Axial Length,12
Cervical Cancer,76
Gynecologic Disease,5
Cervical Cancer (MTAG),37
Ovarian Cancer (MTAG),12
Endometrial Cancer,40
Endometrial Cancer (MTAG),5
Hepatocellular Carcinoma In Hepatitis B Infection,6
Basophil Percentage Of White Cells,113
Basophil Count,229
Cleft Lip With Or Without Cleft Palate X Maternal Periconceptional Smoking Interaction (Parent Of Origin Effect),5
Cleft Lip With Or Without Cleft Palate X Maternal Periconceptional Vitamin Use Interaction (Parent Of Origin Effect),6
Postprandial Phospholipid Levels In IDL,5
Postprandial Triglycerides Levels In IDL,6
Postprandial Linoleic Acid (18:2),6
Adolescent Idiopathic Scoliosis,685
Eosinophil Counts,780
White Matter Microstructure (Mean Diusivities),62
Household Income (MTAG),153
Optic Disc Size,74
Leukocyte Telomere Length,43
Waist-to-hip Ratio Adjusted For BMI,900
Hay Fever And/Or Eczema,97
Coronary Artery Disease,508
Nicotine Dependence Symptom Count,87
Alzheimer's Disease Or HDL Levels (Pleiotropy),13
"Allergic Disease (Asthma, Hay Fever Or Eczema)",118
Household Income,32
Stimulated Adipocyte Lipolysis,23
Cortical Surface Area,506
Fasting Phospholipid Levels In Very Small VLDL,5
Fasting Triglycerides Levels In Very Small VLDL,7
Fasting Free Cholesterol In Very Small VLDL,5
Fasting Total Lipids In Very Small VLDL,5
Self-reported Risk-Taking Behaviour,16
Serum Folate Levels,12
Osteoarthritis Of The Hand,5
Opioid Dependence,5
Insulin-related Traits (Multivariate Analysis),16
Reaction Time,265
Benign Childhood Epilepsy With Centro-Temporal Spikes,8
Alzheimer's Disease (Onset Between Ages 58 And 79),10
Exacerbations Requiring Hospitalisation In Asthma,20
Urinary Calcium Excretion,7
Average Oral Glucocorticoid Dose In Mepolizumab-Treated Eosinophilic Granulomatosis With Polyangiitis,8
Accrued Duration Of Remission In Mepolizumab-Treated Eosinophilic Granulomatosis With Polyangiitis,6
Atopic Asthma,106
Squamous Cell Lung Carcinoma,71
Non-small Cell Lung Cancer,36
Alcohol-associated Liver Disease In Non Drinkers,22
Allergic Rhinitis,61
Allergic Sensitization,17
Central Corneal Thickness,66
Worry,73
Neuroticism,332
Current Cigarettes Per Day In Chronic Obstructive Pulmonary Disease,6
Spherical Equivalent Or Myopia (Age Of Diagnosis),93
Vertical Cup-Disc Ratio,193
Intraocular Pressure And Central Corneal Thickness (Multi-Trait Analysis),5
Uric Acid Levels,41
Blood Urea Nitrogen Levels,236
"Obstructive Sleep Apnea Trait (Apnea Hypopnea Index, Change Over Time)",13
Fasting Very Large HDL Particle Concentration,5
Fasting Phospholipid Levels In Very Large HDL,5
Fasting Triglycerides Levels In Very Large HDL,6
Fasting Mean Diameter Of VLDLD Particles,5
Fasting Cholesterol Esters In Very Large HDL,5
Fasting Free Cholesterol In Very Large HDL,5
Fasting Total Lipids In Very Large HDL,5
Fasting Total Phosphoglycerides,5
Mucinous Adenocarcinoma In Colorectal Cancer,9
Postprandial Triglycerides In LDL,5
Rheumatoid Arthritis,220
Serum Carcinoembryonic Antigen Levels,6
Serum Cancer Antigen 15.3 Levels,5
Postprandial Triglycerides Levels In Small LDL,6
Schizophrenia (MTAG),112
Osteoporosis-related Phenotypes (MTAG),5
Eczema,152
Postprandial Mean Diameter Of HDL Particles,5
Postprandial Triglycerides In HDL,5
Postprandial Phospholipid Levels In Medium VLDL,5
Conjunctival UV Autofluorescence (CUVAF),5
Aortic Valve Stenosis,7
Spontaneous Adipocyte Lipolysis,11
Nonatopic Asthma,52
Serum 25-Hydroxyvitamin D Levels,154
Neonatal Total 25-Hydroxyvitamin D Levels (Maternal Genetic Effect),5
Polymyositis,8
Coronary Heart Disease,67
Hirschsprung Disease,7
Glioblastoma,15
Non-glioblastoma Glioma,21
Rosacea Symptom Severity,62
Optic Disc Area,21
Optic Cup Area,24
Low Tan Response,52
Survival In Colon Cancer,6
Bipolar Disorder Or Major Depressive Disorder,68
Fasting Triglycerides Levels In IDL,5
Fasting Linoleic Acid (18:2),7
Fasting Free Cholesterol In IDL,5
Gynecologic Disease (Multivariate Analysis),6
Cutaneous Squamous Cell Carcinoma,18
Hypertension,167
Spontaneous Coronary Artery Dissection,9
Response To Statins (LDL Cholesterol Change),12
Depressed Affect,67
Heart Rate,22
Non-melanoma Skin Cancer,132
Bone Mineral Density (Total Hip),10
End-stage Renal Disease,6
Fasting Free Cholesterol In Medium VLDL,5
"Fasting Monounsaturated Fatty Acids (16:1, 18:1)",5
Nonalcoholic Fatty Liver Disease,21
Red Blood Cell Traits (Multivariate Analysis),13
Hemoglobin Concentration,536
Cephalic Index,5
Maximum Cranial Width,17
Maximum Cranial Length,12
Myopia (Age Of Diagnosis),76
Breast Size,30
Postprandial Very Large HDL Particle Concentration,5
Postprandial Triglycerides Levels In Very Large HDL,5
Postprandial Mean Diameter Of VLDLD Particles,5
Fasting Total Cholesterol In HDL2,5
Fasting Total Cholesterol In HDL3,5
Fasting Total Cholesterol In HDL,5
Fasting Mean Diameter Of HDL Particles,6
Fasting Apolipoprotein A-I,5
Postprandial Free Cholesterol In Very Large HDL,5
Postprandial Total Lipids In Very Large HDL,5
Fasting Omega-3 Fatty Acids,6
Chronic Kidney Disease,80
Cerebrospinal Fluid Beta-Site APP Cleaving Enzyme Levels,6
Glioma,25
Frontotemporal Dementia With GRN Mutation,7
Memory Dysfunction In Frontotemporal Lobe Dementia,6
Frontotemporal Dementia,13
Optic Nerve Head Parameters (Multi-Trait Analysis),6
Freckles,7
Excessive Hairiness,6
Resistin Levels,13
Fasting Triglycerides Levels In Large LDL,5
Fasting Large HDL Particle Concentration,6
Fasting Phospholipid Levels In Large HDL,6
Fasting Triglycerides In LDL,5
Fasting Total Cholesterol In Large HDL,6
Fasting Cholesterol Esters In Large HDL,6
Fasting Free Cholesterol In Large HDL,5
Fasting Total Lipids In Large HDL,6
Dietary Macronutrient Intake,6
Circulating Odd-Numbered Chain Saturated Fatty Acid Levels (C17:0),6
Circulating Odd-Numbered Chain Saturated Fatty Acid Levels (C15:0),5
Postprandial Total Lipids In Very Small VLDL,6
Postprandial Very Small VLDL Particle Concentration,5
Electroencephalogram Traits,20
Lung Adenocarcinoma,64
Alcohol-associated Liver Disease In Light Drinkers,18
Alcohol-associated Liver Disease In Heavy Drinkers,7
Coronary Artery Disease In Diabetes,16
Age At Loss Of Ambulation In Duchenne Muscular Dystrophy,24
Menstruation Quality Of Life Impact (Acne),8
Menstruation Quality Of Life Impact (Dysmenorrhea),5
Pain Medicine Use During Menstruation,5
Cannabis Use (Age At Onset),6
Fasting Triglycerides Levels In Small LDL,7
FEV1,141
Lung Function (FEV1/FVC),589
Attention Deficit Hyperactivity Disorder,86
Attention Deficit Hyperactivity Disorder (Persistent),6
Peak Expiratory Flow,157
Endometriosis Or Migraine,30
Carotid Intima Media Thickness X Smoking Interaction,16
Total Triglycerides Levels,71
White Matter Microstructure (Radial Diusivities),79
Eosinophil Percentage Of White Cells,390
Caffeine Consumption From Coffee Or Tea,23
Caffeine Consumption From Tea,18
Caffeine Consumption From Coffee,15
Left Ventricular End-Diastolic Volume,6
Left Ventricular End-Systolic Volume,11
Morningness,164
Polycystic Ovary Syndrome,23
Sleep Duration,93
General Cognitive Ability,620
Major Depressive Disorder In Trauma Exposed Individuals,9
Major Depressive Disorder In Trauma-Unexposed Individuals,19
Major Depressive Disorder,226
Trauma Exposure,40
Ease Of Getting Up In The Morning,42
Daytime Nap,74
Calcific Aortic Valve Stenosis,17
Attention Deficit Hyperactivity Disorder (Childhood),9
Weight Gain In Amisulpride-Treated First-Episode Psychosis,13
Creatine Kinase Levels,31
Cleft Lip With Or Without Cleft Palate,14
Systolic Blood Pressure X Educational Attainment (Some College) Interaction (2Df),7
Anthracycline-induced Cardiotoxicity In Early Breast Cancer,6
Trauma Exposure In Major Depressive Disorder-Negative Individuals,21
Lung Function (FVC),466
Hippocampal Volume,40
White Matter Microstructure (Axial Diusivities),50
Migraine And/Or Pulse Pressure,16
Migraine Without Aura And/Or Pulse Pressure,5
Insomnia Symptoms (Never/Rarely Vs. Sometimes/Usually),31
Insomnia Symptoms (Never/Rarely Vs. Usually),35
Intracranial Aneurysm,66
Thyroxine Levels,15
Triiodothyronine Levels,6
Lactate Dehydrogenase Levels,14
Emotional Recognition,12
Postoperative Atrial Fibrillation After Cardiac Surgery,5
Trauma Exposure In Major Depressive Disorder,15
Adult Diffuse Glioma (IDH Mutation),5
Crohn's Disease,192
Nasal Polyps,22
Obese Vs. Thin,6
Obesity (Extreme),22
Ocular Sarcoidosis,40
Follicle Stimulating Hormone Levels,9
Tourette Syndrome,20
Migraine And/Or Diastolic Blood Pressure,18
Migraine And/Or Systolic Blood Pressure,15
Arsenic Metabolism,5
IgG N-glycosylation Phenotypes (Multivariate Analysis),9
Alzheimer's Disease (Late Onset),65
Acute Anterior Uveitis In Ankylosing Spondylitis,6
Thyroid Volume In Hashimotoâ€™s Thyroiditis,5
Serum Urea Levels,6
Autism And Major Depressive Disorder (MTAG),6
Pelvic Organ Prolapse,36
Modic Changes,5
Autism Spectrum Disorder,69
Crohn's Disease (Time To Progression),6
Crohn's Disease (Indolent Vs Progressive),5
Bladder Cancer,20
Autoimmune Thyroid Disease,71
Brain Amyloid Deposition (PET Imaging),12
White Matter Microstructure (Mode Of Anisotropy),37
Rate Of Cognitive Decline In Alzheimer's Disease,77
White Matter Microstructure (Fractional Anisotropy),85
Sweet Taste Preference,7
Essential Hypertension (Time To Event),18
"Gut Microbiota (Bacterial Taxa, Hurdle Binary Method)",168
Evening Vs. Morning Chronotype (sMEQ Score),6
Attention Deficit Hyperactivity Disorder (Inattention Symptoms),16
Attention Deficit Hyperactivity Disorder (Hyperactivity-Impulsivity Symptoms),11
Interleukin-18 Receptor 1 Levels,6
Tumor Necrosis Factor Beta Levels,10
"Gut Microbiota (Bacterial Taxa, Rank Normal Transformation Method)",71
Deliberate Self-Harm,25
Chronic Hepatitis B Infection,10
Suicide Attempts,18
Interleukin-6 Levels,26
Protein Quantitative Trait Loci,88
Parkinson's Disease Progression (Motor),6
Parkinson's Disease Progression (Cognitive),15
Homeostasis Model Assessment Of Insulin Resistance,9
HDL Cholesterol Levels In HIV Infection,21
LDL Cholesterol Levels In HIV Infection,11
Preeclampsia (Maternal Genotype Effect),10
Lymphocyte Count,736
Platelet Reactivity In Response To Clopidogrel Treatment,11
L-selectin Levels,21
Nontraumatic Osteonecrosis Of The Femoral Head,14
Mammographic Density (Non-Dense Area),14
Mammographic Density (Dense Area),20
Percent Mammographic Density,17
Lung Adenocarcinoma (Survival Time) In Never Smokers,5
Stroke,49
Macrovascular Complications In Type 2 Diabetes,7
Peak Hip Bone Mineral Content,5
Thrombosis In Response To Liver Transplant,6
Tau Burden,8
Triglyceride Levels In HIV Infection,9
Help-seeking From A GP,12
Response To Selenium Supplementation (Change In Plasma Selenium Concentration),10
Glycine Levels,62
Lysine Levels,12
Epithelial Ovarian Cancer,105
White Matter Hyperintensity Volume X Hypertension Interaction (2Df),27
Parental Lifespan,10
White Matter Hyperintensity Volume (Adjusted For Hypertension),38
Percent Liver Fat,13
Liver Fibrosis And Steatohepatitis Severity (MRI cT1 Measure),8
PR Interval,180
Diffuse Plaques (SNP X SNP Interaction),9
Distal/Left-sided Colorectal Cancer,5
Distal Colorectal Cancer,6
Rectal Cancer,19
Colon Cancer,13
Alcohol Use Disorder,19
Hepatocyte Growth Factor Levels,22
Problematic Alcohol Use (MTAG),69
Alcohol Consumption (Drinks Per Week) (MTAG),121
Problematic Alcohol Use,17
Systemic Mastocytosis,13
Cutaneous Mastocytosis,13
Cutaneous Mastocytosis (Adult),8
Mastocytosis,23
Cortical Volume,27
High Light Scatter Reticulocyte Count,439
Total PHF-tau (SNP X SNP Interaction),56
Mitochondrial DNA Copy Number,84
Gut Microbiota Relative Abundance (Sutterella),7
Gut Microbiota Relative Abundance (Prevotella),9
Gut Microbiota Relative Abundance (Faecalibacterium),11
Gut Microbiota Relative Abundance (Unclassified Genus Belonging To Family Erysipelotrichaceae),6
Gut Microbiota Relative Abundance (Ruminococcus Belonging To Family Lachnospiraceae),10
High Light Scatter Reticulocyte Percentage Of Red Cells,429
Corneal Curvature,33
Aspartate Aminotransferase Levels,447
Male Puberty Timing (Late Vs. Average Onset Facial Hair),29
Male Puberty Timing (Early Vs. Average Onset Voice Breaking),15
Male Puberty Timing (Early Vs. Average Onset Facial Hair),23
Male Puberty Timing (Late Vs. Average Onset Voice Breaking),13
Reading Ability (Multivariate),15
Gut Microbiota Relative Abundance (Unclassified Genus Belonging To Family Ruminococcaceae),8
Gut Microbiota Relative Abundance (Dorea),5
Factor VII Activity,16
Rapid Automised Naming Of Pictures,7
Short-term Memory (Digit-Span Task),8
Rapid Automised Naming Of Digits,8
Non-word Reading,14
Word Spelling,10
Word Reading,16
Phoneme Awareness,22
Multisite Chronic Pain,51
Glomerular Filtration Rate In Type 2 Diabetes,5
Glomerular Filtration Rate In Diabetes,6
Diabetic Kidney Disease In Type 2 Diabetes (ESRD Vs. No ESRD),5
Body Size At Age 10,191
Atrial Fibrillation,186
Corneal Endothelial Cell Size Variation Coefficient,20
Corneal Endothelial Cell Shape (Percentage Of Hexagonally Shaped Cells),7
Bitter Alcoholic Beverage Consumption,68
Bitter Non-Alcoholic Beverage Consumption,16
Immature Fraction Of Reticulocytes,281
Protein Quantitative Trait Loci (Liver),1008
"Cognitive Ability, Years Of Educational Attainment Or Schizophrenia (Pleiotropy)",159
Glucosuria (Moderate To Severe),6
Proteinuria,5
Glucosuria,7
Emphysema Annual Change Measurement In Smokers (Adjusted Lung Density),24
Emphysema Annual Change Measurement In Smokers (Percent Low Attenuation Area),20
Alzheimer's Disease Or Family History Of Alzheimer's Disease,79
Alzheimer's Disease,156
Central Cerebrospinal Fluid Amyloid Beta 42 To 40 Ratio (Abnormal Vs Normal),5
Central Cerebrospinal Fluid Amyloid Beta 42 To 40 Ratio,9
Tea Consumption,52
Facial Morphology (Columella Inclination),6
Sweet Beverage Consumption,6
Bitter Beverage Consumption,16
Adult Body Size,368
Response To Treatment In Irritable Bowel Syndrome (Pain Frequency),10
Response To Treatment In Irritable Bowel Syndrome (Pain Severity),6
Response To Treatment In Irritable Bowel Syndrome (Symptom Severity),7
Fasting Blood Proinsulin Levels,5
Tuberculosis,63
Asthma (Moderate Or Severe),25
Circulating Fibroblast Growth Factor 23 Levels,14
Cerebellum Cortex Volume Change Rate,6
Cerebellum White Matter Volume Change Rate,6
Caudate Volume Change Rate,8
Cortex Volume Change Rate,5
Testicular Cancer,7
Oral Cavity And Pharyngeal Cancer,11
Myeloproliferative Neoplasms,12
Lateral Ventricle Volume Change Rate,5
Pallidum Volume Change Rate,5
Esophageal Or Stomach Cancer,6
Coffee Consumption (Cups Per Day),28
Cortex Volume Change Rate X Age Interaction (1Df),6
Caudate Volume Change Rate X Age Interaction (1Df),6
Cerebellum Cortex Volume Change Rate X Age Interaction (1Df),7
Thalamus Volume Change Rate,8
Total Brain Volume Change Rate,7
Brain Surface Area Change Rate,6
Fasting Blood Glucose,40
Fasting Blood Insulin,7
Melanoma,83
Pallidum Volume Change Rate X Age Interaction (1Df),6
Putamen Volume Change Rate X Age Interaction (1Df),5
Hippocampus Volume Change Rate X Age Interaction (1Df),5
Thyroid Cancer,15
Lymphocytic Leukemia,19
Lung Cancer,133
Walking Pace,54
Celiac Disease,69
Obsessive-compulsive Traits,11
Mortality In COVID-19,35
Gut Microbiota Relative Abundance (Bacteroides),5
Gut Microbiota Relative Abundance (Ruminococcus Belonging To Family Erysipelotrichaceae),9
Gut Microbiota Relative Abundance (Unclassified Genus Belonging To Family Lachnospiraceae),5
Gut Microbiota Relative Abundance (Blautia),5
Gut Microbiota Relative Abundance (Unclassified Genus Belonging To The Order Clostridiales),9
Differentiated Thyroid Cancer,17
Male Puberty Timing (Age At Voice Breaking MTAG),51
Thyroid Stimulating Hormone Levels,68
Acceptance Of An Invitation To Participate In A Mental Health Questionnaire,32
Participation In An Health Questionnaire (Not Invited Vs Invited),20
Brain Morphology (MOSTest),463
Lean Nonalcoholic Fatty Liver Disease,5
Nonsyndromic Cleft Palate,17
Ceramide Levels (C24:0),7
Subcortical Volume (MOSTest),131
Self-rated Health,15
Iron Status Biomarkers (Ferritin Levels),33
Iron Status Biomarkers (Total Iron Binding Capacity),29
Cortical Surface Area (MOSTest),95
Iron Status Biomarkers (Iron Levels),23
Iron Status Biomarkers (Transferrin Saturation),24
Body Mass Index And Diastolic Blood Pressure (Bivariate Analysis),8
Systolic Blood Pressure And Diastolic Blood Pressure (Bivariate Analysis),9
Cortical Surface Area (min-P),36
Cortical Thickness (min-P),14
Gut Microbiota Alpha Diversity (Chao1 Index),10
Gut Microbiota Alpha Diversity (PD Whole Tree Index),14
Gut Microbiota Alpha Diversity (Shannon Index),18
Alcohol Consumption,78
Post-traumatic Stress Disorder (Re-Experiencing Symptoms),16
Breast Cancer (Male),6
Adverse Response To Chemotherapy (Amenorrhea) In Breast Cancer,5
Toxicity Response To Radiotherapy In Prostate Cancer (Rectal Bleeding) (Time To Event),6
Toxicity Response To Radiotherapy In Prostate Cancer (Hematuria) (Time To Event),7
Toxicity Response To Radiotherapy In Prostate Cancer (Decreased Urine Stream) (Time To Event),12
Response To Radiotherapy In Prostate Cancer (Overall Toxicity),7
Systemic Lupus Erythematosus,314
Percentage Of Invited Food Questionnaires Completed,9
Inflammatory Biomarkers (Multivariate Analysis),10
Cognitive Impairment,5
Serum Total Cholesterol Levels,6
Blood Cell Traits (Multivariate Analysis),8
Esophageal Cancer,10
Gastric Cancer,36
Hepatocellular Carcinoma,5
Pancreatic Cancer,75
Arrhythmia,18
Cataracts,38
Cortical Thickness (MOSTest),53
Urolithiasis,32
Cerebral Aneurysm,6
Osteoporosis,22
Interstitial Lung Disease,19
Depressive Symptoms X Dependent Stressful Life Events Interaction (1Df Test),7
Depressive Symptoms X Dependent Stressful Life Events Interaction (2Df Test),7
Interstitial Lung Diseases In Rheumatoid Arthritis,11
Brain Morphology (min-P),80
Subcortical Volume (min-P),67
Age-related Macular Degeneration,35
Graves' Disease,39
Atopic Dermatitis,75
Oral Cavity Cancer,8
Oropharynx Cancer,11
Anorectal Malformation,17
Body Mass Index And Systolic Blood Pressure (Bivariate Analysis),7
Autism Spectrum Disorder (MTAG),8
Depressive Symptoms (MTAG),73
"Aging Traits (Healthspan, Parental Lifespan Or Longevity) (Multivariate Analysis)",20
Bipolar Disorder (MTAG),51
Tumor Necrosis Factor Levels,8
Hemoglobin,493
Serum Uric Acid Levels,290
Myeloid Clonal Hematopoiesis,6
Periventricular White Matter Hyperintensities,51
Electrocardiographic Traits (Multivariate),50
"Allergic Disease (Asthma, Hay Fever And/Or Eczema) (Age Of Onset)",33
"Allergic Disease (Asthma, Hay Fever And/Or Eczema) (Multivariate Analysis)",36
Response To Esketamine In Treatment Resistant Depression,25
Response To Esketamine (Responder Status) In Treatment Resistant Depression,7
Chronic Hepatitis C Infection,6
Simvastatin-induced Myopathy,14
Atorvastatin-induced Myopathy,5
Statin-induced Myopathy (Severe),5
Suicide,16
Trigger Finger,6
Levodopa-induced Dyskinesia In Levodopa Treated Parkinson's Disease,6
Cognitive Function (Kinship Model),8
Cognitive Function (Mixed Linear Model),8
Cognitive Function (Generalized Correlation Coefficient),35
Cutaneous Mastocytosis (Childhood),13
Facial Morphology Traits (59 NSCL/P Endophenotypic Segments),22
Shoulder Impingement Syndrome,7
Childhood ALL/LBL (Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma) Treatment-Related Venous Thromboembolism,15
N-desmethylclozapine Concentration In Schizophrenia,6
Attention Deficit Hyperactivity Disorder (MTAG),16
Nonalcoholic Steatohepatitis,8
Pancreatic Beta-Cell Glucose Sensitivity,7
Early-onset Ischemic Stroke,21
Neonatal White Matter Microstructure,11
Invasive Breast Cancer,12
"Breast Cancer (Estrogen-Receptor Negative, Progesterone-Receptor Negative, And Human Epidermal Growth Factor-Receptor Negative)",7
Cerebrospinal Fluid t-tau:AB1-42 Ratio,21
Sensory Peripheral Neuropathy In Microtubule Targeting Agent-Treated Breast Cancer,6
Brugada Syndrome,11
Combined Resilience (Covariance Of Educational Attainment With Residual Cognitive Resilience),7
Residual Cognitive Resilience,11
Sarcoidosis,14
Myocardial Fractal Dimension (Slice 8),5
Depressive Symptoms,171
Glucocorticoid Receptor Gene Expression In B-cell Precursor Acute Lymphoblastic Leukaemia,7
Leprosy,46
Chemerin Levels,6
Deep White Matter Hyperintensities,24
Neuroblastoma (Pediatric),13
Postprandial Triglyceride Levels,6
Postprandial Triglyceride Response,6
Myocardial Fractal Dimension (Slice 5),6
Myocardial Fractal Dimension (Slice 2),5
Myocardial Fractal Dimension (Slice 3),7
Myocardial Fractal Dimension (Slice 6),9
Myocardial Fractal Dimension (Slice 4),7
Myocardial Fractal Dimension (Slice 7),7
Circulating Leptin Levels Adjusted For BMI,6
Circulating Leptin Levels,5
Autoimmune Traits,64
Leukoderma In Response To Rhododendrol,7
Cerebellum Cortex Volume Change Rate X Age Interaction (2Df),7
Cerebellum White Matter Volume Change Rate X Age Interaction (2Df),8
Hippocampus Volume Change Rate X Age Interaction (2Df),5
Cancer (Pleiotropy),93
Bioavailable Testosterone Levels,309
Kawasaki Disease,40
Non-HDL Cholesterol Levels,396
Cancer (Pleiotropy)(Bidirectional),14
Brain Surface Area Change Rate X Age Interaction (1Df),10
Kidney Cancer,6
Non-Hodgkin's Lymphoma,5
Keratoconus,23
Brain Surface Area Change Rate X Age Interaction (2Df),10
Thalamus Volume Change Rate X Age Interaction (2Df),6
Lateral Ventricle Volume Change Rate X Age Interaction (2Df),5
Pallidum Volume Change Rate X Age Interaction (2Df),5
Putamen Volume Change Rate X Age Interaction (2Df),6
Non-tuberculous Mycobacterial Pulmonary Disease,5
Barrett's Esophagus Or Esophageal Adenocarcinoma X Sex Interaction (2Df Test),6
Systemic Sclerosis,44
Neurological Blood Protein Biomarker Levels,33
Sedentary Behaviour Duration,6
Physical Activity (Overall Physical Activity Time),5
Varicose Veins,72
Non-alcoholic Fatty Liver Disease Activity Score In Non-Alcoholic Fatty Liver Disease,15
Aspartate Aminotransferase Levels In Non-Alcoholic Fatty Liver Disease,8
Alanine Aminotransferase Levels In Non-Alcoholic Fatty Liver Disease,9
Corneal Endothelial Cell Density,22
Resistant Hypertension,20
Type 2 Diabetes Nephropathy,8
Type 2 Diabetes Nephropathy Including Microalbuminuria,6
Psychological Distress,7
Osteoarthritis (Hip),40
Knee Osteoarthritis,24
Osteoarthritis Of The Hip Or Knee,25
Osteoarthritis,40
Estradiol Levels,19
Sex Hormone-Binding Globulin Levels Adjusted For BMI,552
Interferon-Related Traits,151
Lipoprotein (A) Levels,63
Childhood Asthma With Severe Exacerbations,11
Spondylosis,15
High-sensitivity Cardiac Troponin T Levels,55
Takayasu Arteritis,61
Major Depressive Disorder (MTAG),45
Neuropsychiatric Disorders,21
Waist-hip Ratio,628
IgG Glycosylation Patterns,9
Primary Biliary Cholangitis,72
Serum Metabolite Concentrations In Chronic Kidney Disease,45
Bitter Taste Perception,6
Moderate To Vigorous Physical Activity Levels,11
Vigorous Physical Activity,7
Strenuous Sports Or Other Exercises,6
DHEAS Levels,29
Progesterone Levels,9
17-Hydroxyprogesterone (17-OHP) Levels,9
Keratinocyte Cancer (MTAG),54
Testosterone Levels,179
Basal Cell Carcinoma,76
Educational Attainment (Years Of Education),801
Serum Bilirubin Levels X Sex Interaction In Metabolic Syndrome,9
Serum Bilirubin Levels In Metabolic Syndrome,17
Serum Bilirubin Levels X Mediterranean Diet Adherence Interaction In Metabolic Syndrome,9
Peak Cortisol Response To Low Dose Short Synacthen Test In Corticosteroid Treated Asthma,6
Surgical Necrotising Enterocolitis In Extremely Premature Birth,12
Cough In Response To Angiotensin-Converting Enzyme Inhibitor Drugs,20
Serum Metabolite Ratios In Chronic Kidney Disease,15
Accelerometer-based Physical Activity Measurement (Average Acceleration),5
Cerebrospinal Fluid Biomarker Levels,44
Asthma Or Allergic Disease (Pleiotropy),26
Maximum Habitual Alcohol Consumption,30
Joint Damage In Rheumatoid Arthritis,8
Osteoarthritis (Self-Reported),18
Osteoarthritis Of The Hip Or Knee (Hospital Diagnosed),5
Virologic Severity In Herpes Simplex Virus Type 2 Infection,6
Multiple Sclerosis And Triglyceride Levels (Pleiotropy),5
Risky Sexual Behaviors (Alcohol Dependence Interaction),5
Family History Of Alzheimer's Disease,40
Cisplatin-induced Ototoxicity,9
Erosive Tooth Wear (Severe Vs Non-Severe),30
Erosive Tooth Wear (Severe Vs None Or Mild),8
Mood Instability,26
Ischemic Stroke (Cardioembolic),30
Angiotensin-converting Enzyme Inhibitor Intolerance,19
Type 2 Diabetes (Age Of Onset),19
Attention Deficit Hyperactivity Disorder Or Cannabis Use,8
Alanine Aminotransferase (ALT) Levels After Remission Induction Therapy In Actute Lymphoblastic Leukemia (ALL),35
Optic Nerve Measurement (Cup-To-Disc Ratio),6
Ischemic Stroke (Large Artery Atherosclerosis),9
Ischemic Stroke (Small-Vessel),8
Inflammatory Bowel Disease,196
Osteoarthritis Of The Knee (Hospital Diagnosed),8
Age At First Birth,47
Age At First Sexual Intercourse,161
Systemic Lupus Erythematosus Or Rheumatoid Arthritis,8
Gait Speed In Old Age,12
Number Of Pregnancies,7
Antipsychotic Drug-Induced QTc Interval Change In Schizophrenia,21
Broad Depression Or Schizophrenia,12
Balding Type 1,180
Gastroesophageal Reflux Disease,43
Nevus Count,12
Colorectal Cancer Or Advanced Adenoma,73
Transverse Temporal Cortex Volume,6
Insular Cortex Volume,6
Lysophosphatidylcholine Levels,8
Lysophosphatidylethanolamine Levels,7
Systolic Blood Pressure X Alcohol Consumption Interaction (2Df Test),57
Lateral Ventricle Volume,9
Lateral Ventricle Temporal Horn Volume,30
Phosphatidylcholine Levels,55
Phosphatidylcholine-ether Levels,5
Phosphatidylethanolamine Levels,5
Triacylglyceride Levels,20
Estimated Glomerular Filtration Rate In Non-Diabetics,74
Nonsyndromic Cleft Lip,9
Suicide Attempts In Major Depressive Disorder Or Bipolar Disorder Or Schizophrenia,15
Suicide Attempts In Major Depressive Disorder,7
Familial Lung Adenocarcinoma,18
Familial Squamous Cell Lung Carcinoma,38
Inferior Parietal Cortex Volume,9
Diastolic Blood Pressure X Alcohol Consumption (Light Vs Heavy) Interaction (2Df Test),19
Suicide Attempts In Bipolar Disorder,14
Suicide Attempts In Schizophrenia,9
Suicide Attempts In Bipolar Disorder Or Schizophrenia,7
Lateral Orbital Frontal Cortex Volume,9
Lingual Gyrus Volume,6
Parahippocampal Gyrus Volume,7
Medial Orbital Frontal Cortex Volume,11
Phosphatidylethanolamine-ether Levels,6
Cholesteryl Ester Levels,8
Sphingomyelin Levels,55
Fourth Ventricle Volume,6
Cerebrospinal AB1-42 Levels In Normal Cognition,13
Hippocampal Volume In Alzheimer's Disease Dementia,10
Logical Memory (Immediate Recall) In Normal Cognition,6
Logical Memory (Delayed Recall) In Normal Cognition,14
Estimated Glomerular Filtration Rate In Diabetes,23
N-glycan Levels,12
Subjective Response To Placebo Treatment In Childhood Asthma (Change In Cough/Wheeze),5
Response To Placebo Treatment In Childhood Asthma (FVC Change),7
Bacterial Meningitis,20
Familial Lung Cancer,11
Caudal Anterior-Cingulate Cortex Volume,9
Cuneus Cortex Volume,6
Caudal Middle Frontal Gyrus Volume,6
Handedness (Left-handed Vs. Non-Left-Handed),5
Pericalcarine Cortex Volume,7
Posterior-cingulate Cortex Volume,6
Pars Triangularis Volume,6
Pars Opercularis Volume,7
Superior Parietal Cortex Volume,7
Superior Temporal Gyrus Volume,5
Supramarginal Gyrus Volume,5
Precuneus Cortex Volume,5
Frontal Pole Volume,6
Systolic Blood Pressure X Alcohol Consumption (Light Vs Heavy) Interaction (2Df Test),25
Pulse Pressure X Alcohol Consumption Interaction (2Df Test),28
Corpus Callosum Central Volume,6
Cortex Volume,6
Cerebrospinal Fluid AB1-42 Levels,23
Helping Behaviour (Self Reported),6
Recurrent Major Depressive Disorder,17
Mean Arterial Pressure,261
Epstein-Barr Virus Copy Number In Lymphoblastoid Cell Lines,28
Intelligence (MTAG),238
Obsessive-compulsive Disorder Or Autism Spectrum Disorder,8
Huntington's Disease Progression,15
Papillary Thyroid Cancer,6
Skin Aging (Microtopography Measurement),6
"Coronary Artery Disease (Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass Grafting, Angina Or Chromic Ischemic Heart Disease)",59
Brain Volume In Infants (Grey Matter),6
Alcohol Dependence,40
Restless Legs Syndrome,11
Waist Circumference Adjusted For BMI (Joint Analysis Main Effects And Smoking Interaction),53
Perceived Unattractiveness To Mosquitoes,27
Waist-to-hip Ratio Adjusted For Body Mass Index,65
Body Mass Index (Joint Analysis Main Effects And Physical Activity Interaction),51
Body Mass Index In Physically Active Individuals,49
Body Mass Index In Physically Inactive Individuals,8
Waist-to-hip Ratio Adjusted For BMI In Active Individuals,27
Vitamin D Levels,67
Disease Progression In Age-Related Macular Degeneration,18
Disease Progression In Age-Related Macular Degeneration (Adjusted For Baseline),14
Acute Lymphoblastic Leukemia In Childhood (B Cell Precursor),8
Acute Lymphoblastic Leukemia (B-cell Precursor),5
Acute Lymphoblastic Leukemia (Childhood),37
Sarcoidosis (Lofgren's Syndrome Vs non-Lofgren's Syndrome),20
Serum Uric Acid Levels In Response To Allopurinol In Gout,13
Hand Grip Strength,125
Lower Body Strength,6
Cognitive Function,63
Narcolepsy,8
Cerebellum Cortex Volume,10
Superior Temporal Sulcus Banks Volume,8
HDL Cholesterol,351
Tyrosine Levels,29
Metabolite Risk Score For Predicting Weight Gain,6
Depressive Symptom (Fatigue) (Ordinal Trait),5
Diastolic Blood Pressure X Alcohol Consumption Interaction (2Df Test),47
Nose Morphology,13
Upper Eyelid Morphology,6
Eye Morphology,11
PEG-asparaginase Hypersensitivity Without Enzyme Activity In Childhood Acute Lymphoblastic Leukaemia,8
Depressive Symptom Improvement,12
Parental Longevity (Mother'S Attained Age),5
Parental Longevity (Father'S Age At Death),23
Parental Longevity (Father'S Attained Age),15
"Parental Longevity (Combined Parental Attained Age, Martingale Residuals)",28
Parental Longevity (Mother'S Age At Death),40
Parental Longevity (Combined Parental Age At Death),33
Pulse Pressure X Alcohol Consumption (Light Vs Heavy) Interaction (2Df Test),5
Mean Arterial Pressure X Alcohol Consumption Interaction (2Df Test),40
Triacylglycerol 56:6 Levels,6
Malate Levels,6
Systemising,10
Total Intracranial Volume,10
Cerebellum White Matter Volume,7
Whole Brain Grey Matter Density,12
Sub-cortical Grey Matter Volume,5
Total Grey Matter Volume,5
Cerebrospinal Fluid P-Tau Levels,5
Mean Arterial Pressure X Alcohol Consumption (Light Vs Heavy) Interaction (2Df Test),22
Obsessive-compulsive Disorder,8
Perceived Intensity Of Neohesperidin Dihydrochalcone,9
Intake Of Total Sugars,35
Perceived Sweetness Of Sucrose,7
Intake Of Sweets,7
Perceived Intensity Of Glucose,6
Treatment Resistant Depression,8
HDL Cholesterol And Triglyceride Levels,6
Chronic Central Serous Retinopathy,7
Body Mass Index Variance,18
Waist Circumference Variance,11
Hip Circumference Variance,9
HDL Cholesterol Levels X Alcohol Consumption (Drinkers Vs Non-Drinkers) Interaction (2Df),66
Abstraction And Mental Flexibility,10
Face Memory,8
Sensorimotor Dexterity,20
Antisaccade Task Score,12
Degraded Stimulus Continuous Performance Test Score,7
Letter-number Span Reordering,5
Prepulse Inhibition Of The Startle Response,5
Asthma (Time To Onset),7
Prostate-specific Antigen Levels,22
Triglyceride Levels X Alcohol Consumption (Drinkers Vs Non-Drinkers) Interaction (2Df),46
LDL Cholesterol Levels X Alcohol Consumption (Drinkers Vs Non-Drinkers) Interaction (2Df),56
LDL Cholesterol Levels X Alcohol Consumption (Regular Vs Non-Regular Drinkers) Interaction (2Df),53
Amblyopia,6
Hyperopia,57
Microalbuminuria In Type 1 Diabetes,5
Neuroblastoma Or Malignant Cutaneous Melanoma,13
California Verbal Learning Test Score,13
Spatial Processing,9
Spatial Memory,9
Benign Prostatic Hyperplasia And Lower Urinary Tract Symptoms,14
Benign Prostatic Hyperplasia And Lower Urinary Tract Symptoms (Prostate Cancer Excluded),13
Cognitive Performance (Processing Speed),14
Working Memory,9
Non-lobar Intracerebral Hemorrhage (MTAG),27
Early Cardiac Repolarization,7
Predicted Visceral Adipose Tissue,130
Nicotine Withdrawal Symptom Count,10
Breast Milk Fatty Acid Composition (Maternal Genotype Effect),8
Breast Milk Fatty Acid Composition (Infant Genotype Effect),7
Nicotine Withdrawal,9
Coronary Artery Aneurysm In Kawasaki Disease,25
Normal Facial Asymmetry (Angle Of Surface Orientation Score),7
Free Thyroxine Concentration,18
Hypothyroidism,138
Hyperthyroidism,20
Cleft Palate,16
Squamous Cell Carcinoma,24
Adverse Response To Drug,56
Triglyceride Levels In Current Drinkers,45
HDL Cholesterol Levels In Current Drinkers,56
Parental Longevity (Mother'S Age At Death Or Mother'S Attained Age),26
Parental Longevity (Father'S Age At Death Or Father'S Attained Age),25
Longevity,96
High-grade Serous Ovarian Cancer,19
Urinary Sodium Excretion,37
Urinary Potassium Excretion,5
Gut Microbiota (Beta Diversity),36
Gut Microbiota (Alpha Diversity),16
Stress Sensitivity (Neuroticism Score X Major Depressive Disorder Status Interaction),9
Gut Microbiota Relative Abundance (Bacterial Taxa),26
Gut Microbiota (Bacterial Taxa),32
LDL Cholesterol Levels In Current Drinkers,42
Mental Health Study Participation (Completed Survey),26
Diabetic Retinopathy (All NPDR And PDR),8
Proliferative Diabetic Retinopathy (Vs NPDR And No DR),8
Diabetic Retinopathy (Moderate NPDR And PDR),7
Information Processing Speed,17
Diabetic Maculopathy In Type 2 Diabetes,5
Proliferative Diabetic Retinopathy (Vs No DR),11
Mild To Moderate Chronic Kidney Disease,7
Lung Function (FEV1),210
Mental Health Study Participation (Provided Email Address),6
Fasting Glucose Change (Long-Term),6
End-stage Kidney Disease,6
Longevity (Age >90Th Survival Percentile),5
Longevity (Age >99Th Survival Percentile),6
Plasma Factor V Levels In Venous Thrombosis (Conditioned On Rs6027),7
"Dental Caries (Decayed, Missing And Filled Teeth)",11
"Dental Caries (Decayed, Missing And Filled Tooth Surfaces)",6
Dental Caries (Decayed And Filled Deciduous Teeth),13
Metabolite Levels,940
Dental Caries (Decayed And Filled Deciduous Tooth Surfaces),8
Urinary Albumin-To-Creatinine Ratio,83
Recurrence Of Mild Malaria Attacks,5
Microalbuminuria,29
Urinary Albumin-To-Creatinine Ratio In Diabetes,8
Chronic Lymphocytic Leukemia Or Multiple Sclerosis,5
Marginal Zone Lymphoma Or Multiple Sclerosis,5
Eyebrow Thickness,7
Scalp Hair Shape,5
Beard Thickness,7
Hair Greying,5
White Matter Hyperintensity Burden,19
Gut Microbiome Composition (Winter),15
Plasma Omega-6 Polyunsaturated Fatty Acid Levels (Dihomo-Gamma-Linolenic Acid),10
Plasma Omega-6 Polyunsaturated Fatty Acid Levels (Arachidonic Acid),11
Plasma Omega-3 Polyunsaturated Fatty Acid Level (Eicosapentaenoic Acid),15
Plasma Omega-3 Polyunsaturated Fatty Acid Levels (Docosahexaenoic Acid),10
Plasma Omega-6 Polyunsaturated Fatty Acid Levels (Linoleic Acid),16
Plasma Omega-6 Polyunsaturated Fatty Acid Levels (Gamma-Linolenic Acid),10
Plasma Omega-3 Polyunsaturated Fatty Acid Levels (Alphalinolenic Acid),10
Glaucoma (Low Intraocular Pressure),7
Glaucoma (High Intraocular Pressure),12
"Cholesterol, Total",102
LDL Cholesterol,233
Glomerular Filtration Rate In Non Diabetics (Creatinine),31
Glomerular Filtration Rate (Creatinine),71
Cerebral Amyloid Deposition In APOEe4 Non-Carriers (PET Imaging),19
Cerebrospinal T-tau Levels,14
Cognitive Decline Rate In Late Mild Cognitive Impairment,37
Cerebrospinal P-tau181p Levels,18
Cerebrospinal Fluid p-Tau181p:AB1-42 Ratio,7
Alzheimer Disease And Age Of Onset,96
Morning Vs. Evening Chronotype,59
Chronotype,257
Chronic Lymphocytic Leukemia,72
Low High Density Lipoprotein Cholesterol Levels,15
Congenital Left-Sided Heart Lesions,5
Entorhinal Cortical Thickness,5
Total Ventricular Volume (Alzheimer's Disease Interaction),8
Bone Mineral Density (Spine),40
Bone Mineral Density (Femoral Neck),31
Clozapine-induced Agranulocytosis/Granulocytopenia In Treatment-Resistant Schizophrenia,5
Non-cardia Gastric Cancer,8
Anxiety Disorder,8
Middle Childhood And Early Adolescence Aggressive Behavior,5
Pyoderma Gangrenosum In Inflammatory Bowel Disease,5
Erythema Nodosum In Inflammatory Bowel Disease,5
Magnesium Levels,13
Systolic Blood Pressure (Cigarette Smoking Interaction),37
Epilepsy And Lamotrigine-Induced Maculopapular Eruptions,8
Antipsychotic Drug Dosage In Schizophrenia Or Schizoaffective Disorder,8
Cerebral Amyloid Deposition (PET Imaging),16
Response To anti-TNF Therapy In Rheumatoid Arthritis,8
Periodontal Disease-Related Phenotype (Socransky),10
Response To Cyclophosphamide In Systemic Lupus Erythematosus With Lupus Nephritis,8
Obsessive-compulsive Symptoms,10
Obstructive Sleep Apnea Trait (Apnea Hypopnea Index),16
Obstructive Sleep Apnea Trait (Average Respiratory Event Duration),6
Lewy Body Disease,9
Dementia And Core Alzheimer's Disease Neuropathologic Changes,13
Calcium Levels,308
Post Bronchodilator FEV1/FVC Ratio,258
Hippocampal Sclerosis,7
Plasma Plasminogen Activator Levels,5
Response To Zileuton Treatment In Asthma (FEV1 Change Interaction),16
Cannabis Use (Initiation),10
Classic Bladder Exstrophy,15
Bone Mineral Accretion In Asthma (Oral Corticosteroid Dose Interaction),6
HIV-1 Viral Setpoint,16
Corticobasal Degeneration,7
Yu-Zhi Constitution Type In Type 2 Diabetes,5
IgA Nephropathy,22
Suicide Behavior,19
Response To Simvastatin Treatment (PCSK9 Protein Level Change),6
Warfarin Maintenance Dose,13
Oppositional Defiant Disorder Dimensions In Attention-Deficit Hyperactivity Disorder,11
Brown Vs. Non-Brown Hair Color,6
Light Vs. Dark Hair Color,6
Red Vs Non-Red Hair Color,28
Attention Function In Attention Deficit Hyperactive Disorder,10
Urinary Metabolites,14
Rotator Cuff Tears,5
Diabetic Kidney Disease,36
Mitral Valve Prolapse,13
Myositis,6
Bone Mineral Density (Spine) And Age At Menarche,5
"Chronic Inflammatory Diseases (Ankylosing Spondylitis, Crohn's Disease, Psoriasis, Primary Sclerosing Cholangitis, Ulcerative Colitis) (Pleiotropy)",136
Educational Attainment (College Completion),23
Nonsyndromic Cleft Lip With Cleft Palate,37
Loneliness (Multivariate Analysis),13
Loneliness (Linear Analysis),13
Presence Of Antiphospholipid Antibodies,16
Clopidogrel Active Metabolite Levels,18
Abdominal Aortic Aneurysm,23
Macular Telangiectasia Type 2,14
QT Interval (Sulfonylurea Treatment Interaction),5
JT Interval (Sulfonylurea Treatment Interaction),6
QRS Interval (Sulfonylurea Treatment Interaction),10
Excessive Daytime Sleepiness,9
Small Vessel Stroke,30
Large Artery Stroke,29
Bipolar Disorder Or Attention Deficit Hyperactivity Disorder,8
Carotid Plaque Burden,27
Sum Eosinophil Basophil Counts,139
Stem Cell Growth Factor Beta Levels,30
Stromal-cell-derived Factor 1 Alpha Levels,13
RANTES Levels,15
Stem Cell Factor Levels,26
Tumor Necrosis Factor Alpha Levels,9
TRAIL Levels,32
Plasma Thyroid-Stimulating Hormone Levels,5
Multiple System Atrophy,13
Post Bronchodilator FEV1,152
Systolic Blood Pressure (Long-Term Average),23
Diastolic Blood Pressure (Long-Term Average),23
Mean Arterial Pressure (Long-Term Average),5
Vitamin B12 Levels,6
Myeloid White Cell Count,105
Subclinical Trait Of Interstitial Lung Disease (Basilar Peel-Core Ratio Of High Attentuation Areas On CT Scan),8
Systolic Blood Pressure Change Trajectory,13
Fasting Blood Glucose Adjusted For BMI,12
Very Low Density Lipoprotein Cholesterol Levels,24
Heart Rate Response To Beta Blockers (Atenolol Monotherapy),15
Heart Rate Response To Beta Blockers (Atenolol Add-On Therapy),9
Alcohol Dependence Symptom Count,12
Alcohol Consumption (Max-Drinks),11
Response To Alcohol Consumption (Flushing Response),5
Prudent Dietary Pattern,24
Western Dietary Pattern,10
Rheumatoid Arthritis (ACPA-positive),41
Systolic Blood Pressure X Smoking Status (Current Vs Non-Current) Interaction (1Df Test),5
Systolic Blood Pressure X Smoking Status (Current Vs Non-Current) Interaction (2Df Test),31
Plateletcrit,546
Granulocyte Percentage Of Myeloid White Cells,121
Monocyte Percentage Of White Cells,366
LDL Peak Particle Diameter (Total Fat Intake Interaction),12
Advanced Glycation End-Product Levels,8
Daytime Sleep Phenotypes,37
Night Sleep Phenotypes,95
Granulocyte Count,103
Nonsyndromic Cleft Lip With Or Without Cleft Palate,23
Hepcidin/transferrin Saturation Ratio,7
Hepcidin/ferritin Ratio,16
Hepcidin Levels,6
"Age-related Diseases, Mortality And Associated Endophenotypes",29
Age-related Diseases And Mortality,8
Resting Heart Rate,63
Essential Tremor,55
Age-related Disease Endophenotypes,20
Deep Ovarian And/Or Rectovaginal Disease With Dense Adhesions,5
Pre-treatment Pain In Head And Neck Squamous Cell Carcinoma,5
Otitis Media,14
Low-grade Serous And Serous Borderline Ovarian Cancer,9
Mucinous Ovarian Carcinoma,7
Serous Invasive Ovarian Cancer,17
Sum Neutrophil Eosinophil Counts,103
Attention Deficit Hyperactivity Disorder Symptom Score,10
QRS Complex (12-Leadsum),15
QRS Complex (Cornell),10
QRS Complex (Sokolow-Lyon),7
Invasive Epithelial Ovarian Cancer,16
Serous Borderline Ovarian Cancer,8
Reticulocyte Count,419
Orofacial Clefts,39
Beta-Nerve Growth Factor Levels,15
Neutrophil Percentage Of Granulocytes,109
Eotaxin Levels,27
Fibroblast Growth Factor Basic Levels,14
CTACK Levels,25
Pediatric Bone Mineral Density (Spine),8
Pediatric Bone Mineral Density (Femoral Neck),7
Granulocyte-colony Stimulating Factor Levels,10
Growth-regulated Protein Alpha Levels,16
Interleukin-1-beta Levels,13
Interleukin-1-receptor Antagonist Levels,20
Pediatric Bone Mineral Content (Radius),11
Interferon Gamma Levels,19
Pediatric Bone Mineral Density (Hip),8
Interleukin-2 Levels,15
Pediatric Bone Mineral Content (Hip),6
Interleukin-2 Receptor Antagonist Levels,16
Interleukin-4 Levels,13
Interleukin-7 Levels,9
Interleukin-5 Levels,9
Interleukin-8 Levels,13
Interleukin-9 Levels,20
Interleukin-10 Levels,24
Interleukin-13 Levels,19
Interleukin-18 Levels,32
Interleukin-17 Levels,19
Macrophage Migration Inhibitory Factor Levels,20
Interferon Gamma-Induced Protein 10 Levels,17
Interleukin-16 Levels,15
Monocyte Chemoattractant Protein-1 Levels,41
Interleukin-12p70 Levels,19
Macrophage Inflammatory Protein 1A Levels,14
Macrophage Inflammatory Protein 1B Levels,66
Monocyte Chemoattractant Protein-3 Levels,6
Monokine Induced By Gamma Interferon Levels,21
Macrophage Colony Stimulating Factor Levels,8
Platelet-derived Growth Factor BB Levels,13
Platelet Distribution Width,422
White Blood Cell Count (Basophil),67
Eosinophil Percentage Of Granulocytes,115
Protein C Levels,8
Reticulocyte Fraction Of Red Cells,397
Fibrinogen Levels,57
Sum Basophil Neutrophil Counts,104
Gallstone Disease,62
Cold Medicine-Related Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) With Severe Ocular Complications,12
Rheumatoid Arthritis (Rheumatoid Factor And/Or Anti-Cyclic Citrullinated Peptide Seropositive),92
"B-cell Malignancies (Chronic Lymphocytic Leukemia, Hodgkin Lymphoma Or Multiple Myeloma) (Pleiotropy)",18
Alzheimer's Disease In APOE E4- Carriers,19
Lipoprotein Phospholipase A2 Activity In Cardiovascular Disease,11
Methadone Dose In Opioid Dependence,15
Diastolic Blood Pressure X Smoking Status (Current Vs Non-Current) Interaction (2Df Test),31
Hyperuricemia,24
Systolic Blood Pressure X Smoking Status (Ever Vs Never) Interaction (2Df Test),26
Diastolic Blood Pressure X Smoking Status (Ever Vs Never) Interaction (2Df Test),27
Lumbar Spine Bone Mineral Density,37
Diastolic Blood Pressure (Cigarette Smoking Interaction),33
Body Mass Index X Sex X Age Interaction (4Df Test),12
Limited Cutaneous Systemic Scleroderma,8
Major Depressive Disorder (Broad),7
Smooth-surface Caries,23
Pit-and-Fissure Caries,10
Cystatin C Levels,197
Urinary Albumin Excretion,35
Telomere Length,60
Cognitive Test Performance,6
Diabetic Retinopathy,14
Renal Cell Carcinoma,24
Red Blood Cell Traits,43
Multiple Sclerosis (Severity),7
Multiple Sclerosis (Age Of Onset),5
Normalized Brain Volume,5
Otosclerosis,37
Response To Treatment For Acute Lymphoblastic Leukemia,6
Hippocampal Atrophy,21
Pulmonary Function,45
Electrocardiographic Traits,16
HIV-1 Control,23
Erectile Dysfunction And Prostate Cancer Treatment,14
Two-hour Glucose Challenge,5
Cardiac Hypertrophy,9
C-reactive Protein,148
Prion Diseases,7
Vitiligo,59
Menarche (Age At Onset),276
Obesity,41
Moyamoya Disease,25
Response To Citalopram Treatment,8
Response To Antipsychotic Treatment,29
Smoking Behavior,21
Platelet Aggregation,20
Bipolar Disorder And Schizophrenia,73
Circulating Cell-Free DNA,9
Malaria,36
Response To Statin Therapy,19
Lipid Metabolism Phenotypes,21
Renal Function-Related Traits (BUN),10
Renal Function-Related Traits (sCR),7
Renal Function-Related Traits (eGRFcrea),7
Lentiform Nucleus Volume,6
Blood Trace Element (Se Levels),7
Blood Trace Element (Cu Levels),5
Blood Trace Element (Zn Levels),8
Arthritis (Juvenile Idiopathic),43
IgE Levels,14
Migraine,126
Hematological Parameters,9
Cognitive Performance,200
Response To Hepatitis C Treatment,7
Pubertal Anthropometrics,17
Autism,18
Hypospadias,18
Attention Deficit Hyperactivity Disorder And Conduct Disorder,17
Stroke (Ischemic),5
Attention Deficit Hyperactivity Disorder Symptoms (Maternal Expressed Emotions Interaction),5
Conduct Disorder (Maternal Expressed Emotions Interaction),8
Personality Dimensions,9
Cardiovascular Disease Risk Factors,19
Menopause (Age At Onset),75
Coronary Artery Calcification,33
Relative Hand Skill In Reading Disability,7
Response To Vitamin E Supplementation,7
Activated Partial Thromboplastin Time,17
Prothrombin Time,11
Gamma Glutamyl Transpeptidase,260
Depression (Quantitative Trait),9
Electroencephalographic Traits In Alcoholism,6
Response To Antipsychotic Treatment In Schizophrenia (Working Memory),6
Response To Antipsychotic Treatment In Schizophrenia (Reasoning),8
Clozapine-induced Agranulocytosis,18
Tumor Biomarkers,6
Airflow Obstruction,22
Nodular Sclerosis Hodgkin Lymphoma,6
Metabolite Levels (HVA/5-HIAA Ratio),5
Metabolite Levels (HVA-5-HIAA Factor Score),6
Metabolite Levels (5-HIAA),6
Metabolite Levels (HVA),8
Metabolite Levels (MHPG),9
Metabolite Levels (5-HIAA/ MHPG Ratio),7
Metabolite Levels (HVA/MHPG Ratio),11
Disc Degeneration (Lumbar),12
Homocysteine Levels,17
Inflammatory Biomarkers,18
Amyotrophic Lateral Sclerosis (Age Of Onset),11
Progressive Supranuclear Palsy,13
Breast Cancer In BRCA1 Mutation Carriers,9
Testicular Germ Cell Tumor,47
Response To Fenofibrate,6
Sunburns,56
Tanning,10
Periodontal Microbiota,7
Cholelithiasis-related Traits In Sickle Cell Anemia,8
Liver Enzyme Levels (Gamma-Glutamyl Transferase),184
Liver Enzyme Levels (Alkaline Phosphatase),230
Liver Enzyme Levels (Alanine Transaminase),131
Caffeine Consumption,7
Erythrocyte Sedimentation Rate,5
Homeostasis Model Assessment Of Beta-Cell Function,11
White Blood Cell Types,12
Sex Hormone-Binding Globulin Levels,735
Periodontitis,10
Brain Connectivity,6
Attention Deficit Hyperactivity Disorder (Combined Symptoms),5
Response To Amphetamines,40
Hemostatic Factors And Hematological Phenotypes,14
Corneal Structure,22
Fibrinogen,26
Alzheimer's Disease Biomarkers,6
Eye Color Traits,6
IgG Glycosylation,213
Dupuytren's Disease,22
Quantitative Traits,18
AIDS Progression,8
Hyperactive-impulsive Symptoms,7
Inattentive Symptoms,7
Educational Attainment,2058
Temperament (Bipolar Disorder),9
Obesity (Early Onset Extreme),13
Select Biomarker Traits,10
Waist Circumference - Triglycerides (WC-TG),7
Metabolic Syndrome (Bivariate Traits),7
Triglycerides-Blood Pressure (TG-BP),5
Skin Sensitivity To Sun,6
Obesity-related Traits,498
Asperger Disorder,5
Hair Morphology,5
Response To Methylphenidate Treatment In Attention-Deficit/Hyperactivity Disorder (Blood Pressure),7
Optic Nerve Measurement (Cup Area),5
Optic Nerve Measurement (Rim Area),5
Glioma (High-Grade),5
Brain Structure,11
Insulin-like Growth Factors,5
Liver Enzyme Levels,7
Aortic Root Size,18
Fuchs's Corneal Dystrophy,6
Myocardial Infarction (Early Onset),5
Hepatitis B,25
Biomedical Quantitative Traits,5
Common Traits (Other),10
Follicular Lymphoma,6
Non-alcoholic Fatty Liver Disease Histology (Lobular),8
Non-alcoholic Fatty Liver Disease Histology (Other),10
Left Ventricular Mass,12
Electrocardiographic Conduction Measures,7
Vitamin D Insufficiency,23
Soluble E-selectin Levels,5
Osteosarcoma,6
Serum Selenium Levels,9
Pulmonary Function (Smoking Interaction),33
RR Interval (Heart Rate),15
Sphingolipid Levels,11
Folate Pathway Vitamin Levels,10
Lipoprotein-associated Phospholipase A2 Activity And Mass,10
Biochemical Measures,9
Hip Geometry,9
Tonometry,10
Celiac Disease Or Rheumatoid Arthritis,10
Sudden Cardiac Arrest,28
Osteoporosis-related Phenotypes,5
HIV-1 Susceptibility,24
Atrial Fibrillation/Atrial Flutter,60
Idiopathic Dilated Cardiomyopathy,20
Arterial Stiffness,6
Radiation Response,6
Drug-induced Stevens-Johnson Syndrome Or Toxic Epidermal Necrolysis (SJS/TEN),7
Breast Cancer (Survival),5
Lymphoma,5
Idiopathic Membranous Nephropathy,19
Metabolic Traits,52
Primary Tooth Development (Number Of Teeth),11
Primary Tooth Development (Time To First Tooth Eruption),13
Infantile Hypertrophic Pyloric Stenosis,6
Menarche And Menopause (Age At Onset),6
Myopia (Pathological),37
C-reactive Protein And White Blood Cell Count,6
Thyroid Hormone Levels,19
Retinopathy In Non-Diabetics,5
Cystic Fibrosis Severity,5
Response To Anti-Depressant Treatment In Major Depressive Disorder,10
Type 1 Diabetes Nephropathy,7
QT Interval (Drug Interaction),8
Estradiol Plasma Levels (Breast Cancer),6
Dental Caries,37
IgM Levels,14
Immunoglobulin A,7
Response To Gemcitabine In Pancreatic Cancer,6
Adverse Response To Chemotherapy (Neutropenia/Leucopenia) (Carboplatin),9
Adverse Response To Chemotherapy (Neutropenia/Leucopenia) (All Antimicrotubule Drugs),8
Adverse Response To Chemotherapy (Neutropenia/Leucopenia) (All Anthracycline-Based Drugs),5
Palmitoleic Acid (16:1N-7) Levels,11
Stearic Acid (18:0) Levels,8
Oleic Acid (18:1N-9) Levels,6
Palmitic Acid (16:0) Levels,5
Visceral Fat,55
Age-related Macular Degeneration (Choroidal Neovascularisation),6
Age-related Macular Degeneration (Geographic Atrophy),6
Preeclampsia,13
Lipoprotein-associated Phospholipase A2 Activity Change In Response To Statin Therapy,5
Esophageal Cancer (Squamous Cell),6
Lifetime Average Cigarettes Per Day In Chronic Obstructive Pulmonary Disease,7
Age At Smoking Initiation In Chronic Obstructive Pulmonary Disease,6
Pulmonary Function Decline,27
Capecitabine Sensitivity,8
Multiple Sclerosis (OCB Status),7
Myasthenia Gravis,6
Serum Protein Levels (sST2),8
Periodontitis (PAL4Q3),7
Periodontitis (Mean PAL),22
Anxiety In Major Depressive Disorder,5
Periodontitis (DPAL),12
Alcohol And Nicotine Co-Dependence,6
Periodontitis (CDC/AAP),18
Response To Tocilizumab In Rheumatoid Arthritis,19
End-stage Coagulation,12
Breast Cancer In BRCA2 Mutation Carriers,5
"Autism Spectrum Disorder, Attention Deficit-Hyperactivity Disorder, Bipolar Disorder, Major Depressive Disorder, And Schizophrenia (Combined)",44
Response To Angiotensin II Receptor Blocker Therapy,16
Neuroblastoma,50
Economic And Political Preferences,14
Economic And Political Preferences (Feminism/Equality),6
Economic And Political Preferences (Immigration/Crime),5
Economic And Political Preferences (Time),6
Response To Antineoplastic Agents,5
White Matter Integrity,6
Response To Antidepressants,5
Body Mass Index In Asthmatics,7
Response To Fenofibrate (Adiponectin Levels),9
Haptoglobin Levels,16
Circulating Myeloperoxidase Levels (Serum),5
Non-albumin Protein Levels,206
Dialysis-related Mortality,13
Immune Reponse To Smallpox (Secreted IL-12p40),7
Immune Reponse To Smallpox (Secreted IL-2),8
Immune Reponse To Smallpox (Secreted IL-1beta),8
Immune Response To Smallpox Vaccine (IL-6),30
Immune Reponse To Smallpox (Secreted IL-10),5
Immune Reponse To Smallpox (Secreted IFN-alpha),27
Immune Reponse To Smallpox (Secreted TNF-alpha),5
Fat Distribution (HIV),7
Alzheimer's Disease (Cognitive Decline),47
Hodgkin's Lymphoma,55
Circulating Vasoactive Peptide Levels,5
Phospholipid Levels (Plasma),22
Black Vs. Blond Hair Color,5
Black Vs. Red Hair Color,6
D-dimer Levels,8
Metabolite Levels (Pyroglutamine),14
Metabolite Levels (X-11787),18
Metabolite Levels (Dihydroxy Docosatrienoic Acid),9
Anticoagulant Levels,5
Multiple Myeloma (IgH Translocation),13
Multiple Myeloma (Hyperdiploidy),10
DNA Methylation (Variation),10
Psoriatic Arthritis,43
Post-traumatic Stress Disorder (Asjusted For Relatedness),9
Bulimia Nervosa,11
Eating Disorders (Purging Via Substances),6
Eating Disorders,10
Psychosis And Alzheimer's Disease,6
Psychosis In Alzheimer's Disease,29
Response To Iloperidone Treatment (QT Prolongation),6
Adverse Response To Lamotrigine And Phenytoin,7
Liver Enzyme Levels (Aspartate Transaminase),7
Insulin Resistance/Response,8
Waist Circumference Adjusted For BMI In Active Individuals,58
Survival In Pancreatic Cancer,32
Waist Circumference Adjusted For BMI (Joint Analysis Main Effects And Physical Activity Interaction),60
Low vWF Levels,8
Coronary Artery Calcified Atherosclerotic Plaque (90 Or 130 HU Threshold) In Type 2 Diabetes,36
Response To Bronchodilator In Chronic Obstructive Pulmonary Disease (Change In FEV1),23
"Response To Radiotherapy In Prostate Cancer (Toxicity, Urinary Frequency)",5
Plasma Kynurenine Levels In Major Depressive Disorder,5
Thrombin-activatable Fibrinolysis Inhibitor Levels,6
Thrombin-activatable Fibrinolysis Inhibitor Activation Peptide,5
Total Body Bone Mineral Density,107
Serum Total Protein Level,324
Albumin-globulin Ratio,32
Creatinine Levels,326
Cortisol Levels (Saliva),7
Total Body Bone Mineral Density (Age 45-60),13
Sodium Levels,10
Potassium Levels,15
Total Body Bone Mineral Density (Age Over 60),13
Chloride Levels,17
Phosphorus Levels,9
Total Bilirubin Levels,193
Blood Sugar Levels,14
Ejection Fraction,5
Left Ventricular Internal Dimension In Systole,5
Migraine Without Aura,23
Phospholipid Levels In Large VLDL,57
Phospholipid Levels In Very Large VLDL,56
Triglyceride Levels In Very Large VLDL,61
Triglyceride Levels In Large VLDL,61
Free Cholesterol Levels In Medium HDL,55
Triglyceride Levels In Small HDL,54
Phospholipid Levels In Large HDL,64
Free Cholesterol Levels In Large HDL,67
Phospholipid Levels In Medium HDL,55
Large HDL Particle Concentration,5
Glaucoma (Primary Angle Closure),8
Late-onset Alzheimer's Disease,88
Insulin Levels,35
Bipolar Disorder Lithium Response (Continuous) Or Schizophrenia,5
Bipolar Disorder Lithium Response (Categorical) Or Schizophrenia,5
Hair Shape,6
Ankle Injury,18
Rheumatoid Arthritis (ACPA-negative),5
Headache,23
Sulfasalazine-induced Agranulocytosis,15
Heart Rate Response To Exercise,13
Heart Rate Response To Recovery Post Exercise,9
Offspring Birth Weight,92
Total Cholesterol Levels In LDL,5
Response To Cognitive-Behavioural Therapy In Anxiety Disorder,10
Total Cholesterol Levels In HDL,6
Coenzyme Q10 Levels,17
Phospholipid Levels In Medium VLDL,48
Phospholipid Levels In Small VLDL,55
Free Cholesterol Levels In Small VLDL,49
Triglyceride Levels In Small VLDL,67
Free Cholesterol Levels In Medium VLDL,50
Triglyceride Levels In Medium VLDL,59
Mortality In Heart Failure,6
Food Allergy,5
Psoriasis Vulgaris,30
Docetaxel-induced Peripheral Neuropathy In Metastatic Castrate-Resistant Prostate Cancer,9
Free Cholesterol Levels In Large LDL,51
Phospholipid Levels In Medium LDL,34
Free Cholesterol Levels In IDL,51
Triglyceride Levels In IDL,63
Phospholipid Levels In Very Small VLDL,55
Triglyceride Levels In Very Small VLDL,61
Free Cholesterol Levels In Very Large HDL,59
Triglyceride Levels In Very Large HDL,41
Selective IgA Deficiency,21
Mortality In Sepsis,10
Overall Survival In Osteosarcoma,6
Accelerated Cognitive Decline After Conversion Of Mild Cognitive Impairment To Alzheimer's Disease (Alzhiemer's Diagnosis Trajectory Interaction),10
Red Blood Cell Density In Sickle Cell Anemia,8
P Wave Terminal Force,6
P Wave Duration,10
Sporadic Neuroblastoma,9
"Breast Cancer, Ovarian Cancer Or Prostate Cancer (Pleiotropy)",11
Lobe Attachment (Rater-Scored Or Self-Reported),84
Iris Color (B* Coordinate),26
Iris Heterochromicity,19
Iris Color (L* Coordinate),28
Iris Color (A* Coordinate),18
Lobe Attachment (Rater Scored),10
Cognitive Ability,37
Cardiometabolic And Hematological Traits,11
Common Carotid Intima-Media Thickness In HIV Negative Individuals,10
Common Carotid Intima-Media Thickness,5
Cognitive Ability (MTAG),55
Coronary Artery Calcified Atherosclerotic Plaque (130 HU Threshold) In Type 2 Diabetes,41
Coronary Artery Calcified Atherosclerotic Plaque Score In Type 2 Diabetes,27
Osteoarthritis Of The Hip Or Knee (With Total Joint Replacement),8
Response To Hepatitis B Vaccine,11
Response To Antipsychotic Treatment In Schizophrenia,7
Response To Quetiapine In Schizophrenia,5
Response To Risperidone In Schizophrenia,9
Neurociticism,101
Irritable Mood,38
Feeling Miserable,37
Experiencing Mood Swings,41
Feeling Guilty,24
Worry Too Long After An Embarrassing Experience,26
Feeling Nervous,39
Feeling Fed-Up,32
Feeling Worry,45
Feeling Hurt,25
Suffering From Nerves,5
Feeling Tense,22
Subcortical Brain Region Volumes,8
Cutaneous Psoriasis,7
Nickel Levels,35
Cobalt Levels,35
Exudative Age-Related Macular Degeneration,7
Glucocorticoid-induced Osteonecrosis (Age 10 Years And Older),5
Glucocorticoid-induced Osteonecrosis,5
Trans Fatty Acid Levels,25
Depressive Symptoms (SSRI Exposure Interaction),6
Chronic Bronchitis And Chronic Obstructive Pulmonary Disease,6
Copper Levels,8
Thrombosis,10
Gut Microbiome Composition (Summer),22
Homeostasis Model Assessment Of Beta-Cell Function (Dietary Factor Interaction),8
Fasting Insulin (Dietary Factor Interaction),9
Plasma Omega-3 Polyunsaturated Fatty Acid Levels (Docosapentaenoic Acid),13
PR Interval In Tripanosoma Cruzi Seropositivity,67
QT Interval In Tripanosoma Cruzi Seropositivity,7
Ejection Fraction In Tripanosoma Cruzi Seropositivity,13
Depression And Alcohol Dependence,7
Reading And Spelling,5
QRS Duration In Tripanosoma Cruzi Seropositivity,22
Chagas Cardiomyopathy In Tripanosoma Cruzi Seropositivity,15
Local Histogram Emphysema Pattern,9
Response To Platinum-Based Chemotherapy (Carboplatin),9
Response To Platinum-Based Chemotherapy (Cisplatin),7
Fasting Blood Insulin (BMI Interaction),12
Fasting Blood Glucose (BMI Interaction),26
Coronary Artery Disease Or Ischemic Stroke,8
Coronary Artery Disease Or Large Artery Stroke,11
Antibody Status In Tripanosoma Cruzi Seropositivity,13
Parasitemia In Tripanosoma Cruzi Seropositivity,11
Self-reported Allergy,18
Thyroid Volume,6
Migraine - Clinic-Based,25
Paget's Disease,8
Body Mass Index (SNP X SNP Interaction),5
Advanced Age-Related Macular Degeneration,37
White Matter Hyperintensities In Ischemic Stroke,8
Exploratory Eye Movement Dysfunction In Schizophrenia (Responsive Search Score),14
Exploratory Eye Movement Dysfunction In Schizophrenia (Total Eye Scanning Length),5
Exploratory Eye Movement Dysfunction In Schizophrenia (Number Of Eye Fixations),9
Exploratory Eye Movement Dysfunction In Schizophrenia (Cognitive Search Score),9
3-Hydroxypropylmercapturic Acid Levels In Smokers,124
3-Hydroxy-1-Methylpropylmercapturic Acid Levels In Smokers,127
Multiple Myeloma And Monoclonal Gammopathy,6
Sex Hormone Levels,6
Asparaginase Hypersensitivity In Acute Lymphoblastic Leukemia,24
Pediatric Autoimmune Diseases,30
Post Bronchodilator FEV1 In COPD,47
Depressive And Manic Episodes In Bipolar Disorder,5
Urinary Albumin-To-Creatinine Ratio In Non-Diabetics,7
Mild Influenza (H1N1) Infection,26
Severe Influenza A (H1N1) Infection,19
Influenza A (H1N1) Severity,5
Influenza A (H1N1) Infection,12
Skin Colour Saturation,5
Glomerular Filtration Rate In Chronic Kidney Disease,14
Proteinuria And Chronic Kidney Disease,8
Colorectal Or Endometrial Cancer,18
Airway Imaging Phenotypes,5
Emphysema Imaging Phenotypes,25
Percentage Gas Trapping,7
Adiponectin Levels (BMI-adjusted),10
White Matter Lesion Progression,5
Bipolar Disorder And Eating Disorder,6
Severe Malaria,10
Carotid Intima Media Thickness,29
Juvenile Osteochondritis Dissecans,5
Diastolic Blood Pressure Response To Hydrochlorothiazide In Hypertension,6
Pelvic Organ Prolapse (Moderate/Severe),13
Parental Extreme Longevity (95 Years And Older),40
Spherical Equivalent (Joint Analysis Main Effects And Education Interaction),17
Aggressiveness In Attention Deficit Hyperactivity Disorder,10
Cannabis Use,6
Liver Fibrosis Severity In HIV/hepatitis C Co-Infection,6
Verbal-numerical Reasoning,62
Middle Facial Morphology Traits (Quantitative Measurement),5
Thionamide-induced Agranulocytosis In Graves' Disease,7
Triptolide Cytotoxicity,11
Late-onset Myasthenia Gravis,8
Dysphagia,8
Cerebrospinal Fluid Clusterin Levels,20
Plasma Clusterin Levels,7
Sense Of Smell,13
Cannabis Dependence Symptom Count,18
Pneumococcal Bacteremia,6
Bacteremia,7
Asparaginase-induced Acute Pancreatitis In Acute Lymphoblastic Leukemia (Onset Time),9
SjÃ¶gren's Syndrome,28
Celiac Disease And Rheumatoid Arthritis,17
Gestational Age At Birth In Labor-Initiated Deliveries (Child Effect),10
Gestational Age At Birth In Premature Rupture Of Membrane-Initiated Deliveries (Maternal Effect),7
Subjective Well-Being,78
EGFR Mutation-Positive Lung Adenocarcinoma,6
Positive Affect,113
Life Satisfaction,87
Bone Mineral Density (Ward's Triangle Area),14
Clinical Laboratory Measurements,6
Developmental Language Disorder (Linguistic Errors),5
Endometrial Endometrioid Carcinoma,6
Cluster Headache,5
Systemic Juvenile Idiopathic Arthritis,9
Tonsillectomy,126
Response To Selective Serotonin Reuptake Inhibitors In Depression,5
Response To Bupropion And Depression,5
Posterior Cortical Atrophy And Alzheimer's Disease,10
Major Depressive Episode Treated With Electroconvulsive Therapy,15
Major Depressive Disorder And Major Depressive Episode Treated With Electroconvulsive Therapy,11
Cognitive Impairment Test Score,12
Lymphocyte Percentage Of White Cells,364
Diverticular Disease,107
Academic Attainment (Maths),17
Academic Attainment (Science),13
Joint Destruction In Rheumatoid Arthritis (Rapid Vs Slow),8
Vesicoureteral Reflux,16
Systolic Blood Pressure (Baseline),22
Diastolic Blood Pressure Change Trajectory,13
Ferritin Levels,17
Declining Hemoglobin Trajectory In Blood Donors,5
Mouth Ulcers,52
Insulin-like Growth Factor 1 Levels,265
Hypertrophic Cardiomyopathy (MTAG),9
Dilated Cardiomyopathy (MTAG),11
Left Ventricular Global Radial Strain,5
Left Ventricle Wall Thickness,18
Dilated Cardiomyopathy,8
Left Ventricular Global Circumferential Strain,7
Left Ventricular Mass To End-Diastolic Volume Ratio,6
Addison's Disease,7
Cognitive Function In Longevity,7
Mental Composite Score,21
Diabetic Retinopathy In Type 2 Diabetes,6
Cutaneous Leishmaniasis,13
Diastolic Blood Pressure (Baseline),12
Metabolically Unhealthy In Normal Weight,7
Carpal Tunnel Syndrome,14
Hypertrophic Cardiomyopathy,13
Hip Bone Mineral Density And Total Body Fat Mass (Bivariate Analysis),9
Academic Attainment (English),9
Peptic Ulcer Disease,7
"Gastroesophageal Reflux Disease, Peptic Ulcer Disease And/Or Corresponding Medications And Treatment",8
Irritable Bowel Syndrome,19
BRCA1 Mutation In Breast Cancer,6
Frontal Fibrosing Alopecia,17
Triiodothyronine Levels And Thyroxine Levels,7
BRCA1/2-negative High-Risk Breast Cancer,12
Early Age-Related Macular Degeneration,7
Alcohol Use Disorder (Total Score),10
Alcohol Use Disorder (Consumption Score),18
IgA Levels,12
Composite Immunoglobulin Trait (IgA/IgG),11
Composite Immunoglobulin Trait (IgA X IgG/IgM),5
Lung Cancer In Never Smokers,16
IgG Levels,6
Serum Urate Levels In Chronic Kidney Disease,5
Hip Shape (DXA Scan),6
Facial Pigmentation Measurement (UV Light),6
Facial Pigmentation Measurement (Polar Light),6
Mitochondrial DNA Levels,67
Serum Levels Of Protein CXCL2;CXCL3,5
Serum Levels Of Protein CXCL5,6
Serum Levels Of Protein FTH1;FTL,5
Phosphatidylcholine-O 31:0 [M+H]1+/Phosphatidylethanolamine-O 34:0 [M+H]1+ Levels,6
Phosphatidylcholine-O 32:1 [M+H]1+/Phosphatidylcholine-P 32:0 [M+H]1+/Phosphatidylethanolamine-O 35:1 [M+H]1+ Levels,8
White Blood Cell Count (Neutrophil),39
Phosphatidylcholine-O 42:6 [M+OAc]1-/Phosphatidylcholine-P 42:5 [M+OAc]1- Levels,6
Phosphatidylcholine-O 44:5 [M+H]1+/Phosphatidylcholine-P 44:4 [M+H]1+ Levels,8
Serum Levels Of Protein SECTM1,5
Lung Function (FEV1) And Body Mass Index,6
Lung Function (FEV1) And Waist To Hip Ratio Adjusted For BMI,6
Phosphatidylcholine-O(36:5) [M+H]1+/Phosphatidylcholine-P(36:4) [M+H]1+ Levels,9
Lung Function (FEV1) And Waist Circumference Adjusted For BMI,5
Complement Factor H-related Protein 1 Levels,27
Complement Factor H-related Protein 2 Levels,11
Complement Factor H-related Protein 3 Levels,64
Complement Factor H-related Protein 5 Levels,14
Inguinal Hernia,127
Externalizing Behaviour (Multivariate Analysis),339
Mean Reticulocyte Volume,452
Phosphatidylcholine(33:2) [M+H]1+/Phosphatidylethanolamine(36:2) [M+H]1+/Phosphatidate(38:3) [M+NH4]1+ Levels,8
Mean Sphered Cell Volume,22
Phosphatidylcholine(36:2) [M+H]1+/Phosphatidylethanolamine(39:2) [M+H]1+/Phosphatidate(41:3) [M+NH4]1+ Levels,5
Phosphatidylcholine(36:3) [M+H]1+/Phosphatidylethanolamine(39:3) [M+H]1+/Phosphatidate(41:4) [M+NH4]1+ Levels,8
Phosphatidylcholine(35:4) [M+H]1+/Phosphatidylethanolamine(38:4) [M+H]1+/Phosphatidate(40:5) [M+NH4]1+ Levels,8
Educational Attainment (MTAG),753
Serum Levels Of Protein GRAMD1C,5
"Bilirubin (Z,Z) Levels",13
Betaine Levels,9
Ethylmalonate Levels,7
Methionine Sulfone Levels,8
N-acetylglutamate Levels,5
N-acetylhistidine Levels,5
N-delta-acetylornithine Levels,9
Tryptophan Betaine Levels,5
5-Methyluridine (Ribothymidine) Levels,6
10-Undecenoate (11:1N1) Levels,5
Cis-4-decenoylcarnitine (C10:1) Levels,5
Nonanoylcarnitine (C9) Levels,6
2-Aminooctanoate Levels,7
"5Alpha-Pregnan-3Beta,20Beta-Diol Monosulfate (1) Levels",9
Arachidonoylcarnitine (C20:4) Levels,8
Phosphatidylcholine 40:7 [M+H]1+ Levels,7
Phosphatidylcholine 42:4 [M+OAc]1- Levels,7
Phosphatidylcholine 40:6 [M+OAc]1-/Phosphatidylserine 44:5 [M-H]1- Levels,7
X-12112 Levels,5
X-21607 Levels,6
Asparagine Levels,6
Dimethylglycine Levels,15
N-acetylarginine Levels,6
N-acetylglucosaminylasparagine Levels,5
"N6,N6-dimethyllysine Levels",6
"Cys-gly, Oxidized Levels",5
N6-acetyllysine Levels,5
X-18921 Levels,5
X-16946 Levels,9
Biliverdin Levels,10
X-24947 Levels,7
X-11470 Levels,9
Metabolonic Lactone Sulfate Levels,86
Phosphatidylcholine-O 34:3 [M+H]1+/Phosphatidylcholine-P 34:2 [M+H]1+/Phosphatidylethanolamine-P 37:2 [M+H]1+ Levels,7
Phosphatidylcholine-O 35:4 [M+OAc]1-/Phosphatidylcholine-P 35:3 [M+OAc]1- Levels,5
Phosphatidylcholine-O 36:1 [M+H]1+/Phosphatidylcholine-P 36:0 [M+H]1+/Phosphatidylethanolamine-O 39:1 [M+H]1+ Levels,7
Phosphatidylcholine-O 34:1 [M+H]1+/Phosphatidylcholine-P 34:0 [M+H]1+/Phosphatidylethanolamine-O 37:1 [M+H]1+ Levels,9
Vitamin D-binding Protein Levels,5
Phosphatidylcholine-O(38:5) [M+H]1+/Phosphatidylcholine-P(38:4) [M+H]1+ Levels,5
Edge-level Brain Connectivity (Multivariate Analysis),133
Phosphatidylcholine(32:0) [M+H]1+/Phosphatidylethanolamine(35:0) [M+H]1+/Phosphatidate(37:1) [M+NH4]1+ Levels,8
Electrocardiogram Morphology (Amplitude At Temporal Datapoints),269
Facial Morphology (Segment 1),15
Facial Morphology (Segment 3),5
Facial Morphology (Segment 11),8
Serum Levels Of Protein POFUT2,5
Placenta Growth Factor Levels,5
Phosphatidylcholine 37:3 [M+OAc]1-/Phosphatidylserine 41:2 [M-H]1- Levels,8
Phosphatidylcholine 37:4 [M+H]1+/Phosphatidylethanolamine 40:4 [M+H]1+/Phosphatidate 42:5 [M+NH4]1+ Levels,8
Phosphatidylcholine 37:5 [M+H]1+/Phosphatidylethanolamine 40:5 [M+H]1+/Phosphatidate 42:6 [M+NH4]1+ Levels,8
Thoracic Aortic Aneurysms,12
White Blood Cell Count (Eosinophil),6
Response To Taxane Treatment (Docetaxel),10
Response To Cytidine Analogues (Gemcitabine),10
Serum Levels Of Protein SEPT10,6
Serum IgE Levels,9
Phosphatidylcholine-O(36:3) M+H]1+/Phosphatidylcholine-P(36:2) M+H]1+ Levels,5
Node-level Brain Connectivity (Multivariate Analysis),83
Phosphatidylcholine-O(36:4) [M+H]1+/Phosphatidylcholine-P(36:3) [M+H]1+ Levels,5
Serum Levels Of Protein SIRT2,6
Phosphatidylcholine-O(40:5) [M+H]1+/Phosphatidylcholine-P(40:4) [M+H]1+ Levels,5
Serum Levels Of Protein TMCC3,11
Serum Levels Of Protein TYK2,10
Phosphatidylcholine(34:2) [M+H]1+/Phosphatidylethanolamine(37:2) [M+H]1+/Phosphatidate(39:3) [M+NH4]1+ Levels,5
Phosphatidylcholine(33:3) [M+H]1+/Phosphatidylethanolamine(36:3) [M+H]1+/Phosphatidate(38:4) [M+NH4]1+ Levels,8
Heel Bone Mineral Density T Score,9
Phosphatidylcholine(36:3) [M+OAc]1-/Phosphatidylserine(40:2) [M-H]1- Levels,5
Phosphatidylcholine(36:4) [M+H]1+/Phosphatidylethanolamine(39:4) [M+H]1+/Phosphatidate(41:5) [M+NH4]1+ Levels,5
Phosphatidylcholine(36:5) [M+OAc]1-/Phosphatidylserine(40:4) [M-H]1- Levels,5
Phosphatidylcholine(38:3) [M+H]1+/Phosphatidylethanolamine(41:3) [M+H]1+/Phosphatidate(43:4) [M+NH4]1+ Levels,8
Serum Levels Of Protein GBP6,5
Phosphatidylcholine 38:2 [M+H]1+/Phosphatidylethanolamine 41:2 [M+H]1+ Levels,12
Phosphatidylcholine 38:3 [M+H]1+/Phosphatidylethanolamine 41:3 [M+H]1+/Phosphatidate 43:4 [M+NH4]1+ Levels,11
Language Functional Connectivity,12
White Blood Cell Count (Monocyte),25
Direct Low Density Lipoprotein Cholesterol Levels,12
Vitamin D-binding Protein Levels (Adjusted For GC Haplotype),8
Phosphatidylcholine-O(40:6) [M+H]1+/Phosphatidylcholine-P(40:5) [M+H]1+ Levels,5
Phosphatidylcholine(35:3) [M+H]1+/Phosphatidylethanolamine(38:3) [M+H]1+/Phosphatidate(40:4) [M+NH4]1+ Levels,5
Serum Levels Of Protein VEGFA,5
Phosphatidylcholine(38:2) [M+H]1+/Phosphatidylethanolamine(41:2) [M+H]1+ Levels,7
Phosphatidylcholine(37:4) [M+H]1+/Phosphatidylethanolamine(40:4) [M+H]1+/Phosphatidate(42:5) [M+NH4]1+ Levels,5
Serum Levels Of Protein FRZB,5
Serum Levels Of Protein LGMN,6
Phosphatidylcholine 36:2 [M+OAc]1-/Phosphatidylserine 40:1 [M-H]1- Levels,7
Serum Levels Of Protein MCTS1,8
Phosphatidylcholine 44:5 [M+OAc]1- Levels,5
Phosphatidylcholine 52:4 [M+OAc]1- Levels,5
Phosphatidylcholine-2O 32:0 [M+H]1+ Levels,5
Etiocholanolone Glucuronide Levels,10
Butyrylcarnitine (C4) Levels,5
Glycochenodeoxycholate Glucuronide (1) Levels,8
Deoxycarnitine Levels,6
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) Levels,8
1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) Levels,6
Decadienedioic Acid (C10:2-DC) Levels,6
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) Levels,7
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) Levels,7
1-palmitoyl-GPE (16:0) Levels,5
Pregnenetriol Disulfate Levels,9
Dihomo-linolenoylcarnitine (C20:3n3 Or 6) Levels,9
"5Alpha-Androstan-3Alpha,17Alpha-Diol Monosulfate Levels",8
"5Alpha-Androstan-3Alpha,17Beta-Diol Monosulfate (1) Levels",8
"5Alpha-Androstan-3Beta,17Beta-Diol Monosulfate (2) Levels",5
Androsterone Sulfate Levels,11
Epiandrosterone Sulfate Levels,11
Carnitine Levels,10
1-oleoyl-2-linoleoyl-GPE (18:1/18:2) Levels,5
1-stearoyl-2-linoleoyl-GPE (18:0/18:2) Levels,7
1-Stearoyl-2-Arachidonoyl-Gpc (18:0/20:4) Levels,5
Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] Levels,8
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) Levels,5
Androsterone Glucuronide Levels,7
"Bilirubin (E,E) Levels",10
"Bilirubin (E,Z Or Z,E) Levels",10
Imidazole Lactate Levels,8
3-Methylglutarylcarnitine (2) Levels,8
N-acetylkynurenine (2) Levels,6
N-acetylleucine Levels,7
N-acetylphenylalanine Levels,7
Serum Levels Of Protein SELL,5
Phosphatidylcholine-O 44:5 [M+OAc]1-/Phosphatidylcholine-P 44:4 [M+OAc]1- Levels,8
Serum Levels Of Protein TMEM52B,10
Human Papilloma Virus 16 Positive Oropharyngeal Cancer,8
Human Papilloma Virus 16 Negative Oropharyngeal Cancer,15
Oropharynx Cancer And Human Papilloma Virus 16 Negative Oropharyngeal Cancer,24
Change In High-Sensitivity Cardiac Troponin I Concentration,5
High-sensitivity Cardiac Troponin I Concentration,64
Serum Levels Of Protein GP6,5
Phosphatidylcholine 40:4 [M+H]1+/Phosphatidylethanolamine 43:4 [M+H]1+ Levels,8
Phosphatidylcholine 40:5 [M+H]1+ Levels,8
Phosphatidylcholine 40:6 [M+H]1+/Phosphatidylethanolamine 43:6 [M+H]1+ Levels,7
Serum Levels Of Protein GSTM3,5
Serum Levels Of Protein MRPL58,6
Phosphatidylcholine-O 36:4 [M+H]1+/Phosphatidylcholine-P 36:3 [M+H]1+ Levels,11
White Blood Cell Count (Lymphocyte),6
Phosphatidylcholine-O 38:4 [M+H]1+/Phosphatidylcholine-P 38:3 [M+H]1+ Levels,6
Phosphatidylcholine-O 38:5 [M+H]1+/Phosphatidylcholine-P 38:4 [M+H]1+ Levels,8
Phosphatidylcholine-O 40:5 [M+H]1+/Phosphatidylcholine-P 40:4 [M+H]1+ Levels,8
Serum Phosphate Levels,104
Osteoarthritis (With Total Hip Replacement),19
Phosphatidylcholine(37:4) [M+H]1+/Phosphatidylethanolamine(40:3) [M+H]1+ Levels,5
Serum Levels Of Protein DCUN1D5,5
Phosphatidylcholine 36:3 [M+H]1+/Phosphatidylethanolamine 39:3 [M+H]1+/Phosphatidate 41:4 [M+NH4]1+ Levels,11
Phosphatidylcholine 36:5 [M+H]1+/Phosphatidylethanolamine 39:5 [M+H]1+/Phosphatidate 41:6 [M+NH4]1+ Levels,5
Phosphatidylcholine-O 33:3 [M+H]1+/Phosphatidylcholine-P 33:2 [M+H]1+/Phosphatidylethanolamine-O 36:3 [M+H]1+ Levels,5
Direct Bilirubin Levels,76
Glycated Hemoglobin HbA1c Levels,22
Serum Lipopolysaccharide Activity,5
Serum Levels Of Protein LRP1B,5
Serum Levels Of Protein LRPAP1,5
Serum Levels Of Protein CXCL11,5
Serum Levels Of Protein CTSA,6
Phosphatidylcholine 38:5 [M+H]1+/Phosphatidylethanolamine 41:5 [M+H]1+/Phosphatidate 43:6 [M+NH4]1+ Levels,9
Phosphatidylcholine 38:6 [M+H]1+/Phosphatidylethanolamine 41:6 [M+H]1+ Levels,5
Phosphatidylcholine 39:6 [M+OAc]1- Levels,5
Phosphatidylcholine-O 40:6 [M+H]1+/Phosphatidylcholine-P 40:5 [M+H]1+ Levels,6
Serum Levels Of Protein UGT1A6,9
Left-handedness,31
Mean Spheric Corpuscular Volume,545
BMI X Environmental Factors (Excluding Physical Activity) Interaction,6
Macular Thickness,100
Hypertrophic Cardiomyopathy (Sarcomere Positive),14
Hypertrophic Cardiomyopathy (Sarcomere Negative),18
Neutrophil Percentage Of White Cells,342
CD24 On IgD+ CD24+ B Cell,5
CD27 On IgD- CD38dim B Cell,6
CD27 On Unswitched Memory B Cell,6
CD27 On Switched Memory B Cell,6
CD27 On CD24+ CD27+ B Cell,6
CD40 On Monocytes,5
IDP dMRI TBSS ICVF Genu Of Corpus Callosum,7
IDP dMRI TBSS ICVF Body Of Corpus Callosum,7
IDP dMRI TBSS ICVF Splenium Of Corpus Callosum,8
CD11c On Granulocyte,5
IDP dMRI TBSS ICVF Anterior Corona Radiata R,5
Receptor For Advanced Glycosylation End Products Levels,11
C-C Motif Chemokine 3 Levels,10
C-X-C Motif Chemokine 6 Levels,8
C-X-C Motif Chemokine 16 Levels,19
Agouti-related Protein Levels,10
Proheparin-binding EGF-like Growth Factor Levels,7
Dickkopf-related Protein 1 Levels,10
IDP dMRI ProbtrackX ICVF Ar L,5
IDP dMRI ProbtrackX ICVF Cst L,6
Wg Lh Intensity-Contrast Precuneus,10
Wg Lh Intensity-Contrast Rostralanteriorcingulate,6
Wg Lh Intensity-Contrast Rostralmiddlefrontal,9
Wg Lh Intensity-Contrast Superiorfrontal,6
Wg Lh Intensity-Contrast Insula,6
Wg Lh Intensity-Contrast Superiorparietal,10
Wg Lh Intensity-Contrast Superiortemporal,6
Wg Lh Intensity-Contrast Supramarginal,10
Cognitive Traits (MTAG),21
T Cell Lymphocyte Profile Difference,11
Body Mass Index And Type 2 Diabetes (Pairwise),12
Body Fat Percentage And Type 2 Diabetes (Pairwise),7
Body Mass Index And HDL-C (Pairwise),12
Body Fat Percentage And HDL-C (Pairwise),10
Body Fat Percentage And LDL-C (Pairwise),17
Body Mass Index And Triglycerides (Pairwise),13
Body Mass Index And LDL-C (Pairwise),5
IDP SWI T2star Right Caudate,7
IDP SWI T2star Left Putamen,11
IDP SWI T2star Right Putamen,11
IDP SWI T2star Left Pallidum,9
IDP SWI T2star Left Caudate,7
IDP SWI T2star Right Pallidum,9
Brainstem Global Volume Pons,7
Brainstem Global Volume Whole-brainstem,8
IgD On IgD+ CD24- B Cell,5
IDP dMRI ProbtrackX MD Fmi,6
Aspartate Aminotransferase Platelet Ratio Index In High Alcohol Intake,27
Fibrosis-4 Index In High Alcohol Intake,25
Leftâ€“right Brain Asymmetry,21
IDP dMRI TBSS ICVF Cerebral Peduncle L,7
IDP dMRI TBSS ICVF Anterior Limb Of Internal Capsule R,7
IDP dMRI TBSS ICVF Anterior Limb Of Internal Capsule L,7
Matrix Metalloproteinase-1 Levels,10
Pappalysin-1 Levels,11
Chitinase-3-like Protein 1 Levels,8
ST2 Protein Levels,6
Kidney Injury Molecule 1 Levels,6
TNF-related Activation-Induced Cytokine Levels,6
Pentraxin-related Protein PTX3 Levels,9
Renin Levels,6
Serum 25-Hydroxyvitamin D Level Variance,15
IDP dMRI TBSS ICVF Cingulum Hippocampus R,5
IDP dMRI TBSS ICVF Cingulum Hippocampus L,6
IDP dMRI TBSS ICVF Fornix cres+Stria Terminalis R,5
IDP dMRI TBSS ICVF Fornix cres+Stria Terminalis L,5
Type 1 Diabetes (Age At Diagnosis),23
Stool Frequency,11
Aseg Rh Intensity Putamen,8
Wg Lh Intensity-Contrast Caudalmiddlefrontal,5
Skin Reflectance (Melanin Index),28
Aseg Lh Volume Cerebellum-White-Matter,6
Aseg Global Volume VentricleChoroid,5
Glucose-dependent Insulinotropic Peptide Levels,13
Adipsin Levels In Type 2 Diabetes,10
Adipsin Levels,14
Ghrelin Levels,16
Tinnitus,49
Tinnitus (Severest),6
Cardio-cerebrovascular Disease In Hypertension,7
Coronary Artery Disease In Hypertension,10
Ischemic Stroke In Hypertension,14
Ischemic Stroke In Dyslipidemia,26
LDL Levels X SSRI Defined Daily Dose Interaction In Schizophrenia Or Bipolar Disorder,6
Triglyceride Levels X SSRI Defined Daily Dose Interaction In Schizophrenia Or Bipolar Disorder,10
HOMA-B (Corrected For HOMA-IR),15
Clostridioides Difficle Infection,14
Clostridioides Difficle Infection In Antibiotics-Users,10
Hair Curvature (Quantitative),22
Low Myopia,45
Gut Microbiota Abundance (Order Bifidobacteriales Id.432),10
Gut Microbiota Abundance (Phylum Actinobacteria Id.400),9
Low Myopia Vs Hyperopia,90
Cardio-cerebrovascular Disease In Dyslipidemia,5
Coronary Artery Disease In Dyslipidemia,12
Ischemic Stroke In Diabetes Mellitus,21
LDL Levels X SSRI Levels (Escitalopram Or Citalopram) Interaction In Schizophrenia Or Bipolar Disorder,10
Tea Intake (UKB Data Field 1488),25
Gut Microbiota Abundance (Class Actinobacteria Id.419),10
Gut Microbiota Abundance (Family Bifidobacteriaceae Id.433),10
Glucose-dependent Insulinotropic Peptide Levels In Overweight Individuals,5
Cardio-cerebrovascular Disease In Diabetes Mellitus,15
Mitochondrial Heteroplasmy Measurement,12
Waist-to-hip Ratio Adjusted For BMI (Additive Genetic Model),62
Total Testosterone Levels,413
General Factor Of Neuroticism,71
Neurofibrillary Tangles (SNP X SNP Interaction),30
Asthma (Adult Onset),54
Morning Person,171
Plasma Factor VII Activating Protease Levels,26
Plasma Anastrozole Concentration In Anastrozole-Treated Estrogen Receptor Positive Breast Cancer,11
Tinnitus In Cisplatin-Treated Testicular Cancer,5
Glioblastoma (Age-Stratified),7
Anxiety/tension (Special Factor Of Neuroticism),11
Breast Cancer Specific Mortality In Breast Cancer,18
Breast Cancer Specific Mortality In Estrogen Receptor Negative Breast Cancer,15
Osteolysis In Total Hip Arthroplasty (Time To Prosthesis Revision),8
Anti-Mullerian Hormone Levels In Pre-Menopausal Women Of Late Reproductive Age,8
Monoclonal Gammopathy Of Undetermined Significance,10
Bronchopulmonary Dysplasia In Preterm Infants,6
Estimated Glomerular Filtration Rate After 5 Years In Renal Transplantation (Recipient Effect),5
Thyroglobulin Plasma Levels,5
Alpha Synuclein Levels (MTAG),7
Worry/vulnerability (Special Factor Of Neuroticism),5
Post Bronchodilator Percent Predicted FEV1 In Smoking,8
Neonatal Cytokine/Chemokine Levels (Fetal Genetic Effect),14
Plasma Parathyroid Hormone Levels,21
Cognitive Flexibility,6
Photic Sneeze Reflex,27
Shoulder Impingement Or Rotator Cuff Tear,6
Facial Morphology Traits (63 Three-Dimensional Facial Segments),8
Idiopathic Osteonecrosis Of The Femoral Head,6
Cervical High-Risk Human Papilloma Virus Infection,6
Sick Sinus Syndrome,5
Vegetable Consumption,6
IDP T2 FLAIR BIANCA WMH Volume,5
Wg Rh Intensity-Contrast Superiorfrontal,6
Wg Rh Intensity-Contrast Superiorparietal,8
Wg Rh Intensity-Contrast Superiortemporal,6
Wg Rh Intensity-Contrast Supramarginal,10
Sensitivity To Environmental Stress And Adversity,30
Shigella-associated Diarrhea,8
Cannabis Smoking Or Cigarette Smoking Or Schizophrenia,12
IDP dMRI TBSS FA Splenium Of Corpus Callosum,5
IDP dMRI TBSS MO Pontine Crossing Tract,8
Aerodigestive Squamous Cell Cancer (Pleiotropy),110
Response To Cognitive-Behavioural Therapy In Major Depressive Disorder,7
IDP dMRI TBSS MD Anterior Corona Radiata R,5
IDP dMRI TBSS MD External Capsule L,5
IDP dMRI TBSS MD Anterior Limb Of Internal Capsule L,5
Autoimmune Hepatitis Type-1,7
Low Hand Grip Strength (60 Years And Older) (EWGSOP),16
Childhood Asthma Exacerbations In Long-Acting Beta2-Agonist Treatment,5
Liver Fibrogenesis (Alpha Smooth Muscle Actin Levels),5
Odorant Perception,5
Mean Degree Of Stenosis,9
Sum Of Stenosis,5
Adiponectin Levels X Mediterranean Diet Adherence Interaction,5
Childhood Body Fatness,8
Body Fat Percentage And Triglycerides (Pairwise),10
Wg Rh Intensity-Contrast Posteriorcingulate,6
Wg Rh Intensity-Contrast Precuneus,10
Wg Rh Intensity-Contrast Rostralanteriorcingulate,5
Wg Rh Intensity-Contrast Rostralmiddlefrontal,10
Generalized Anxiety Disorder (Phenotype Risk Score),10
Post-traumatic Stress Disorder (Phenotype Risk Score),23
Generalized Anxiety Disorder (Mental Health Questionnaire Or Predicted),9
Post-traumatic Stress Disorder (Mental Health Questionnaire Or Predicted),25
Body Mass Index And Systole Blood Pressure (Pairwise),9
CD62L- Monocyte Absolute Count,5
Aseg Rh Volume Cerebellum-White-Matter,5
Age-related Hearing Impairment (MTAG),28
Major Depressive Disorder X Sex Interaction,11
Diacylglycerol 38:3 [M+H-H2O]1+ Levels,14
Major Adverse Cardiovascular Events In Response To Aspirin And Clopidogrel Treatment,9
Diacylglycerol 38:4 [M+H-H2O]1+ Levels,10
Diacylglycerol 38:5 [M+H-H2O]1+ Levels,13
"Schizophrenia, Bipolar Disorder Or Major Depressive Disorder X Sex Interaction (3Df)",12
"Schizophrenia, Bipolar Disorder Or Recurrent Major Depressive Disorder X Sex Interaction",14
"Schizophrenia, Bipolar Disorder Or Recurrent Major Depressive Disorder X Sex Interaction (3Df)",8
Diacylglycerol 38:6 [M+H-H2O]1+ Levels,8
Diacylglycerol 42:7 [M+H-H2O]1+ Levels,6
Diacylglycerol 44:7 [M+H-H2O]1+ Levels,8
Corneal Resistance Factor (MTAG),181
Diacylglycerol(36:2) [M+H-H2O]1+ Levels,8
Diacylglycerol(36:3) [M+H-H2O]1+ Levels,7
Phosphatidylcholine(38:5) [M+H]1+/Phosphatidylethanolamine(41:5) [M+H]1+/Phosphatidate(43:6) [M+NH4]1+ Levels,5
Phosphatidylcholine(39:6) [M+OAc]1-/Phosphatidylserine(43:5) [M-H]1- Levels,5
Cholesterol [M+H-H2O]1+ Levels,7
Cholesteryl Ester(16:0) [M+NH4]1+ Levels,7
Cholesteryl Ester(20:5) [M+NH4]1+ Levels,7
Major Depressive Disorder Or Stress-Related Disorder,17
Phosphatidylethanolamine 37:2 [M-H]1- Levels,6
Phosphatidylethanolamine 37:3 [M-H]1- Levels,6
Phosphatidylethanolamine-O 36:5 [M-H]1-/Phosphatidylethanolamine-P 36:4 [M-H]1- Levels,7
Phosphatidylethanolamine-O 38:3 [M-H]1-/Phosphatidylethanolamine-P 38:2 [M-H]1- Levels,6
Phosphatidylethanolamine-O 36:3 [M-H]1-/Phosphatidylethanolamine-P 36:2 [M-H]1- Levels,5
Phosphatidylethanolamine-O 36:4 [M-H]1-/Phosphatidylethanolamine-P 36:3 [M-H]1- Levels,5
Phosphatidylethanolamine-O(38:4) [M-H]1-/Phosphatidylcholine-O(35:4) [M-H]1-/Phosphatidylcholine-P(35:3) [M-H]1- Levels,5
Phosphatidylethanolamine-O(38:6) [M+H]1+/Phosphatidylcholine-P(35:5) [M+H]1+ Levels,5
Phosphatidylcholine(38:3) [M+OAc]1-/Phosphatidylserine(42:2) [M-H]1- Levels,8
Phosphatidylcholine(40:5) [M+H]1+ Levels,5
Phosphatidylcholine(40:5) [M+OAc]1-/Phosphatidylserine(44:4) [M-H]1- Levels,5
Cholesteryl Ester 18:3 [M+NH4]1+ Levels,12
Cholesteryl Ester 20:3 [M+NH4]1+ Levels,14
Cholesteryl Ester(18:3) [M+NH4]1+ Levels,8
Developmental Stuttering,5
Cholesteryl Ester(20:4) [M+NH4]1+ Levels,10
Phosphatidylethanolamine 35:2 [M-H]1- Levels,8
Phosphatidylethanolamine 36:2 [M-H]1- Levels,8
Phosphatidylethanolamine 36:3 [M-H]1- Levels,11
Total Cerebellar Volume (Excluding Crus I Vermis),19
Phosphatidylethanolamine-O 34:3 [M-H]1-/Phosphatidylethanolamine-P 34:2 [M-H]1- Levels,7
Phosphatidylethanolamine 40:6 [M-H]1- Levels,7
Phosphatidylethanolamine 39:4 [M-H]1- Levels,7
Diacylglycerol 34:2 [M+H-H2O]1+ Levels,9
Diacylglycerol 36:2 [M+H-H2O]1+ Levels,10
Phosphatidylcholine(38:4) [M+H]1+/Phosphatidylethanolamine(41:4) [M+H]1+ Levels,5
Sleepwalking,6
Cardiorespiratory Fitness (Vo2 Max),7
Phosphatidylcholine(40:4) [M+OAc]1-/Phosphatidylserine(44:3) [M-H]1- Levels,5
Physical Activity,10
Colorectal Polyp And Colorectal Cancer (MTAG),13
Body Fat Percentage Or Coronary Artery Disease (MTAG),11
Cholesteryl Ester 20:5 [M+NH4]1+ Levels,8
Cholesteryl Ester 22:5 [M+NH4]1+ Levels,5
Cholesteryl Ester 22:6 [M+NH4]1+ Levels,8
Cholesteryl Ester(20:3) [M+NH4]1+ Levels,7
Thyroid Peroxidase Antibody Levels,6
Phosphatidylethanolamine-O 38:5 [M-H]1-/Phosphatidylethanolamine-P 38:4 [M-H]1- Levels,7
Phosphatidylethanolamine-O 38:6 [M-H]1-/Phosphatidylethanolamine-P 38:5 [M-H]1- Levels,5
Alzheimer's Disease In APOE E4+ Carriers,17
Schizophrenia X Sex Interaction,20
Plasma PCSK9 Levels,7
"Schizophrenia, Bipolar Disorder Or Major Depressive Disorder X Sex Interaction",11
"Schizophrenia, Bipolar Disorder Or Major Depressive Disorder",8
Estimated Glomerular Filtration Rate After 1 Year In Renal Transplantation (Recipient Effect),5
Energy Expenditure,6
Breast Cancer Specific Mortality In Estrogen Receptor Positive Breast Cancer,13
Smoking Initiation (Ever Regular Vs Never Regular) (MTAG),401
Clostridium Difficile Infection In Multiple Myeloma,35
Lipid Traits (Pleiotropy) (HIPO Component 1),21
Lipid Traits (Pleiotropy) (HIPO Component 2),7
DNA Methylation Variation (Age Effect),215
Response To Long-Term Oxygen Therapy In Chronic Obstructive Pulmonary Disease,9
Diffusing Capacity Of Carbon Monoxide,35
Cigarettes Smoked Per Day (MTAG),94
Plasma Norclozapine Levels In Treatment-Resistant Schizophrenia,8
Plasma Clozapine Levels In Treatment-Resistant Schizophrenia,6
Cardiac troponin-I Levels,11
Global Electrical Heterogeneity Phenotypes,6
Idiopathic Intracranial Hypertension,12
Social Science Traits (Pleiotropy) (HIPO Component 1),11
Asthma Exacerbations In Inhaled Corticosteroid Treatment,15
Placental Abruption,7
Age Of Smoking Initiation (MTAG),111
Smoking Cessation (MTAG),49
Spine Bone Size,10
Fasting Blood Insulin Adjusted For BMI,6
Upper Eyelid Sagging Severity,14
Lysophosphatidylcholine(20:4) [M+H]1+ Levels,5
Lysophosphatidylethanolamine 18:2 [M-H]1- Levels,7
Neuroticism Conditioned On Educational Attainment (Multi-Trait Conditioning And Joint Analysis),53
Right Unilateral Cleft Lip And Palate,10
Lysophosphatidylethanolamine 20:4 [M-H]1- Levels,11
Left Unilateral Cleft Lip,16
Phosphatidate(39:1) [M+H]1+ Levels,6
Neuroticism Conditioned On Self-Rated Math Ability (Multi-Trait Conditioning And Joint Analysis),44
Phosphatidate(40:5) [M+OAc]1-/Phosphatidylglycerol(39:5) [M-H]1- Levels,5
Phosphatidate(41:2) [M+H]1+ Levels,5
Phosphatidylcholine 31:2 [M+H]1+/Phosphatidylethanolamine 34:2 [M+H]1+/Phosphatidate 36:3 [M+NH4]1+ Levels,11
Phosphatidylcholine 32:0 [M+H]1+/Phosphatidylethanolamine 35:0 [M+H]1+/Phosphatidate 37:1 [M+NH4]1+ Levels,17
Phosphatidylcholine 32:2 [M+H]1+/Phosphatidylethanolamine 35:2 [M+H]1+/Phosphatidate 37:3 [M+NH4]1+ Levels,11
Phosphatidylcholine 32:0 [M+OAc]1- Levels,6
Platelet-to-lymphocyte Ratio,196
Phosphatidylcholine 35:4 [M+H]1+/Phosphatidylethanolamine 38:4 [M+H]1+/Phosphatidate 40:5 [M+NH4]1+ Levels,11
Phosphatidylcholine 35:3 [M+H]1+/Phosphatidylethanolamine 38:3 [M+H]1+/Phosphatidate 40:4 [M+NH4]1+ Levels,12
Phosphatidylcholine 35:5 [M+OAc]1-/Phosphatidylserine 39:4 [M-H]1- Levels,5
HTLV-1 Associated Myelopathy,6
Phosphatidylinositol-O 36:0 [M-H]1- Levels,6
Phosphatidylinositol-O(33:0) [M-H]1- Levels,5
Global Cognition (Clinical Dementia Rating Scale Sum Of Boxes),8
Cognitive Impairment Level,7
Phosphatidylinositol-O(36:0) [M-H]1-/Phosphatidylglycerol(37:0) [M+OAc]1- Levels,6
Phosphatidylethanolamine(34:2) [M+H]1+ Levels,8
Medial Thalamic Nuclei Volume,5
Emphysema,5
Weight Loss In Chronic Obstructive Pulmonary Disease,5
Central Corneal Thickness (MTAG),128
Lymphocyte-to-monocyte Ratio,159
Phosphatidylinositol 36:2 [M-H]1- Levels,10
Phosphatidylinositol 36:2 [M+H]1+ Levels,8
Phosphatidylinositol 34:2 [M-H]1- Levels,10
Nausea Incidence In Varenicline-Treated Smokers,5
Phosphatidylinositol 36:3 [M-H]1- Levels,10
Phosphatidylinositol 35:2 [M-H]1- Levels,5
Lysophosphatidylcholine-O 16:1 [M+H]1+/Lysophosphatidylcholine-P 16:0 [M+H]1+ Levels,9
Lysophosphatidylcholine 22:6 [M+H]1+ Levels,6
Neuroticism Conditioned On Townsend Deprivation Index (Multi-Trait Conditioning And Joint Analysis),64
Lysophosphatidylethanolamine 22:4 [M-H]1- Levels,11
Lysophosphatidylethanolamine-O 18:1 [M-H]1-/Lysophosphatidylethanolamine-P 18:0 [M-H]1- Levels,5
Phosphatidate 34:2 [M-H]1- Levels,5
Neuroticism Conditioned On Average Household Income Before Tax (Multi-Trait Conditioning And Joint Analysis),39
Neuroticism Conditioned On Highest Math Class (Multi-Trait Conditioning And Joint Analysis),51
Phosphatidate(34:2) [M-H]1- Levels,5
Phosphatidate(43:4) [M-H]1- Levels,5
Phosphatidylcholine 35:2 [M+H]1+/Phosphatidylethanolamine 38:2 [M+H]1+/Phosphatidate 40:3 [M+NH4]1+ Levels,8
Executive Function (Trail Making Test B),10
Disability Level (Impaired Activities Of Daily Living),6
Phosphatidylinositol(34:2) [M-H]1- Levels,11
Lysophosphatidylcholine 20:4 [M+H]1+ Levels,13
Right Unilateral Cleft Lip,11
Left Unilateral Cleft Lip And Palate,11
Idiopathic Central Precocious Puberty,10
Hearing Function,11
Hearing Function (Left/Right Asymmetry),6
Recurrence-free Survival In Non-Muscle-Invasive Bladder Cancer,9
Progression-free Survival In Non-Muscle-Invasive Bladder Cancer,5
Phosphatidylcholine 34:2 [M+H]1+/Phosphatidylethanolamine 37:2 [M+H]1+/Phosphatidate 39:3 [M+NH4]1+ Levels,11
Phosphatidylcholine 34:2 [M+OAc]1-/Phosphatidylserine 38:1 [M-H]1- Levels,8
SARS-CoV-2 Infection,16
COVID-19 (Hospitalized Vs Population),91
Opioid Dependence (Time To Event),7
Phosphatidylcholine 34:3 [M+H]1+/Phosphatidylethanolamine 37:3 [M+H]1+/Phosphatidate 39:4 [M+NH4]1+ Levels,7
Phosphatidylcholine 34:4 [M+H]1+/Phosphatidylethanolamine 37:4 [M+H]1+/Phosphatidate 39:5 [M+NH4]1+ Levels,6
Phosphatidylinositol(36:0) [M+OAc]1- Levels,5
Phosphatidylglycerol 34:0 [M-H]1- Levels,5
Phosphatidylglycerol 35:3 [M-H]1- Levels,6
Phosphatidylglycerol 36:0 [M-H]1- Levels,5
Phosphatidylglycerol-O 40:0 [M-H]1- Levels,5
Neutrophil-to-lymphocyte Ratio,96
Fatty Acid(18:4) [M-H]1- Levels,5
Fatty Acid(20:3) [M-H]1- Levels,6
Fatty Acid(20:4) [M-H]1- Levels,11
Neuroticism Conditioned On Cognitive Performance (Multi-Trait Conditioning And Joint Analysis),60
Trunk Fat Mass,46
Fatty Acid(22:4) [M-H]1- Levels,7
Fatty Acid(22:5) [M-H]1- Levels,8
Phosphatidylethanolamine(38:5) [M-H]1- Levels,8
Plasma Amyloid Beta Peptide Concentrations (ABx-40),7
Plasma Amyloid Beta Peptide Concentrations (ABx-42),5
Phosphatidylinositol 35:0 [M-H]1- Levels,5
Phosphatidylinositol 34:0 [M+H]1+ Levels,7
Phosphatidylglycerol(36:0) [M-H]1- Levels,5
Phosphatidylglycerol(35:3) [M-H]1- Levels,5
Sociability Score,9
Phosphatidylglycerol(34:0) [M-H]1- Levels,5
Phosphatidylinositol 38:4 [M-H]1- Levels,10
Phosphatidylinositol 36:4 [M-H]1- Levels,9
Phosphatidylinositol 38:0 [M-H]1- Levels,6
Frailty Index,9
Fatty Acid(22:6) [M-H]1- Levels,5
Phosphatidylcholine(38:4) [M+OAc]1-/Phosphatidylserine(42:3) [M-H]1- Levels,5
Phosphatidylethanolamine 34:2 [M-H]1- Levels,11
Phosphatidylethanolamine 38:3 [M-H]1- Levels,12
Phosphatidylethanolamine 38:4 [M-H]1- Levels,10
Phosphatidylethanolamine 38:2 [M-H]1- Levels,6
Phosphatidylethanolamine-O 40:5 [M-H]1-/Phosphatidylethanolamine-P 40:4 [M-H]1- Levels,7
Phosphatidylethanolamine-O 40:6 [M-H]1-/Phosphatidylethanolamine-P 40:5 [M-H]1- Levels,5
Phosphatidylcholine(40:6) [M+H]1+/Phosphatidylethanolamine(43:6) [M+H]1+ Levels,7
Alanine Aminotransferase Level After Methotrexate Initiation In Rheumatoid Arthritis,10
Cholesteryl Ester 16:0 [M+NH4]1+ Levels,6
Reduction In HbA1c Levels In Response To Sulfonylureas Treatment In Type 2 Diabetes,9
Vertigo,58
Aldosterone Levels,9
Parenchymal Hematoma In Thrombolytic-Treated Acute Ischaemic Stroke,6
Alcohol Consumption X Traumatic Event In Childhood (Felt Hated By Family Member) Interaction,47
Cholesteryl Ester 18:2 [M+NH4]1+ Levels,6
Alcohol Consumption X Experiences In Childhood (Felt Loved By Family Member) Interaction,30
Smoking X Traumatic Event In Childhood (Sexually Molested) Interaction,17
Phosphatidylcholine(40:8) [M+H]1+ Levels,5
Phosphatidylcholine(42:4) [M+OAc]1- Levels,5
Phosphatidylethanolamine 38:5 [M-H]1- Levels,11
Diacylglycerol 34:1 [M+H-H2O]1+ Levels,6
Cholesteryl Ester 14:0 [M+NH4]1+ Levels,5
Anxiety And Stress-Related Disorders,8
Phosphatidylethanolamine 34:0 [M-H]1- Levels,5
Diacylglycerol 36:3 [M+H-H2O]1+ Levels,9
Phosphatidylinositol(36:1) [M+OAc]1- Levels,5
Switch To Non-Stimulant Treatment In ADHD,12
Phosphatidylinositol(36:2) [M-H]1- Levels,14
Bullous Pemphigoid,9
Complement Factor H-related Protein 4 Levels,14
Age At Menopause,127
Phosphatidylinositol(36:3) [M-H]1- Levels,5
Phosphatidylinositol(36:4) [M-H]1- Levels,7
Complement Factor H-like 1 Protein Levels,10
Complement Factor H Measurement,12
Hemolysis Of Donated Blood (Osmotic),12
Phosphatidylinositol(40:6) [M-H]1- Levels,6
Phosphatidylinositol(38:4) [M-H]1- Levels,10
Inflammatory Skin Disease,49
Response To Radiotherapy In Cancer (Late Toxicity),7
Plasma Omega-6 Polyunsaturated Fatty Acid Levels (Adrenic Acid),8
Shingles,37
Toenail Selenium Levels,8
Blood And Toenail Selenium Levels,6
Longevity (90 Years And Older),5
Glycemic Traits (Pregnancy),6
Vitamin B Levels In Ischemic Stroke,6
Illicit Drug Use,9
Behavioural Disinhibition (Generation Interaction),14
Anger,11
Infant Length,9
Alzheimer's Disease (Age Of Onset),10
Serum Thyroid-Stimulating Hormone Levels,15
Plasma Homocysteine Levels (Post-Methionine Load Test),5
Episodic Memory,9
Cannabis Dependence,6
Systolic Blood Pressure In Sickle Cell Anemia,7
Amyotrophic Lateral Sclerosis (Sporadic),63
Social Communication Problems,12
Superior Frontal Gyrus Grey Matter Volume,5
Asymmetrical Dimethylarginine Levels,12
Symmetrical Dimethylarginine Levels,15
Obstructive Sleep Apnea,8
Blood Pressure (Smoking Interaction),18
Red Blood Cell Fatty Acid Levels,11
Conduct Disorder (Symptom Count),10
Conduct Disorder,8
Eosinophilic Esophagitis (Pediatric),6
Plasminogen Activator Inhibitor Type 1 Levels (PAI-1),7
Response To Anti-Retroviral Therapy (ddI/d4T) In HIV-1 Infection (Grade 1 Peripheral Neuropathy),6
Response To Anti-Retroviral Therapy (ddI/d4T) In HIV-1 Infection (Grade 3 Peripheral Neuropathy),9
Response To Anti-Retroviral Therapy (ddI/d4T) In HIV-1 Infection (Grade 2 Peripheral Neuropathy),6
Factor VII Levels,10
Electrodermal Activity,6
Esophageal Squamous Cell Carcinoma,9
Urinary Metabolites (H-NMR Features),7
Bone Properties (Heel),7
Sensory Disturbances After Bilateral Sagittal Split Ramus Osteotomy,5
Bipolar Disorder With Mood-Incongruent Psychosis,11
Homeostasis Model Assessment Of Insulin Resistance (Dietary Factor Interaction),10
Response To Antipsychotic Therapy (Extrapyramidal Side Effects),10
Temperament,14
Aging (Time To Event),5
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis,7
Digit Length Ratio,5
Migraine With Aura,15
Colorectal Cancer (Diet Interaction),7
Preschool Internalizing Problems,8
Chronic Obstructive Pulmonary Disease (Moderate To Severe),5
Asthma (Sex Interaction),5
Breast Cancer (Early Onset),9
Acute Urticaria And Angioedema (Non-Steroidal Anti-Inflammatory Drug-Induced),6
Interferon Alpha Levels In Systemic Lupus Erythematosus,5
Personality Traits In Bipolar Disorder,6
Bilirubin Levels In Extreme Obesity,9
Alcohol Dependence (Age At Onset),17
Myopia,76
Breastfeeding Duration,6
Chronic Mucus Hypersecretion,5
Bipolar Disorder (Body Mass Index Interaction),23
Fractional Exhaled Nitric Oxide (Childhood),12
Airway Responsiveness In Chronic Obstructive Pulmonary Disease,13
Cervical Artery Dissection,6
Thyroid Peroxidase Antibody Positivity,8
Cerebrospinal Fluid Levels Of Alzheimer's Disease-Related Proteins,5
Methotrexate Pharmacokinetics (Acute Lymphoblastic Leukemia),8
Lupus Nephritis In Systemic Lupus Erythematosus,12
Osteoprotegerin Levels,10
Response To Taxane Treatment (Placlitaxel),7
Response To Cytadine Analogues (Cytosine Arabinoside),11
Airway Wall Thickness,5
"Bone Mineral Density (Paediatric, Skull)",6
Psychosis (Atypical),10
Bronchopulmonary Dysplasia,18
Crohn's Disease-Related Phenotypes,6
Tourette's Syndrome Or Obsessive-Compulsive Disorder,7
Urgency Urinary Incontinence,5
Beta-2 Microglubulin Plasma Levels,6
Cytomegalovirus Antibody Response,7
Febrile Seizures,13
Febrile Seizures (MMR Vaccine-Unrelated),5
Febrile Seizures (MMR Vaccine-Related),10
Serum Dimethylarginine Levels (Asymmetric/Symetric Ratio),16
Anti-saccade Response,17
Asthma And Hay Fever,11
Lung Function (Forced Vital Capacity),172
Elevated Serum Carcinoembryonic Antigen Levels,9
PR Segment Duration,6
Very Long-Chain Saturated Fatty Acid Levels (Fatty Acid 20:0),13
Age-related Nuclear Cataracts,13
Lipoprotein (A) - Cholesterol Levels,8
Plasma Renin Activity Levels,6
Urate Levels In Lean Individuals,22
Urate Levels (BMI Interaction),9
Cutaneous Lupus Erythematosus,5
Polychlorinated Biphenyl Levels,26
Lifespan,7
Creutzfeldt-Jakob Disease (Sporadic),5
Type 1 Diabetes And Autoimmune Thyroid Diseases,11
Diisocyanate-induced Asthma,101
Complement C3 And C4 Levels,7
Response To Methotrexate In Juvenile Idiopathic Arthritis,10
Cardiac Troponin-T Levels,21
Systemic Lupus Erythematosus And Systemic Sclerosis,13
Heschl's Gyrus Morphology,17
Maximal Oxygen Uptake Response,5
Urate Levels In Overweight Individuals,20
Urate Levels In Obese Individuals,20
Sitting Height Ratio,20
Response To Serotonin Reuptake Inhibitors In Major Depressive Disorder,13
Total Bilirubin Levels In HIV-1 Infection,10
Survival In Rectal Cancer,7
Acute Anterior Uveitis (With Or Without Ankylosing Spondylitis),9
Cocaine Dependence,14
IgE Levels In Asthmatics,5
Response To Efavirenz-Containing Treatment In HIV 1 Infection (Virologic Failure),15
Response To Abacavir-Containing Treatment In HIV-1 Infection (Virologic Failure),14
Chronic Obstructive Pulmonary Disease-Related Biomarkers,19
Motion Sickness,21
Response To Chemotherapy In Breast Cancer Hypertensive Cases (Cumulative Dose) (Bevacizumab),8
Iron Status Biomarkers (Transferrin Levels),6
Mammographic Density,5
Thiazide-induced Adverse Metabolic Effects In Hypertensive Patients,36
Sickle Cell Anemia (Haemolysis),5
Gastritis,7
Lead Levels In Blood,12
Verbal Declarative Memory,15
Proinsulin Levels,7
Alzheimer's Disease (Survival Time),6
Parkinson Disease And Lewy Body Pathology,6
Homoarginine Levels,6
Clozapine-induced Cytotoxicity,8
Lipoprotein(a) Levels Adjusted For Apolipoprotein(A) Isoforms,7
Cold Sores,21
Mumps,36
IgG Sialylation Phenotypes (Multivariate Analysis),5
IgG Galactosylation Phenotypes (Multivariate Analysis),7
IgG Fucosylation Phenotypes (Multivariate Analysis),5
IgG Digalactosylation Phenotypes (Multivariate Analysis),5
Urinary Tract Infection Frequency,35
Chronic Sinus Infection,28
Number Of Common Colds,20
Hepatitis A,18
Rheumatic Fever,17
Subjective Well-Being (MTAG),31
Neuroticism (MTAG),18
Autism Spectrum Disorder Or Schizophrenia,127
Pneumonia,45
Conotruncal Heart Defects (Maternal Effects),13
Left Ventricular Obstructive Tract Defect (Inherited Effect),10
Left Ventricular Obstructive Tract Defect (Maternal Effect),5
Borderline Personality Disorder,13
Congenital Heart Disease (Maternal Effect),9
Chickenpox,16
Alcohol Consumption In Current Drinkers,7
Plantar Warts,32
Strep Throat,29
Scarlet Fever,35
Peripheral Arterial Disease (Traffic-Related Air Pollution Interaction),88
Childhood Ear Infection,49
"1,5-Anhydroglucitol Levels",5
Heart Rate Variability Traits (RMSSD),8
Heart Rate Variability Traits (SDNN),9
Rubella,23
Mononucleosis,24
Waist-to-hip Ratio Adjusted For BMI X Sex X Age Interaction (4Df Test),49
Basophil Percentage Of Granulocytes,33
GIP Levels In Response To Oral Glucose Tolerance Test (120 Minutes),9
Pursuit Maintenance Gain In Psychotic Disorders,7
Initial Pursuit Acceleration,22
Major Depression And Alcohol Dependence,25
Craniofacial Microsomia,11
Blood Osmolality (Transformed Sodium),18
Heart Rate Response To Recovery Post Exercise (40 Sec),7
Heart Rate Response To Recovery Post Exercise (50 Sec),10
Heart Rate Response To Recovery Post Exercise (30 Sec),6
Heart Rate Response To Recovery Post Exercise (20 Sec),7
Heart Rate Response To Recovery Post Exercise (10 Sec),6
Decline In Glucose Metabolism In Posterior Cingulate Cortex,8
Body Mass Index (Age <50),9
Waist-to-hip Ratio Adjusted For BMI (Age <50),7
Body Mass Index (Age>50),5
Progression Free Survival In Serous Epithelial Ovarian Cancer Treated With Carboplatin And Paclitaxel,22
Initial Pursuit Acceleration In Psychotic Disorders,12
Pursuit Maintenance Gain,46
Colorectal Adenoma (Advanced),23
Colonoscopy-negative Controls Vs Population Controls,73
Waist-to-hip Ratio Adjusted For BMI X Sex Interaction,14
Waist-to-hip Ratio Adjusted For BMI (Age >50),9
Paclitaxel Disposition In Epithelial Ovarian Cancer,17
Carboplatin Disposition In Epthelial Ovarian Cancer,9
Severe Malaria (Adjusted For Sickle Cell Variant Rs334),8
C-reactive Protein Levels Or LDL-cholesterol Levels (Pleiotropy),14
C-reactive Protein Levels Or Total Cholesterol Levels (Pleiotropy),14
Response To Paliperidone In Schizophrenia (Positive Marder Score),29
Response To Paliperidone In Schizophrenia (Negative Marder Score),33
Response To Paliperidone In Schizophrenia (PANSS Score),31
"Caffeine Metabolism (Plasma 1,7-Dimethylxanthine (Paraxanthine) To 1,3,7-Trimethylxanthine (Caffeine) Ratio)",9
Prostate-specific Antigen Levels (Conditioned On Lead SNPs),14
Chin Dimples,24
Age At Voice Drop,7
Body Mass Index (Change Over Time) In Chronic Obstructive Pulmonary Disease,5
Left Atrial Antero-Posterior Diameter,11
Erythrocyte Cadmium Concentration In Never Smokers,8
Venous Thromboembolism Adjusted For Sickle Cell Variant rs77121243-T,48
C-reactive Protein Levels Or Triglyceride Levels (Pleiotropy),13
C-reactive Protein Levels Or HDL-cholesterol Levels (Pleiotropy),13
Response To Paliperidone In Schizophrenia (Multivariate),19
Response To Paliperidone In Schizophrenia (CGI-S Score),16
Gut Microbiota (Functional Units),28
Allergy,18
Midgestational Circulating Levels Of PBDEs,5
Midgestational Circulating Levels Of PBDEs (Fetal Genetic Effect),7
Midgestational Circulating Levels Of PCBs,6
Urea Levels,108
Monobrow,33
Joint Mobility (Beighton Score),19
Nose Size,10
Incident Atrial Fibrillation,5
Prevalent Atrial Fibrillation,6
Small Cell Lung Carcinoma,35
Estrone/androstenedione Ratio In Resected Early Stage-Receptor Positive Breast Cancer,5
"Facial Morphology (Factor 4, Facial Height Related To Vertical Position Of Gnathion)",8
"Facial Morphology (Factor 5, Width Of Mouth Relative To Central Midface)",9
"Facial Morphology (Factor 6, Height Of Vermillion Lower Lip)",12
"Facial Morphology (Factor 2, Vertical Position Of Orbits Relative To Midface)",5
Facial Morphology (Factor 20),7
Facial Morphology (Factor 19),16
Residual Cognition,5
Time-dependent Creatinine Clearance Change Response To Tenofovir Treatment In HIV Infection (Time And Treatment Arm Interaction),19
Waist Circumference Adjusted For BMI (Adjusted For Smoking Behaviour),56
Obstetric Antiphospholipid Syndrome,7
Body Mass Index (Adult),8
6-Month Creatinine Clearance Change Response To Tenofovir Treatment In HIV Infection (Treatment Arm Interaction),17
Blood Pressure Traits (Multi-Trait Analysis),13
Tenofovir Clearance In HIV Infection,21
Bilirubin Levels In Tenofovir-Treated HIV Infection,10
Waist-to-hip Ratio Adjusted For BMI (Adjusted For Smoking Behaviour),38
Juvenile Idiopathic Arthritis (Oligoarticular Or Rheumatoid Factor-Negative Polyarticular),25
Immunoglobulin Light Chain (AL) Amyloidosis,10
Hashimoto Thyroiditis,13
Autoimmune Thyroid Diseases (Graves Disease Or Hashimoto's Thyroiditis),7
Caudate Activity During Reward,16
Fear Of Severe Pain,6
Fear Of Minor Pain,13
Myringotomy,23
Measles,19
Yeast Infection,28
Lung Cancer In Ever Smokers,68
Neurocognitive Impairment In HIV-1 Infection (Continuous),5
Neurocognitive Impairment In HIV-1 Infection (Dichotomous),7
"Facial Morphology (Factor 1, Breadth Of Lateral Portion Of Upper Face)",9
"Facial Morphology (Factor 10, Width Of Nasal Floor)",6
"Facial Morphology (Factor 15, Philtrum Width)",18
Facial Morphology (Factor 16),12
"Facial Morphology (Factor 17, Height Of Vermillion Upper Lip)",11
Facial Morphology (Factor 18),12
"Facial Morphology (Factor 3, Length Of Philtrum)",5
"Facial Morphology (Factor 8, Orbital Inclination Due To Vertical And Horizontal Position Of Exocanthion)",8
"Facial Morphology (Factor 9, Facial Height Related To Vertical Position Of Nasion)",11
"Facial Morphology (Factor 11, Projection Of The Nose)",11
"Facial Morphology (Factor 12, Vertical Position Of Sublabial Sulcus Relative To Central Midface)",9
"Facial Morphology (Factor 13, Vertical Position Of Alar Curvature Relative To Upper Lip)",10
"Facial Morphology (Factor 14, Intercanthal Width)",10
"Facial Morphology (Factor 21, Depth Of Nasal Alae)",8
"Facial Morphology (Factor 7, Width Of Cartilaginous Portion Of Nose)",6
Facial Morphology (Factor 22),11
Facial Morphology (Factor 23),8
Itch Intensity From Mosquito Bite,55
Language Performance In Older Adults (Adjusted For Episodic Memory),7
Bone Ultrasound Measurement (Broadband Ultrasound Attenuation),10
Bone Ultrasound Measurement (Velocity Of Sound),9
Total Lipid Levels In Large VLDL,60
Concentration Of Large VLDL Particles,59
"Glycosyl Ceramide (D18:2/24:1, D18:1/24:2) Levels In Elite Athletes",5
Hexanoylglutamine Levels In Elite Athletes,5
Medication Use (Drugs Used In Diabetes),107
Maleate Levels In Elite Athletes,7
Angina Pectoris,47
Ceramide (D20:1/24:1) Levels,5
Dehydrocholesteryl Ester (18:2) Levels,6
Dehydrocholesteryl Ester (20:4) Levels,6
Phospholipids To Total Lipids Ratio In Large VLDL,55
Octanoylcarnitine (C8) Levels In Elite Athletes,7
A Body Shape Index,410
Estimated Glomerular Filtration Rate (Creatinine),734
Pregnanediol-3-glucuronide Levels In Elite Athletes,8
Pregnenolone Sulfate Levels In Elite Athletes,5
Smoking Status,115
Self-reported Math Ability (MTAG),440
Free Cholesterol Levels In LDL,42
Gro-gamma Level In Chronic Kidney Disease With Hypertension And No Diabetes (2986 49),5
Lysophosphatidylcholine (15-MHDA) [Sn2] Levels,5
Lysophosphatidylcholine (18:2) [Sn1] Levels,5
Monohexosylceramide (D18:2/24:0) Levels,5
Palmitoylcarnitine (C16) Levels In Elite Athletes,6
Lysophosphatidylethanolamine (18:2) [Sn1] Levels,5
Lysophosphatidylethanolamine (18:2) [Sn2] Levels,5
S100 Calcium-Binding Protein Levels,13
Concentration Of LDL Particles,46
Phospholipid Levels In LDL,38
Histidylalanine Levels In Elite Athletes,8
Salicylate Levels In Elite Athletes,5
Sarcosine Levels In Elite Athletes,16
C-X-C Motif Chemokine 6 Level In Chronic Kidney Disease With Hypertension And No Diabetes (3495 15),8
Ceramide (D16:1/24:0) Levels,6
Ceramide (D16:1/24:1) Levels,6
Ceramide (D17:1/16:0) Levels,6
Ceramide (D17:1/18:0) Levels,5
Ceramide (D16:1/20:0) Levels,8
Ceramide (D16:1/22:0) Levels,6
Lactosyl-N-nervonoyl-sphingosine (D18:1/24:1) Levels In Elite Athletes,6
Medication Use (Antimigraine Preparations),8
"Medication Use (Adrenergics, Inhalants)",39
Medication Use (Glucocorticoids),19
Medication Use (Antihistamines For Systemic Use),7
Medication Use (Antiglaucoma Preparations And Miotics),16
Aortic Aneurysm,5
Medication Use (Drugs Affecting Bone Structure And Mineralization),11
Medication Use (Salicylic Acid And Derivatives),21
Ceramide (D19:1/20:0) Levels,7
Ceramide (D19:1/22:0) Levels,5
N-oleoyltaurine Levels In Elite Athletes,5
Chronic Heart Failure,5
Dihexosylceramide (D16:1/16:0) Levels,8
Dihexosylceramide (D16:1/24:1) Levels,5
Bell's Palsy,29
Monohexosylceramide (D16:1/20:0) Levels,6
Monohexosylceramide (D16:1/22:0) Levels,7
Monohexosylceramide (D16:1/24:0) Levels,5
Ratio Of Linoleic Acid To Total Fatty Acids,29
"Sphingomyelin (D18:1/22:2, D18:2/22:1, D16:1/24:2) Levels In Elite Athletes",6
"Sphingomyelin (D18:1/25:0, D19:0/24:1, D20:1/23:0, D19:1/24:0) Levels In Elite Athletes",12
Lysoalkenylphosphatidylcholine (P-16:0) Levels,5
Lysophosphatidylethanolamine (16:0) [Sn1] Levels,6
Pyridoxate Levels In Elite Athletes,10
Pyroglutamine Levels In Elite Athletes,5
Total Lipid Levels In LDL,41
Pediatric Asthma,24
Phosphatidylcholine (16:0 18:2) Levels,5
Phosphatidylcholine (16:0 20:3) (A) Levels,7
Average Diameter For LDL Particles,28
"1,3-Dimethylurate Levels In Elite Athletes",5
3-(3-Hydroxyphenyl)Propionate Sulfate Levels In Elite Athletes,5
Phosphatidylcholine (17:0 20:4) Levels,10
Ceramide (D18:2/20:0) Levels,5
Ceramide (D19:1/16:0) Levels,5
Ceramide (D19:1/18:0) Levels,6
Ceramide (D19:1/26:0) Levels,5
Triglyceride Levels In LDL,70
Cholesteryl Ester (20:3) Levels,6
Cholesteryl Ester (20:4) Levels,8
Lactosyl-N-behenoyl-sphingosine (D18:1/22:0) Levels In Elite Athletes,11
Medication Use (Beta Blocking Agents),60
Medication Use (Calcium Channel Blockers),114
Medication Use (Antithrombotic Agents),24
Medication Use (Vasodilators Used In Cardiac Diseases),18
Medication Use (Antihypertensives),7
Medication Use (Diuretics),73
Margaroylcarnitine Levels In Elite Athletes,7
Diacylglycerol (18:1 20:3) Levels,11
Diacylglycerol (18:1 20:4) Levels,9
Oleoyl-oleoyl-glycerol (18:1/18:1) [2] Levels In Elite Athletes,9
Vertex-wise Sulcal Depth,576
Cholelithiasis,47
Colon Polyp,30
Trihexosylcermide (D18:1/24:0) Levels,6
Trihexosylcermide (D18:1/24:1) Levels,5
"Sphingomyelin (D18:1/20:2, D18:2/20:1, D16:1/22:2) Levels In Elite Athletes",5
Octadecanedioate Levels In Elite Athletes,5
Gro-beta Level In Chronic Kidney Disease With Hypertension And No Diabetes (3148 49),5
Lysophosphatidylethanolamine (16:0) [Sn2] Levels,6
Quinate Levels In Elite Athletes,10
Serum Levels Of Protein IGF1,6
Serum Levels Of Protein IGFBP3,5
IGF-1 And IGFBP-3 Levels (Bivariate Analysis),8
Phosphatidylcholine (16:0 20:4) Levels,11
Phosphatidylcholine (16:0 20:5) Levels,6
Phosphatidylcholine (16:1 18:2) Levels,6
Cholesteryl Ester (20:5) Levels,6
Cholesteryl Ester (22:5) (N6) Levels,5
Cholesteryl Ester (24:4) Levels,6
Cholesteryl Ester (24:5) Levels,5
Ceramide (D16:1/16:0) Levels,5
Ceramide (D16:1/18:0) Levels,6
Ceramide (D18:1/20:0) Levels,5
Ceramide (D18:1/24:1) Levels,8
Back Pain,22
Diacylglycerol (18:2 20:4) Levels,5
Gastric Polyp,5
Cholesteryl Ester Levels In LDL,41
Monohexosylceramide (D18:1/22:0) Levels,5
Monohexosylceramide (D18:1/24:0) Levels,8
Oxalate (Ethanedioate) Levels In Elite Athletes,5
"Sphingomyelin (D18:2/16:0, D18:1/16:1) Levels In Elite Athletes",5
"Sphingomyelin (D18:2/21:0, D16:2/23:0) Levels In Elite Athletes",5
Dihydroorotate Levels In Elite Athletes,5
Pro-hydroxy-pro Levels In Elite Athletes,8
N1-methylinosine Levels In Elite Athletes,6
Radiation-Induced Toxicity (Physician-Rated Acute Mucositis),7
Lysophosphatidylcholine (22:5) [Sn1] (N6) Levels,5
Lysophosphatidylcholine (20:4) [Sn2] Levels,7
Radiation-Induced Toxicity (Physician-Rated Acute Dysphagia),6
N6-carbamoylthreonyladenosine Levels In Elite Athletes,7
Radiation-Induced Toxicity (Standardized Total Average Toxicity Patient),5
Gro-gamma Level In Chronic Kidney Disease With Hypertension And No Diabetes (22973 8),5
Laurylcarnitine (C12) Levels In Elite Athletes,5
Leukotriene B4 Levels In Elite Athletes,5
Medication Use (HMG CoA Reductase Inhibitors),104
Medication Use (Thyroid Preparations),101
Medication Use (Agents Acting On The Renin-Angiotensin System),140
Diacylglycerol (16:0 20:4) Levels,6
Oleoyl-oleoyl-glycerol (18:1/18:1) [1] Levels In Elite Athletes,8
N-acetylmethionine Levels In Elite Athletes,5
Relapse After Allogeneic Hematopoietic Cell Transplantation (Donor Effect),5
Cholecystitis,12
Trihexosylcermide (D18:1/18:0) Levels,6
Triglycerides To Total Lipids Ratio In Large VLDL,44
Trihexosylcermide (D18:1/20:0) Levels,6
Trihexosylcermide (D18:1/22:0) Levels,6
"Sphingomyelin (D18:1/18:1, D18:2/18:0) Levels In Elite Athletes",5
Paraxanthine Levels In Elite Athletes,6
Phosphatidylcholine (15:0 20:3) Levels,6
Phosphatidylcholine (15:0 20:4) Levels,12
Leucylglycine Levels In Elite Athletes,10
Serine Levels In Elite Athletes,6
Supranormal Left Ventricular Ejection Fraction,11
Indoleacetate Levels In Elite Athletes,5
Biological Age (PhenoAge),9
Ceramide (D17:1/24:1) Levels,6
N-acetylglycine Levels In Elite Athletes,5
Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] Levels In Elite Athletes,5
Dihexosylceramide (D18:1/24:0) Levels,7
Dihexosylceramide (D18:1/24:1) Levels,6
Goiter,11
Monohexosylceramide (D18:1/24:1) Levels,5
Monohexosylceramide (D18:2/22:0) Levels,6
P-cresol Sulfate Levels In Elite Athletes,6
Lysophosphatidylethanolamine (18:0) [Sn2] Levels,6
Lysophosphatidylethanolamine (18:1) [Sn1] Levels,5
Lysophosphatidylethanolamine (18:1) [Sn2] Levels,7
Lysophosphatidylethanolamine (18:0) [Sn1] Levels,5
Ceramide (D17:1/20:0) Levels,5
Linolenoylcarnitine (C18:3) Levels In Elite Athletes,5
Acute Pancreatitis,9
N-acetyl-beta-alanine Levels In Elite Athletes,5
N-acetylarginine Levels In Elite Athletes,6
Eotaxin Level In Chronic Kidney Disease With Hypertension And No Diabetes (5301 7),5
Dihexosylceramide (D18:1/22:0) Levels,5
COVID-19 (Covid Vs Negative),144
Lysophosphatidylcholine (20:3) [Sn1] Levels,9
Lysophosphatidylcholine (20:3) [Sn2] Levels,10
Lysophosphatidylcholine (20:4) [Sn1] Levels,5
Phenyllactate (PLA) Levels In Elite Athletes,5
2'-Deoxyuridine Levels In Elite Athletes,5
2'-O-methyluridine Levels In Elite Athletes,5
Peripheral Blood CD34+ Cell Levels,6
Ovarian Cyst,5
Phosphatidylcholine (15-MHDA 18:2) Levels,5
Stable Angina Pectoris,39
Random Glucose Levels,14
Albumin Levels,120
Waist-hip Index,625
Femur Bone Mineral Density X Serum Urate Levels Interaction,8
DNA Methylation PhenoAge Acceleration,12
Metabolic Biomarkers (Multivariate Analysis),180
Alzheimer's Disease Or Gastroesophageal Reflux Disease,111
"Hair Colour (Natural, Before Greying): Blonde (UKB Data Field 1747 1)",20
"Hair Colour (Natural, Before Greying): Red (UKB Data Field 1747 2)",33
Cystatin C Plasma Levels,8
Cardiovascular Disease,227
L1-L4 Bone Mineral Density X Serum Urate Levels Interaction,10
Sphingomyelin(32:1) [M+H]1+ Levels,10
Frozen Shoulder,5
Total Protein Levels X Insomnia Interaction,59
Sphingomyelin(37:1) [M+H]1+ Levels,7
Respiratory Diseases,80
Retinal Vascular Fractal Dimension,91
Hip Index,255
Triacylglycerol 56:4 [M+NH4]1+ Levels,6
Triacylglycerol 56:5 [M+NH4]1+ Levels,7
Triacylglycerol 52:3 [M+NH4]1+ Levels,5
Triacylglycerol 52:6 [M+NH4]1+ Levels,6
Triacylglycerol 54:7 [M+NH4]1+ Levels,5
Triacylglycerol 52:2 [M+NH4]1+ Levels,5
Triacylglycerol(56:4) [M+NH4]1+ Levels,7
DNA Methylation-Estimated Plasminogen Activator Inhibitor-1 Levels,15
Bisoprolol Clearance In non-ST Elevation Acute Coronary Syndrome,13
Hearing Difficulty/Problems: No (UKB Data Field 2247 0),5
Hearing Difficulty/Problems: Yes (UKB Data Field 2247 1),5
Serine To Glycine Ratio,5
Dyslipidemia,20
Cognitive Function (Processing Speed) X Major Depressive Disorder Interaction (2Df),17
Cognitive Function (Global Cognition) X Major Depressive Disorder Interaction (2Df),5
Mild Obesity-Related Type 2 Diabetes,8
Mild Age-Related Type 2 Diabetes,16
Brain rsFMRI Measurement (Amplitude Of Low Frequency Fluctations) (Net25 Node21),5
Decaffeinated Coffee Consumption Or Major Depression Disorder,15
Decaffeinated Coffee Consumption And/Or Neuroticism,17
Decaffeinated Coffee Consumption And/Or Insomnia,6
COVID-19,127
Ascending Aorta Diameter,73
Ocular Disease,27
Alzheimer's Disease Or Peptic Ulcer Disease,18
Alzheimer's Disease Or Gastroesophageal Reflux Disease And/Or Peptic Ulcer Disease,8
"Hair Colour (Natural, Before Greying): Black (UKB Data Field 1747 5)",5
"Hair Colour (Natural, Before Greying): Dark Brown (UKB Data Field 1747 4)",28
Cognitive Function (Executive Function) X Major Depressive Disorder Interaction (1Df),9
Cognitive Function (Executive Function) X Major Depressive Disorder Interaction (2Df),16
Cognitive Function (Delayed Memory),11
DNA Methylation Hannum Age Acceleration,11
DNA Methylation GrimAge Acceleration,12
Neonatal Abstinence Syndrome,26
Carotid Artery Intima-Media Thickness In Type 2 Diabetes,5
Coronary Artery Calcification In Type 2 Diabetes (Excluding Prevalent Cardiovascular Disease),5
Cognitive Function (Processing Speed) X Major Depressive Disorder Interaction (1Df),7
Severe Autoimmune Type 2 Diabetes,10
Severe Insulin-Deficient Type 2 Diabetes,6
Severe Insulin-Resistant Type 2 Diabetes,6
Platelet Response To Aspirin,13
Low Testosterone Levels,22
Direct Bilirubin Levels X Insomnia Interaction,11
Total Bilirubin Levels X Insomnia Interaction,11
Sphingomyelin(39:1) [M+H]1+ Levels,6
Retinal Vascular Fractal Density,91
Sphingomyelin(44:9) [M+H]1- Levels,6
Triacylglycerol(54:3) [M+NH4]1+ Levels,7
Type Ii Diabetes,19
Stimulant Dependence,5
Cleft Lip With Or Without Cleft Palate Or Cleft Palate (Pleiotropy),5
Hearing Function (2 kHz),10
Hearing Function (8 kHz),9
PCSK9 Levels,15
Triacylglycerol 58:7 [M+NH4]1+ Levels,8
Triacylglycerol 58:8 [M+NH4]1+ Levels,5
Triacylglycerol 58:10 [M+NH4]1+ Levels,7
Triacylglycerol 58:9 [M+NH4]1+ Levels,7
Triacylglycerol(56:6) [M+NH4]1+ Levels,6
Conotruncal Heart Defects With Normally Related Great Vessels (Without 22Q.11.2 Deletion Syndrome),14
Conotruncal Heart Defects With Normally Related Great Vessels,8
Chronic Widespread Musculoskeletal Pain,7
Human Milk Oligosaccharide Concentration (lacto-N-fucopentaose III) In Non-Secretors,26
Human Milk Oligosaccharide Concentration (lacto-N-fucopentaose III) In Secretors,8
Parkinson's Disease Motor Subtype (Tremor To Postural Instability/Gait Difficulty Score Ratio),13
Triacylglycerol 46:5 [M+NH4]1+ Levels,5
Triacylglycerol 45:4 [M+NH4]1+ Levels,8
Triacylglycerol(58:9) [M+NH4]1+ Levels,5
Triacylglycerol(56:7) [M+NH4]1+ Levels,5
Sphingomyelin 40:2 [M+H]1+ Levels,5
Sphingomyelin(38:1) [M+H]1+ Levels,5
Liver Iron Content,7
Pancreas Volume,5
Kidney Volume,8
Spleen Volume,28
Progression Free Survival In Epithelial Ovarian Cancer,10
Progression Free Survival In Serous Epithelial Ovarian Cancer,11
DNA Methylation-Estimated Granulocyte Proportions,15
Cognitive Performance (MTAG),365
COVID-19 (Hospitalized Covid Vs Population),57
COVID-19 (Hospitalized Vs Not Hospitalized),74
COVID-19 (Covid Respiratory Support Vs Population),48
Lifetime Smoking,78
Aspartate Aminotransferase To Alanine Aminotransferase Ratio,134
Liver Volume,7
Triacylglycerol 56:7 [M+NH4]1+ Levels,8
Triacylglycerol 56:8 [M+NH4]1+ Levels,6
Triacylglycerol 56:6 [M+NH4]1+ Levels,10
Progression Free Survival In Epithelial Ovarian Cancer Treated With Carboplatin And Paclitaxel,18
COVID-19 (Covid Pneumonia Vs Population),38
COVID-19 (Severe Respiratory Symptoms Vs Population),29
Medium Chain Acylcarnitines Levels (Additive Genetic Model),7
Short-chain Dicarboxylacylcarnitine Levels (Additive Genetic Model),8
Medium Chain Acylcarnitines Levels (Dominant Genetic Model),6
Long-chain Dicarboxylacylcarnitines Levels (Additive Genetic Model),5
Short-chain Dicarboxylacylcarnitine Levels (Dominant Genetic Model),8
Facial Morphology (Segment 9),5
X-11530 Levels,9
X-24849 Levels,9
X-11522 Levels,9
X-21448 Levels,11
X-24747 Levels,7
X-13431 Levels,5
X-21441 Levels,15
Glycocholenate Sulfate Levels,5
Lifetime Smoking (Without Educational Attainment),36
Occupational Attainment,19
Facial Morphology (Segment 2),9
Facial Morphology (Segment 5),5
Facial Morphology (Segment 7),6
Age Related Hearing Loss-Related Regional Glucose Metabolism (Bilateral Heschlâ€™s Gyrus),6
Age Related Hearing Loss-Related Regional Glucose Metabolism (Inferior Colliculus),9
Endometriosis Or Asthma (Pleiotropy),37
Familial Combined Hyperlipidemia Defined By Brunzell Criteria,20
Familial Combined Hyperlipidemia Defined By Goldstein Criteria,10
Familial Combined Hyperlipidemia Defined By Dutch Criteria,47
Cholesterol To Total Lipids Ratio In Medium HDL,61
Sphingomyelin (D18:0/22:0) Levels,5
Sphingomyelin (D18:1/14:0) levels/Sphingomyelin (D16:1/16:0) Levels,6
Sphingomyelin (D18:1/20:0) levels/Sphingomyelin (D16:1/22:0) Levels,5
Urinary Uromodulin Levels (Indexed To Creatinine),26
Estriol Levels,6
Cholesteryl Esters To Total Lipids Ratio In Medium HDL,63
Unstable Angina Pectoris,21
Total Lysoalkenylphosphatidylcholine Levels,5
Total Lysophosphatidylethanolamine Levels,5
Free Cholesterol To Total Lipids Ratio In Medium HDL,63
Alkenylphosphatidylethanolamine (P-19:0/20:4) (A) Levels,7
Alkenylphosphatidylethanolamine (P-20:0/18:2) Levels,7
Alkenylphosphatidylethanolamine (P-20:0/20:4) Levels,5
Alkenylphosphatidylethanolamine (P-20:1/20:4) Levels,7
Spinal Canal Stenosis,7
Sphingomyelin (D16:1/23:0) levels/Sphingomyelin (D17:1/22:0) Levels,5
Glycosphingolipids (D42:2) Levels,10
Sphingomyelin (D32:2) Levels,17
White Matter Mean Diffusivity X Age Interaction (2Df),16
Sphingomyelin (D19:1/24:1) Levels,5
Glycosphingolipids (D40:1) Levels,11
Glycosphingolipids (D41:1) Levels,10
Glycosphingolipids (D42:1) Levels,8
Phosphatidylethanolamine (17:0 20:4) Levels,5
Phosphatidylethanolamine (18:0 18:1) Levels,5
Phosphatidylethanolamine (18:0 18:2) Levels,10
Phosphatidylethanolamine (18:0 20:3) (A) Levels,11
Phosphatidylethanolamine (18:0 20:4) Levels,5
Acylcarnitine (18:1) Levels,9
Acylcarnitine (18:2) Levels,5
Phosphatidylethanolamine (16:0 18:3) (A) Levels,7
Phosphatidylethanolamine (16:0 18:3) (B) Levels,5
Phosphatidylethanolamine (16:0 20:3) Levels,10
Phosphatidylethanolamine (16:1 18:2) Levels,6
Phosphatidylethanolamine (17:0 18:1) Levels,5
Phosphatidylethanolamine (17:0 18:2) Levels,7
Vertex-wise Cortical Surface Area,427
Sphingomyelin (D18:0/16:0) Levels,5
Phospholipids To Total Lipids Ratio In Medium HDL,64
Cholesteryl Ester Levels In Medium HDL,55
Glycosphingolipids (D38:1) Levels,8
Phosphatidylcholine (20:0 20:4) Levels,7
Phosphatidylcholine (38:2) Levels,5
Phosphatidylcholine (38:5) (A) Levels,6
Phosphatidylcholine (38:5) (B) Levels,12
Phosphatidylcholine (38:6) (A) Levels,5
Alkylphosphatidylcholine (O-18:0/20:4) Levels,5
Total Phosphatidylinositol Levels,6
Total Alkyldiacylglycerol Levels,6
Total Trihexosylcermide Levels,5
Uterine Prolapse,6
Circulating Levels Of Total-Tau,10
Cholesteryl Ester (16:0) Levels,5
Phosphatidylethanolamine (18:1 18:1) Levels,5
Phosphatidylethanolamine (18:1 18:2) Levels,10
Phosphatidylethanolamine (18:1 22:6) (A) Levels,5
Alkenylphosphatidylethanolamine (P-16:0/20:3) (A) Levels,10
Alkenylphosphatidylethanolamine (P-18:0/20:3) (A) Levels,10
Alkenylphosphatidylethanolamine (P-18:1/20:3) (A) Levels,8
Alkenylphosphatidylethanolamine (P-18:1/20:3) (B) Levels,5
Total Lipid Levels In Medium HDL,50
Fornix Volume,5
Brain Age (Difference Between Predicted And Chronological Age),6
Urinary Uromodulin Levels (Raw),18
Sphingomyelin (D17:1/16:0) Levels,5
Androstenediol Levels,8
Cholesteryl Ester (18:3) Levels,8
Phosphatidylethanolamine (38:6) Levels,5
Sphingomyelin (D43:1) Levels,7
Predicted Developmental Stuttering,49
Alkyldiacylglycerol (O-50:1) [NL-16:0] Levels,7
Alkyldiacylglycerol (O-52:2) [NL-16:0] Levels,5
Total Cholesteryl Ester Levels,7
Total Phosphatidylethanolamine Levels,6
Phosphatidylinositol (36:2) Levels,6
Phosphatidylcholines (36:3E)1 Levels,5
Phosphatidylcholines (37:4) Levels,10
Phosphatidylcholines (38:4)A Levels,7
Phosphatidylcholine (17:1 18:2) Levels,5
Phosphatidylcholine (18:0 20:3) Levels,5
Phosphatidylcholine (18:0 20:4) Levels,13
Phosphatidylcholine (18:1 20:3) Levels,11
Triacylglycerol (56:6) [NL-20:4] Levels,9
Triacylglycerol (56:8) [NL-20:4] Levels,5
Cerebrospinal Fluid Amyloid Beta 42 Levels (12 Month Visit),5
Total Monohexosylceramide Levels,6
Alkenylphosphatidylcholine (P-20:0/20:4) Levels,8
Alkenylphosphatidylcholine (P-38:5) (A) Levels,8
Alkenylphosphatidylcholine (P-38:5) (B) Levels,6
Phosphatidylethanolamine (15-MHDA 18:1) Levels,7
Phosphatidylethanolamine (15-MHDA 18:2) Levels,10
Phosphatidylethanolamine (16:0 16:1) Levels,5
Phosphatidylethanolamine (16:0 18:1) Levels,5
Phosphatidylethanolamine (16:0 18:2) Levels,8
Phosphatidylinositol (15-MHDA 20:4) levels/Phosphatidylinositol (17:0 20:4) Levels,7
Phosphatidylinositol (16:0 20:3) (A) Levels,7
Phosphatidylinositol (15-MHDA 18:2) levels/Phosphatidylinositol (17:0 18:2) Levels,5
Phosphatidylinositol (18:0 18:1) Levels,7
Phosphatidylinositol (18:0 20:2) Levels,7
Phosphatidylinositol (18:0 20:3) (A) Levels,7
Phosphatidylinositol (18:0 20:4) Levels,9
Skin Cancer,38
Phosphatidylcholines (38:4)C Levels,5
Sphingomyelin (D43:2) Levels,7
Total Free Cholesterol Levels,51
Acylcarnitine (12:0) Levels,5
Acylcarnitine (16:0) Levels,8
Alkylphosphatidylcholine (O-38:5) Levels,5
Alkylphosphatidylcholine (O-40:5) Levels,5
Alkenylphosphatidylcholine (P-16:0/20:4) Levels,6
Alkenylphosphatidylcholine (P-17:0/20:4) (A) Levels,7
Alkenylphosphatidylcholine (P-17:0/20:4) (B) Levels,7
Alkenylphosphatidylcholine (P-18:0/20:4) Levels,8
Alkenylphosphatidylcholine (P-18:0/22:5) Levels,6
COVID-19 (Critical Illness Vs Population Or Mild Symptoms),23
Executive Function (Longitudinal),16
Cognitive Performance (Visuoconstruction),11
Executive Function,19
Triglycerides To Total Lipids Ratio In Medium HDL,53
Cholesterol Levels In Medium LDL,36
Cognitive Performance (Language Ability) (Longitudinal),19
Cognitive Function (Delayed Memory) (Longitudinal),9
Cutaneous Melanoma (MTAG),39
Cholesterol To Total Lipids Ratio In Medium LDL,28
Cognitive Function (Immediate Memory),9
Cognitive Function (Immediate Memory) (Longitudinal),29
Vaginal Microbiome MetaCyc Pathway (CATECHOL-ORTHO-CLEAVAGE-PWY|catechol Degradation To &Beta;-Ketoadipate),22
White Matter Lesions (Fazekas Score),19
Cholesteryl Esters To Total Lipids Ratio In Medium LDL,32
Free Cholesterol Levels In Medium LDL,39
Vaginal Microbiome MetaCyc Pathway (KDO-NAGLIPASYN-PWY|superpathway Of (Kdo)2-lipid A Biosynthesis),17
Actinic Keratosis,12
"Vaginal Microbiome MetaCyc Pathway (P125-PWY|superpathway Of (R,R)-butanediol Biosynthesis)",8
Vaginal Microbiome MetaCyc Pathway (P562-PWY|myo-inositol Degradation I),11
Concentration Of Medium LDL Particles,37
BMI At Birth,7
BMI At 3 Months Old,8
BMI At 6 Months Old,12
Alkenylphosphatidylethanolamine (P-18:0/20:5) Levels,5
Triglyceride Levels In Medium HDL,53
Cognitive Performance (Attention),11
Cognitive Performance (Attention) (Longitudinal),11
Cognitive Performance (Language Ability),15
Global Cognition (Mini Mental State Examination),25
Vaginal Microbiome MetaCyc Pathway (COMPLETE-ARO-PWY|superpathway Of Aromatic Amino Acid Biosynthesis),5
Vaginal Microbiome MetaCyc Pathway (ENTBACSYN-PWY|enterobactin Biosynthesis),19
Global Cognition (Mini Mental State Examination) (Longitudinal),30
Right Hippocampal Volume,11
Cholesteryl Ester Levels In Medium LDL,36
Vaginal Microbiome MetaCyc Pathway (LEU-DEG2-PWY|L-leucine Degradation I),7
Vaginal Microbiome MetaCyc Pathway (METH-ACETATE-PWY|methanogenesis From Acetate),17
Free Cholesterol To Total Lipids Ratio In Medium LDL,65
Total Lipid Levels In Medium LDL,37
Vaginal Microbiome MetaCyc Pathway (PROTOCATECHUATE-ORTHO-CLEAVAGE-PWY|protocatechuate Degradation II (Ortho-Cleavage Pathway)),11
COVID-19 (Critical Illness Vs Mild Symptoms),5
Cognitive Performance (Visuoconstruction) (Longitudinal),21
Vaginal Microbiome MetaCyc Pathway (ALL-CHORISMATE-PWY|superpathway Of Chorismate Metabolism),7
Cardiovascular Delta Age (Difference Between ECG-predicted And Chronological Age),15
Vaginal Microbiome MetaCyc Pathway (FUC-RHAMCAT-PWY|superpathway Of Fucose And Rhamnose Degradation),13
Vaginal Microbiome MetaCyc Pathway (FUCCAT-PWY|fucose Degradation),13
Vaginal Microbiome MetaCyc Pathway (NAD-BIOSYNTHESIS-II|NAD Salvage Pathway II),14
Vaginal Microbiome MetaCyc Pathway (P381-PWY|adenosylcobalamin Biosynthesis II (Late Cobalt Incorporation)),10
Phospholipids To Total Lipids Ratio In Medium LDL,34
BMI At 8 Months Old,14
Vaginal Microbiome MetaCyc Pathway (PWY-1622|formaldehyde Assimilation I (Serine Pathway)),24
Vaginal Microbiome MetaCyc Pathway (PWY-181|photorespiration),5
Vaginal Microbiome MetaCyc Pathway (PWY-1861|formaldehyde Assimilation II (RuMP Cycle)),6
BMI At 1 Year Old,14
Phosphatidylcholine (36:0) Levels,5
Phosphatidylcholine (40:7) (A) Levels,7
Alkenylphosphatidylcholine (P-36:3) Levels,7
Cholesteryl Ester (20:2) Levels,6
Vaginal Microbiome MetaCyc Pathway (GLUCOSE1PMETAB-PWY|glucose And Glucose-1-Phosphate Degradation),8
Vaginal Microbiome MetaCyc Pathway (GLUCUROCAT-PWY|superpathway Of &beta;-D-glucuronide And D-glucuronate Degradation),7
Vaginal Microbiome MetaCyc Pathway (NONOXIPENT-PWY|pentose Phosphate Pathway (Non-Oxidative Branch)),5
Vaginal Microbiome MetaCyc Pathway (P221-PWY|octane Oxidation),16
Vaginal Microbiome MetaCyc Pathway (P163-PWY|L-lysine Fermentation To Acetate And Butanoate),10
Acylcarnitine (15:0) (B) Levels,6
Acylcarnitine (17:0) (B) Levels,7
Acylcarnitine (18:0) Levels,7
Vaginal Microbiome Beta Diversity (Unweighted Unifrac),8
Vaginal Microbiome Beta Diversity (Weighted Unifrac),5
Vaginal Microbiome Beta Diversity (Bray-curtis Dissimilarity),6
Vaginal Microbiome MetaCyc Pathway (FAO-PWY|fatty Acid &Beta;-Oxidation I),8
Vaginal Microbiome MetaCyc Pathway (FASYN-INITIAL-PWY|superpathway Of Fatty Acid Biosynthesis Initiation (E. Coli)),6
"Vaginal Microbiome MetaCyc Pathway (GOLPDLCAT-PWY|superpathway Of Glycerol Degradation To 1,3-Propanediol)",6
Triglyceride Levels In Medium LDL,66
Triglycerides To Total Lipids Ratio In Medium LDL,52
QTc Interval,27
Cholesterol To Total Lipids Ratio In Medium VLDL,64
Vaginal Microbiome MetaCyc Pathway (PWY-5741|ethylmalonyl-CoA Pathway),28
Vaginal Microbiome MetaCyc Pathway (PWY-5747|2-methylcitrate Cycle II),12
Vaginal Microbiome MetaCyc Pathway (PWY-5860|superpathway Of Demethylmenaquinol-6 Biosynthesis I),14
Vaginal Microbiome MetaCyc Pathway (PWY-5861|superpathway Of Demethylmenaquinol-8 Biosynthesis),10
Vaginal Microbiome MetaCyc Pathway (PWY-5896|superpathway Of Menaquinol-10 Biosynthesis),13
Free Cholesterol To Total Lipids Ratio In Medium VLDL,59
"Vaginal Microbiome MetaCyc Pathway (PWY-6383|mono-trans, Poly-Cis Decaprenyl Phosphate Biosynthesis)",5
"Vaginal Microbiome MetaCyc Pathway (PWY-6396|superpathway Of 2,3-Butanediol Biosynthesis)",7
Vaginal Microbiome MetaCyc Pathway (PWY-6507|4-deoxy-L-threo-hex-4-enopyranuronate Degradation),8
Vaginal Microbiome MetaCyc Pathway (PWY-6519|8-amino-7-oxononanoate Biosynthesis I),5
Vaginal Microbiome MetaCyc Pathway (PWY-6562|norspermidine Biosynthesis),18
Vaginal Microbiome MetaCyc Pathway (PWY-5180|toluene Degradation I (Aerobic) (Via O-Cresol)),19
Vaginal Microbiome MetaCyc Pathway (PWY-5005|biotin Biosynthesis II),15
Vaginal Microbiome MetaCyc Pathway (PWY-5022|4-aminobutanoate Degradation V),6
Hexanoylcarnitine Levels (Biocrates Platform),6
Vaginal Microbiome MetaCyc Pathway (PWY-5182|toluene Degradation II (Aerobic) (Via 4-Methylcatechol)),15
Vaginal Microbiome MetaCyc Pathway (PWY-5415|catechol Degradation I (Meta-Cleavage Pathway)),15
Cholesteryl Ester Levels In Medium VLDL,44
"Vaginal Microbiome MetaCyc Pathway (PWY-5837|1,4-dihydroxy-2-naphthoate Biosynthesis I)",9
Vaginal Microbiome MetaCyc Pathway (PWY-5838|superpathway Of Menaquinol-8 Biosynthesis I),5
Vaginal Microbiome MetaCyc Pathway (PWY-5845|superpathway Of Menaquinol-9 Biosynthesis),14
Vaginal Microbiome MetaCyc Pathway (PWY-5855|ubiquinol-7 Biosynthesis (Prokaryotic)),6
Vaginal Microbiome MetaCyc Pathway (PWY-5856|ubiquinol-9 Biosynthesis (Prokaryotic)),5
Vaginal Microbiome MetaCyc Pathway (PWY-5850|superpathway Of Menaquinol-6 Biosynthesis I),14
Cholesteryl Esters To Total Lipids Ratio In Medium VLDL,61
Vaginal Microbiome MetaCyc Pathway (PWY-5863|superpathway Of Phylloquinol Biosynthesis),10
Highest Math Class Taken,211
BMI At 2 Years Old,7
BMI At 5 Years Old,8
BMI At 7 Years Old,7
BMI At 1.5 Years Old,10
BMI At 8 Years Old,7
X-11793 Levels,8
X-12844 Levels,6
Cholesterol Levels In Medium VLDL,45
Vaginal Microbiome MetaCyc Pathway (PWY-5384|sucrose Degradation IV (Sucrose Phosphorylase)),5
Rheumatoid Arthritis (Rheumatoid Factor And Anti-Cyclic Citrullinated Peptide Seronegative),5
Vaginal Microbiome MetaCyc Pathway (PWY-5705|allantoin Degradation To Glyoxylate III),20
Vaginal Microbiome MetaCyc Pathway (PWY-5862|superpathway Of Demethylmenaquinol-9 Biosynthesis),15
Vaginal Microbiome MetaCyc Pathway (PWY-6397|mycolyl-arabinogalactan-peptidoglycan Complex Biosynthesis),13
Sphingomyeline C16:0 Levels,11
Sphingomyeline C16:1 Levels,5
Sphingomyeline C18:0 Levels,13
Succinylcarnitine Levels,5
Isobutyrylcarnitine (C4) Levels,6
Phosphatidylcholine Diacyl C36:2 Levels,6
Phosphatidylcholine Diacyl C36:4 Levels,5
Phosphatidylcholine Diacyl C36:5 Levels,6
Phosphatidylcholine Diacyl C38:3 Levels,5
Phosphatidylcholine Diacyl C38:4 Levels,6
Phosphatidylcholine Diacyl C38:5 Levels,8
Phosphatidylcholine Acyl-Alkyl C34:2 Levels,6
Phosphatidylcholine Acyl-Alkyl C36:2 Levels,5
Phosphatidylcholine Acyl-Alkyl C36:3 Levels,5
Phosphatidylcholine Acyl-Alkyl C36:5 Levels,6
Vaginal Microbiome MetaCyc Pathway (PWY-5304|superpathway Of Sulfur Oxidation (Acidianus Ambivalens)),6
Estimated Glomerular Filtration Rate (Cystatin C),111
Vaginal Microbiome MetaCyc Pathway (PWY-7332|superpathway Of UDP-N-acetylglucosamine-derived O-antigen Building Blocks Biosynthesis),7
"Vaginal Microbiome MetaCyc Pathway (PWY-7371|1,4-dihydroxy-6-naphthoate Biosynthesis II)",11
Vertex-wise Cortical Thickness,405
F-sharp Flavour Liking (Derived Food-Liking Factor),15
Shellfish Liking,15
Descending Aorta Minimum Area,16
Vaginal Microbiome MetaCyc Pathway (PWY-7373|superpathway Of Demethylmenaquinol-6 Biosynthesis II),11
F-small Fish Liking (Derived Food-Liking Factor),14
Smoked Fish Liking,9
"Vaginal Microbiome MetaCyc Pathway (PWY-7376|cob(II)yrinate A,C-Diamide Biosynthesis II (Late Cobalt Incorporation))",10
Spicy Food Liking,8
F-strong Flavour Liking (Derived Food-Liking Factor),20
Triglycerides To Total Lipids Ratio In Medium VLDL,65
Vaginal Microbiome MetaCyc Pathway (PWY-7456|mannan Degradation),8
Vaginal Microbiome MetaCyc Pathway (PWY-7664|oleate Biosynthesis IV (Anaerobic)),6
Vaginal Microbiome MetaCyc Pathway (PWY-7431|aromatic Biogenic Amine Degradation (Bacteria)),6
F-strong Vegetable Liking (Derived Food-Liking Factor),14
F-sweet Food Liking (Derived Food-Liking Factor),10
Vaginal Microbiome MetaCyc Pathway (PWY0-1241|ADP-L-glycero-&beta;-D-manno-heptose Biosynthesis),6
Total Lipid Levels In Medium VLDL,52
Vaginal Microbiome MetaCyc Pathway (PWY-6708|ubiquinol-8 Biosynthesis (Prokaryotic)),8
Vaginal Microbiome MetaCyc Pathway (PWY-6749|CMP-legionaminate Biosynthesis I),11
F-highly Palatable Foods Liking (Derived Food-Liking Factor),10
Lager Liking,5
Lamb Liking,5
Vaginal Microbiome MetaCyc Pathway (PWY-7007|methyl Ketone Biosynthesis),10
"Vaginal Microbiome MetaCyc Pathway (PWY-7013|L-1,2-propanediol Degradation)",13
F-acquired Taste Liking (Derived Food-Liking Factor),21
Facial Wrinkles (Crow'S Feet),11
F-oily Fish Liking (Derived Food-Liking Factor),6
Milky Sweets Liking,7
Phospholipids To Total Lipids Ratio In Medium VLDL,50
Ascending Aorta Maximum Area,51
"Vaginal Microbiome MetaCyc Pathway (PWY-7159|chlorophyllide A Biosynthesis III (Aerobic, Light Independent))",24
Salami Liking,8
F-salty Food Liking (Derived Food-Liking Factor),8
Salty Food Liking,11
Descending Aorta Maximum Area (MTAG),24
Ascending Aorta Minimum Area,51
F-savoury Food Liking (Derived Food-Liking Factor),13
F-savour/caloric Food Liking (Derived Food-Liking Factor),7
F-seafood Liking (Derived Food-Liking Factor),17
"Vaginal Microbiome MetaCyc Pathway (PWY-7237|myo-, Chiro- And Scillo-Inositol Degradation)",9
Vaginal Microbiome MetaCyc Pathway (PWY-7315|dTDP-N-acetylthomosamine Biosynthesis),6
Concentration Of Medium VLDL Particles,49
Vaginal Microbiome MetaCyc Pathway (PWY-6897|thiamin Salvage II),6
Herring Liking,9
Grapefruit Liking,7
Horseradish Liking,12
Vaginal Microbiome MetaCyc Pathway (PWY-7094|fatty Acid Salvage),5
Mackerel Liking,8
Liver Liking,7
Facial Wrinkles (Under Eye),9
F-salad Vegetables Liking (Derived Food-Liking Factor),5
Raw Carrot Liking,8
Descending Aorta Maximum Area,31
Ascending Aorta Distensibility,10
Descending Aorta Distensibility,7
Sardines Liking,10
Ascending Aorta Distensibility (MTAG),11
Descending Aorta Distensibility (MTAG),8
Ascending Aorta Maximum Area (MTAG),36
Serum Uromodulin Levels (Aptamer-Based Assay),12
F-vegetarian Liking (Derived Food-Liking Factor),10
F-wine Liking (Derived Food-Liking Factor),6
Vaginal Microbiome MetaCyc Pathway (PWY0-1533|methylphosphonate Degradation I),10
Alcohol Liking,6
Beans Liking,5
F-bitter Food Liking (Derived Food-Liking Factor),7
Monounsaturated Fatty Acid Levels,66
Avocado Liking,7
Baked/steamed Fish Liking,5
Broad Bean Liking,6
F-burn/spicy Liking (Derived Food-Liking Factor),8
Vaginal Microbiome MetaCyc Pathway (PWY0-321|phenylacetate Degradation I (Aerobic)),20
Vaginal Microbiome MetaCyc Pathway (PWY0-42|2-methylcitrate Cycle I),11
F-caffeinated/sweet Liking (Derived Food-Liking Factor),5
F-cake/biscuits Liking (Derived Food-Liking Factor),10
Cake Icing Liking,6
Vaginal Microbiome MetaCyc Pathway (PWY0-845|superpathway Of Pyridoxal 5'-Phosphate Biosynthesis And Salvage),5
Vaginal Microbiome MetaCyc Pathway (PWY1G-0|mycothiol Biosynthesis),11
Capers Liking,8
F-capsicum Liking (Derived Food-Liking Factor),10
Vaginal Microbiome MetaCyc Pathway (PWY490-3|nitrate Reduction VI (Assimilatory)),5
Ratio Of Monounsaturated Fatty Acids To Total Fatty Acids,60
Age Related Hearing Loss-Related Regional Glucose Metabolism (Cochlear Nucleus),7
Gestational Diabetes Mellitus,10
Phosphatidylserine 40:3 [M+H]1+/Phosphatidylglycerol 40:5 [M+NH4]1+ Levels,6
Phosphatidylserine 40:5 [M+H]1+/Phosphatidylglycerol 40:7 [M+NH4]1+ Levels,6
Phosphatidylserine-P 42:1 [M+H]1+/Phosphatidylglycerol-P 42:6 [M+NH4]1+ Levels,5
Phosphatidylserine(35:2) [M+OAc]1- Levels,5
Phosphatidylserine(42:5) [M+OAc]1- Levels,5
Phosphatidylserine(42:7) [M+OAc]1- Levels,5
Phosphatidylserine(44:6) [M+OAc]1- Levels,5
Sphingomyelin 32:1 [M+H]1+ Levels,8
Sphingomyelin 33:1 [M+H]1+ Levels,7
Sphingomyelin 34:0 [M+H]1+ Levels,7
Sphingomyelin 34:1 [M+H]1+ Levels,7
Sphingomyelin 39:1 [M+H]1+ Levels,9
Sphingomyelin 38:2 [M+H]1+ Levels,9
Sphingomyelin 38:1 [M+H]1+ Levels,15
Sphingomyelin 34:2 [M+H]1+ Levels,9
Sphingomyelin 36:0 [M+H]1+ Levels,7
Sphingomyelin 36:1 [M+H]1+ Levels,6
Sphingomyelin 36:2 [M+H]1+ Levels,11
Sphingomyelin 37:1 [M+H]1+ Levels,5
Pancreas Fat,7
Cholesterol Levels In Large HDL,70
Whole Brain Restricted Isotropic Diffusion (Multivariate Analysis),202
Testis-expressed Sequence 29 Protein Levels (TEX29.10557.6.3),5
Cholesterol To Total Lipids Ratio In Large HDL,65
Torsin-1A-interacting Protein 1 Levels (TOR1AIP1.9039.47.3),5
Inter-alpha-trypsin Inhibitor Heavy Chain H1 Levels (ITIH1.7955.195.3),5
Cholesteryl Ester Levels In Large HDL,72
Self-reported Math Ability,326
Tumor Necrosis Factor Receptor Superfamily Member 16 Levels (NGFR.8949.3.3),5
Cholesteryl Esters To Total Lipids Ratio In Large HDL,60
Killer Cell Immunoglobulin-Like Receptor 2DL5A Levels (KIR2DL5A.8000.17.3),5
Whole Brain Restricted Directional Diffusion (Multivariate Analysis),180
Protein Z-dependent Protease Inhibitor Levels (SERPINA10.13119.26.3),5
Protein-tyrosine Kinase 6 Levels (PTK6.3832.51.1),8
Cholesteryl Esters To Total Lipids Ratio In IDL,55
Conversion From Active Surveillance To Active Treatment In Prostate Cancer,10
Retinol Dehydrogenase 16 Levels (RDH16.12881.17.3),9
Free Cholesterol To Total Lipids Ratio In IDL,34
Total Lipid Levels In IDL,46
Concentration Of IDL Particles,41
Phospholipid Levels In IDL,48
Phospholipids To Total Lipids Ratio In IDL,36
Testosterone Levels In Postmenopausal Women,45
Sex Hormone-Binding Globulin Levels In Postmenopausal Women,120
Triglycerides To Total Lipids Ratio In IDL,63
Sex Hormone-Binding Globulin Levels In Premenopausal Women,36
Detectable Estradiol Levels,10
Testosterone Levels In Premenopausal Women,29
Testis-specific Chromodomain Protein Y 1 Levels (CDY1.7097.8.3),8
Thioredoxin Domain-Containing Protein 12 Levels (TXNDC12.4815.25.3),7
Atopic Dermatitis (Moderate To Severe),14
Verbal Learning,23
Coagulation Factor VII Levels,6
Apolipoprotein A-I Levels,6
Interleukin-10 Receptor Subunit Alpha Levels,7
Neutrophil Collagenase Levels,5
Highest Math Class Taken (MTAG),644
Omega-6 Fatty Acid Levels,53
Vaginal Microbiome Relative Abundance (G Dialister),5
Vaginal Microbiome Relative Abundance (G Megasphaera),6
Vaginal Microbiome Relative Abundance (G Anaerococcus),5
Verbal Learning (Visual Presentation),7
Ratio Of Omega-6 Fatty Acids To Total Fatty Acids,43
Vaginal Microbiome Relative Abundance (S Aerococcus Christensenii),17
Vaginal Microbiome Relative Abundance (S Dialister Micraerophilus),9
"Remnant Cholesterol (non-HDL, non-LDL -Cholesterol)",44
Phospholipid Levels In Small HDL,44
Phospholipids To Total Lipids Ratio In Small HDL,39
"Superoxide Dismutase [Mn], Mitochondrial Levels",5
Scavenger Receptor Cysteine-Rich Type 1 Protein M130 Levels,5
NAD-dependent Protein Deacetylase Sirtuin-2 Levels,5
Hemopexin Levels,6
Leisure Screen Time,63
Fractalkine Levels,5
Kunitz-type Protease Inhibitor 1 Levels,5
Hepatocyte Growth Factor Receptor Levels,6
Triglycerides To Total Lipids Ratio In Small HDL,59
Cholesterol Levels In Small LDL,40
Ascending Thoracic Aortic Diameter,65
Free Cholesterol Levels In Small LDL,42
Free Cholesterol To Total Lipids Ratio In Small LDL,56
Calpastatin Levels,5
Ck-beta-8-1 Levels,7
CD209 Antigen Levels,6
C-C Motif Chemokine 1 Levels,6
Moderate-to-vigorous Intensity Physical Activity During Leisure Time,6
Depression (Age Of Onset),16
Kunitz-type Protease Inhibitor 2 Levels,8
"Tyrosine-protein Kinase Receptor Tie-1, Soluble Levels",5
Moderate-to-vigorous Intensity Physical Activity During Leisure Time (MTAG),8
Cholesterol To Total Lipids Ratio In Small LDL,27
Descending Thoracic Aortic Diameter,43
Proprotein Convertase Subtilisin/Kexin Type 7 Levels,8
ICOS Ligand Levels,5
CMRF35-like Molecule 6 Levels,5
Ectonucleoside Triphosphate Diphosphohydrolase 5 Levels,15
Gremlin-1 Levels,5
MHC Class I Polypeptide-Related Sequence B Levels,14
Neurogenic Locus Notch Homolog Protein 1 Levels,5
Tumor Necrosis Factor Receptor Superfamily Member 19L Levels,7
Cholesteryl Ester Levels In Small LDL,38
Dodecanoylcarnitine Levels,5
Aspartate Levels,7
Decanoylcarnitine Levels,6
Butyrylcarnitine Levels,9
Hexanoylcarnitine Levels,6
Octanoylcarnitine Levels,6
Acetylcarnitine Levels,6
Serine Levels,8
lysoPhosphatidylcholine Acyl C20:3 Levels,5
Phosphatidylcholine Diacyl C34:4 Levels,6
Cholesteryl Esters To Total Lipids Ratio In Small HDL,43
Tetradecenoylcarnitine Levels,7
Proline Levels,5
Free Cholesterol Levels In Small HDL,43
Propionylcarnitine Levels,9
Histidine Levels,27
Phenylalanine Levels,15
Facial Phenotypes (Nasion To Pogonion),5
Facial Phenotypes (Subnasale To Right Alare),5
Facial Phenotypes (Nasal Bridge Height),5
Concentration Of Medium HDL Particles,54
Interleukin-23 Levels,5
Leucine-rich Repeat Serine/Threonine-Protein Kinase 2 Levels,6
Heat Shock Protein Beta-1 Levels,5
Apolipoprotein L1 Levels,13
ICD10 K44: Diaphragmatic Hernia,7
Complement Factor D Levels,6
Vitamin K-dependent Protein C Levels,6
C-C Motif Chemokine 14 Levels,7
Hepatocyte Growth Factor-Like Protein Levels,24
Interleukin-17 Receptor B Levels,5
Interleukin-22 Receptor Subunit Alpha-2 Levels,5
Interleukin-23 Receptor Levels,5
Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 Levels,8
Cholesteryl Esters To Total Lipids Ratio In Small LDL,44
Natural Cytotoxicity Triggering Receptor 3 Levels,5
Post-traumatic Stress Disorder (MTAG),7
DNA Repair Protein RAD51 Homolog 1 Levels,5
Intercellular Adhesion Molecule 1 Levels,12
Intercellular Adhesion Molecule 5 Levels,7
Sialic Acid-Binding Ig-like Lectin 14 Levels,5
Total Cerebellar Volume,8
Phospholipid Levels In Very Large HDL,57
Total Lipid Levels In Small HDL,43
Phospholipid Levels In Large LDL,40
Triglyceride Levels In Chylomicrons And Extremely Large VLDL,49
Alanine Levels,44
Average Diameter For HDL Particles,73
Citrate Levels,34
Concentration Of Small HDL Particles,40
Glucose Levels,105
Glutamine Levels,40
Pyruvate Levels,23
Valine Levels,21
Platelet Glycoprotein 4 Levels,5
Desmoglein-1 Levels,6
Tumor Necrosis Factor Receptor Superfamily Member EDAR Levels,10
C-X-C Motif Chemokine 5 Levels,6
Serum Amyloid A-1 Protein Levels,11
Ectonucleoside Triphosphate Diphosphohydrolase 3 Levels,5
Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2 Levels,5
Killer Cell Immunoglobulin-Like Receptor 2DL4 Levels,5
Non-receptor Tyrosine-Protein Kinase TYK2 Levels,9
Breast Cancer Anti-Estrogen Resistance Protein 3 Levels,6
Copine-1 Levels,7
Metabolite Peak Levels (QI11739),8
Arginine Levels,10
Time To Recovery From Peripheral Sensory Neuropathy In Colon Cancer,6
Oxaliplatin-induced Allergic Reactions In Colon Cancer,12
Alpha-2-Macroglobulin Receptor-Associated Protein Levels,7
Galactoside 3(4)-L-fucosyltransferase Levels,5
Hepatocyte Growth Factor Activator Levels,6
Extracellular Matrix Protein 1 Levels,8
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Levels,9
Fetuin-B Levels,5
Cystatin-F Levels,12
Lactoperoxidase Levels,6
Granulins Levels,6
Vaginal Microbiome MetaCyc Pathway (TYRFUMCAT-PWY|L-tyrosine Degradation I),12
Vaginal Microbiome MetaCyc Pathway (UBISYN-PWY|superpathway Of Ubiquinol-8 Biosynthesis (Prokaryotic)),5
Vaginal Microbiome Presence (C Actinobacteria),5
Total Cholesterol Minus HDL-C Levels,43
F-fatty/salty Food Liking (Derived Food-Liking Factor),9
F-fatty Food Liking (Derived Food-Liking Factor),6
F-fish Liking (Derived Food-Liking Factor),14
F-dessert Liking (Derived Food-Liking Factor),8
Complement C4 Levels,17
Complement C4b Levels,10
Cathepsin D Levels,7
Cathepsin H Levels,5
Complement Factor B Levels,5
Interstitial Collagenase Levels,7
Vaginal Microbiome Relative Abundance (O Fusobacteriales),21
Vaginal Microbiome Relative Abundance (P Actinobacteriota),5
Vaginal Microbiome Relative Abundance (S Peptoniphilus Vaginalis),11
Vaginal Microbiome Relative Abundance (S Prevotella Bivia),9
Ratio Of Polyunsaturated Fatty Acids To Monounsaturated Fatty Acids,45
Cholesterol Levels In Small HDL,39
Low-carbohydrate Diet (LCD) Score,12
Cholesteryl Ester Levels In Small HDL,38
Heparin Cofactor 2 Levels,5
Protein Z-dependent Protease Inhibitor Levels,12
Interferon Alpha/Beta Receptor 1 Levels,6
Tumor Necrosis Factor Ligand Superfamily Member 8 Levels,6
Layilin Levels,5
Cathepsin S Levels,5
WNT1-inducible-signaling Pathway Protein 1 Levels,7
Endothelin-converting Enzyme 1 Levels,5
Bone Morphogenetic Protein 7 Levels,6
Interleukin-1 Receptor-Like 1 Levels,10
Cadherin-3 Levels,5
C-C Motif Chemokine 16 Levels,6
Vascular Endothelial Growth Factor Receptor 3 Levels,6
Coagulation Factor Xa Levels,5
C-X-C Motif Chemokine 11 Levels,7
Endothelial Monocyte-Activating Polypeptide 2 Levels,6
Galectin-3 Levels,12
Kallikrein-12 Levels,8
Crisps Liking,6
Vitronectin Levels,12
Coagulation Factor V Levels,6
Granulysin Levels,7
Gamma-enolase Levels,5
Human Chorionic Gonadotropin Levels,6
Vaginal Microbiome Relative Abundance (P Proteobacteria),11
Oral Corticosteroid Burst In Asthma,6
Vaginal Microbiome Relative Abundance (S Lactobacillus Jensenii),9
Phosphoglycerides Levels,47
Cholesterol To Total Lipids Ratio In Small HDL,46
Coagulation Factor XI Levels,5
Free Cholesterol To Total Lipids Ratio In Small HDL,53
Apolipoprotein E Levels,5
Complement Component C8 Levels,6
Ficolin-3 Levels,7
Urokinase Plasminogen Activator Surface Receptor Levels,7
Cathepsin Z Levels,5
Low Affinity Immunoglobulin Gamma Fc Region Receptor III-B Levels,7
N-acylethanolamine-hydrolyzing Acid Amidase Levels,6
Contactin-2 Levels,5
ADP-ribosyl Cyclase/Cyclic ADP-ribose Hydrolase 2 Levels,5
CD177 Antigen Levels,5
Tyrosine-protein Phosphatase Non-Receptor Type Substrate 1 Levels,5
Lysosomal Protective Protein Levels,6
Omega-3 Fatty Acid Levels,42
Vaginal Microbiome Relative Abundance (C Actinobacteria),8
Facial Skin Gloss,7
Facial Skin Hydration,8
Facial Wrinkles,27
Facial Skin Melanin,8
Facial Skin Elasticity,9
Von Willebrand Factor Levels,13
Beta-endorphin Levels,7
Plasma Protease C1 Inhibitor Levels,9
Ratio Of Omega-6 Fatty Acids To Omega-3 Fatty Acids,23
Vaginal Microbiome Relative Abundance (O Campylobacterales),6
Vaginal Microbiome Relative Abundance (S Megasphaera Genomosp Type 1),15
C-C Motif Chemokine 25 Levels,5
Tumor Necrosis Factor Ligand Superfamily Member 18 Levels,5
Interleukin-37 Levels,8
Macrophage-stimulating Protein Receptor Levels,5
Oncostatin-M Levels,7
Sialic Acid-Binding Ig-like Lectin 6 Levels,7
Sialic Acid-Binding Ig-like Lectin 7 Levels,5
Autoimmune Neurological Syndromes With anti-GAD65 Autoantibodies,15
Vaginal Microbiome Relative Abundance (C Gammaproteobacteria),10
Ratio Of Omega-3 Fatty Acids To Total Fatty Acids,31
Vaginal Microbiome Relative Abundance (S Dialister Propionicifaciens),18
Afamin Levels,5
Apolipoprotein M Levels,5
MAP Kinase-Activated Protein Kinase 3 Levels,6
Tropomyosin Beta Chain Levels,7
Retinoic Acid Receptor Responder Protein 2 Levels,5
Teratocarcinoma-derived Growth Factor 1 Levels,5
Protein FAM3B Levels,5
Alcohol Dehydrogenase [NADP(+)] Levels,5
F-fruit Liking (Derived Food-Liking Factor),7
Globe Artichoke Liking,5
Complement Component C1q Receptor Levels,5
Arylsulfatase A Levels,5
Alpha-2-macroglobulin Levels,7
Lymphatic Vessel Endothelial Hyaluronic Acid Receptor 1 Levels,7
Macrophage Colony-Stimulating Factor 1 Receptor Levels,6
Mucin-1 Levels,5
Vaginal Microbiome Relative Abundance (G Streptococcus),12
Vaginal Microbiome Relative Abundance (Lactobacillus Crispatus Or Lactobacillus Iners Or Gardnerella Vaginalis) (Pleiotropy),11
Vaginal Microbiome Relative Abundance (Pleiotropy),6
Ratio Of Polyunsaturated Fatty Acids To Total Fatty Acids,38
R-spondin-3 Levels,6
Protein FAM3D Levels,9
"Complement Component 1 Q Subcomponent-Binding Protein, Mitochondrial Levels",5
Endoplasmic Reticulum Resident Protein 29 Levels,7
Cholesterol Levels In Very Large HDL,65
Cholesterol To Total Lipids Ratio In Very Large HDL,34
Triglyceride Levels In Large HDL,37
Degree Of Unsaturation,40
Triglycerides To Total Lipids Ratio In Very Small VLDL,65
Docosahexaenoic Acid Levels,33
High-density Lipoprotein 3 Cholesterol Levels,8
Cholesteryl Ester Levels In Very Large HDL,68
Cholesteryl Ester Levels In Very Large VLDL,53
Phospholipids To Total Lipids Ratio In Small LDL,43
Phospholipids To Total Lipids Ratio In Large HDL,56
Attention Deficit Hyperactivity Disorder Or Autism Spectrum Disorder Or Intelligence (Pleiotropy),196
Free Cholesterol To Total Lipids Ratio In Very Large HDL,58
Water Consumption (Glasses Per Day) (UKB Data Field 1528),15
Ximenoylcarnitine (C26:1) Levels,8
Nervonoylcarnitine (C24:1) Levels,8
Lignoceroylcarnitine (C24) Levels,7
Cerotoylcarnitine (C26) Levels,8
"Sphingomyelin (D18:0/20:0, D16:0/22:0) Levels",5
Right Ventricular End Systolic Volume,11
Right Ventricular Ejection Fraction,7
Right Ventricular End Diastolic Volume,7
Total Lipid Levels In Very Large HDL,56
Cholesteryl Esters To Total Lipids Ratio In Very Large HDL,33
Drinks Usually With Meals In Current Drinkers (Yes Vs No) (UKB Data Field 1618),11
Never Eat Sugar Vs No Sugar Restrictions (UKB Data Field 6144),7
Spread Type: Flora Pro-Active/Benecol (UKB Data Field 1428 2),6
"Alcohol Consumption (Drinks Per Month) (UKB Data Field 1578, 4424)",35
"Depression, Cognition And Memory (Multivariate Analysis)",7
Coffee Type: Decaffeinated Coffee (Any Type) (UKB Data Field 1508 1),7
Cooked Vegetables Consumption,6
Fresh Fruit Consumption,25
"Champagne Or White Wine Consumption (Glasses Per Month) (UKB Data Field 1578, 4418)",6
"Beer Or Cider Consumption (Glasses Per Month) (UKB Data Field 1578, 4420)",8
Dried Fruit Consumption,7
1-stearoyl-2-linoleoyl-GPI (18:0/18:2) Levels,7
Adipoylcarnitine (C6-DC) Levels,5
"Sphingomyelin (D18:1/20:0, D16:1/22:0) Levels",5
"Sphingomyelin (D18:1/20:1, D18:2/20:0) Levels",5
Glycochenodeoxycholate 3-Sulfate Levels,5
"Sphingomyelin (D18:1/22:1, D18:2/22:0, D16:1/24:1) Levels",5
1-Stearoyl-2-Docosahexaenoyl-Gpc (18:0/22:6) Levels,6
Palmitoyl Dihydrosphingomyelin (D18:0/16:0) Levels,5
Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] Levels,7
Lamb Or Mutton Consumption (UKB Data Field 1379),6
Cheese Consumption,13
Predicted Heart Recovery Rate,5
1-palmitoyl-2-oleoyl-GPE (16:0/18:1) Levels,5
1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) Levels,5
Bread Type: White Vs Wholemeal/Wholegrain And Brown (UKB Data Field 1448),5
Cereal Consumption (Bowls Per Week) (UKB Data Field 1458),12
Bread Consumption (Slices Per Week) (UKB Data Field 1438),11
1-stearoyl-2-oleoyl-GPI (18:0/18:1) Levels,5
1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) Levels,5
Glycosyl-N-palmitoyl-sphingosine (D18:1/16:0) Levels,5
1-(1-Enyl-Palmitoyl)-2-Oleoyl-Gpc (P-16:0/18:1) Levels,6
Behenoyl Dihydrosphingomyelin (D18:0/22:0) Levels,5
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) Levels,7
"Glycosyl Ceramide (D18:1/20:0, D16:1/22:0) Levels",7
11Beta-Hydroxyandrosterone Glucuronide Levels,5
Hydroxypalmitoyl Sphingomyelin (d18:1/16:0(OH)) Levels,5
Pregnenetriol Sulfate Levels,9
Concentration Of Very Large HDL Particles,63
Added Salt Consumption,26
Oral Microbiome Beta Diversity (Euclidian Distance) In Oral Squamous Cell Carcinoma,6
Oral Microbiome Beta Diversity (Bray-Curtis) In Oral Squamous Cell Carcinoma,5
Drink Temperature,20
2'-Deoxyuridine Levels,5
Principal Component-Derived Dietary Pattern 1,42
Principal Component-Derived Dietary Pattern 3,18
Principal Component-Derived Dietary Pattern 4,6
Principal Component-Derived Dietary Pattern 7,13
X-21467 Levels,6
X-21470 Levels,7
X-21471 Levels,5
X-21796 Levels,10
Phospholipids To Total Lipids Ratio In Very Large HDL,46
X-24588 Levels,10
Uterine Leiomyoma Or Breast Cancer (Pleiotropy),21
Uterine Leiomyoma Or ER Positive Breast Cancer (Pleiotropy),13
Uterine Leiomyoma Or ER Negative Breast Cancer (Pleiotropy),8
X-12216 Levels,5
X-12707 Levels,7
X-16935 Levels,5
X-17357 Levels,5
X-17654 Levels,7
X-17676 Levels,6
X-18899 Levels,6
Principal Component-Derived Dietary Pattern 8,5
X-26054 Levels,5
Triglycerides To Total Lipids Ratio In Very Large HDL,60
Chlamydia Trachomatis-Related Tubal Factor Infertility,5
"Androstenediol (3Beta,17Beta) Monosulfate (2) Levels",8
Pregnenediol Sulfate (C21H34O5S) Levels,5
"Sphingomyelin (D18:1/18:1, D18:2/18:0) Levels",5
16A-Hydroxy DHEA 3-Sulfate Levels,5
Platelet Endothelial Cell Adhesion Molecule Levels,7
Serine Protease 27 Levels,11
P-selectin Glycoprotein Ligand 1 Levels,10
Total Lipid Levels In Very Large VLDL,55
Pulse Rate,17
Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] Levels,5
Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] Levels,6
Pregnanediol-3-glucuronide Levels,5
Andro Steroid Monosulfate C19H28O6S (1) Levels,5
1-eicosapentaenoyl-GPE (20:5) Levels,5
1-dihomo-linolenoyl-GPE (20:3N3 Or 6) Levels,5
Concentration Of Very Large VLDL Particles,59
Angiopoietin-1 Receptor Levels,6
Transferrin Receptor Protein 1 Levels,5
TNF-related Apoptosis-Inducing Ligand Receptor 2 Levels,5
Tyrosine-protein Kinase Receptor TYRO3 Levels,6
Versican Core Protein Levels,5
Chronic Chagas Cardiomyopathy In Chagas Disease,5
Argininate Levels,6
N-acetylcarnosine Levels,6
Cholesterol Levels In Very Large VLDL,54
Cholesterol To Total Lipids Ratio In Very Large VLDL,56
Umbilical Hernia,6
COVID-19 Or Coronary Artery Disease (Pleiotropy),6
COVID-19 Or Hypertension (Pleiotropy),15
"N,N,N-trimethyl-5-aminovalerate Levels",6
6-Bromotryptophan Levels,6
Posterior Urethral Valves,9
Cholesteryl Esters To Total Lipids Ratio In Very Large VLDL,56
Lactate Levels,8
Ribitol Levels,5
"1,5-Anhydroglucitol (1,5-Ag) Levels",6
Succinylcarnitine (C4-Dc) Levels,5
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) Levels,7
Free Testosterone Levels,96
X-10458 Levels,8
X-11315 Levels,5
X-11381 Levels,6
X-11441 Levels,9
X-11442 Levels,9
X-11880 Levels,9
X-21339 Levels,6
X-21410 Levels,8
X-23974 Levels,10
X-24309 Levels,13
Principal Component-Derived Dietary Pattern 43,5
Ergothioneine Levels,5
Sulfate Levels,5
Xanthurenate Levels,12
ACE-inhibitor Discontinuation,5
Free Cholesterol Levels In Very Large VLDL,56
1-arachidonoyl-GPE (20:4N6) Levels,7
Bone Morphogenetic Protein 6 Levels,5
Coiled-coil Domain-Containing Protein 80 Levels,7
C-C Motif Chemokine 15 Levels,6
C-C Motif Chemokine 17 Levels,9
Angiopoietin-related Protein 1 Levels,5
Cadherin-related Family Member 5 Levels,7
Carboxypeptidase B Levels,5
1-arachidonoyl-GPI (20:4) Levels,5
2-arachidonoyl-GPE (20:4) Levels,5
Free Cholesterol To Total Lipids Ratio In Very Large VLDL,50
1-linoleoyl-GPI (18:2) Levels,5
1-stearoyl-2-oleoyl-GPE (18:0/18:1) Levels,6
Glycosyl-N-stearoyl-sphingosine (D18:1/18:0) Levels,7
Heme Oxygenase 1 Levels,5
Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b Levels,12
Pro-interleukin-16 Levels,5
"5Alpha-Androstan-3Beta,17Beta-Diol Disulfate Levels",7
"5Alpha-Pregnan-3Beta,20Alpha-Diol Disulfate Levels",5
Pregnenediol Disulfate (C21H34O8S2) Levels,5
Interleukin-27 Levels,14
"5Alpha-Androstan-3Beta,17Alpha-Diol Disulfate Levels",5
"Androstenediol (3Alpha, 17Alpha) Monosulfate (3) Levels",6
Low-density Lipoprotein Receptor-Related Protein 11 Levels,6
Matrix Metalloproteinase-3 Levels,5
Myeloperoxidase Levels,12
Drusen Area Within A Central 5 Mm Circle (Model 1),6
Alpha-hydroxyisovalerate Levels,6
Pyroglutamine Levels,5
2-Hydroxy-3-Methylvalerate Levels,6
Glutarylcarnitine (C5-Dc) Levels,9
Orbital Telorism,37
Kynurenine Levels,5
Indoleacetoylcarnitine Levels,5
N-acetyl-isoputreanine Levels,5
2-Ketocaprylate Levels,7
Sulfate Of Piperine Metabolite C18H21NO3 (1) Levels,6
N-acetyl-4-chlorophenylalanine Levels,5
COVID-19 Or Obesity (Pleiotropy),6
3-Methoxytyrosine Levels,7
Beta-hydroxyisovalerate Levels,9
Threonine Levels,8
Tryptophan Levels,5
Guanidinoacetate Levels,6
Isoleucine Levels,13
Citrulline Levels,7
Leucine Levels,23
Ornithine Levels,7
Ascorbic Acid 3-Sulfate Levels,6
Propionylcarnitine (C3) Levels,6
Premature Atrial Contraction Frequency,24
Phospholipids To Total Lipids Ratio In Very Large VLDL,38
Triglycerides To Total Lipids Ratio In Very Large VLDL,50
S-6-hydroxywarfarin Levels,128
R-6-hydroxywarfarin Levels,51
Platelet Factor 4/Heparin Antibody Levels In Heparin Treatment,5
Alzheimer's Disease In non-APOE E4 Carriers,23
Dementia In APOE E4+ Carriers,5
Dementia In non-APOE E4 Carriers,19
RS-6-hydroxywarfarin Levels,57
RS-10-hydroxywarfarin Levels,35
S-warfarin To R-warfarin Ratio,55
RS-10-hydroxywarfarin To RS-warfarin Ratio,43
COVID-19 Hospitalization Or Rheumatoid Arthritis (MTAG),23
Severe COVID-19 Or Systemic Lupus Erythematosus (MTAG),11
COVID-19 Hospitalization Or Systemic Lupus Erythematosus (MTAG),12
COVID-19 Infection Or Systemic Lupus Erythematosus (MTAG),6
Maximum Measurement Of Hepatic Fat,9
Median Measurement Of Hepatic Fat,14
Minimum Measurement Of Hepatic Fat,11
Facial Morphology (Multitrait Analysis),17
C-reactive Protein Levels (MTAG),393
Chronic Obstructive Pulmonary Disease Liability (Machine Learning-Based Score),249
Medication Use For Hypertension (Number Of Purchases),121
Internet Addiction Disorder,25
"COVID-19 (Hospitalized Vs Tested, Not Hospitalized)",61
Medication Use For Hyperlipidemia (Number Of Purchases),49
Mitral Valve Annular Diameter (Left Ventricle Systole),5
Years Ovulating,11
Heart Failure (Multivariate Analysis),44
Cholesterol Levels In Chylomicrons And Extremely Large VLDL,56
Cholesterol To Total Lipids Ratio In Chylomicrons And Extremely Large VLDL,16
Early Neurological Instability After Acute Ischemic Stroke,5
Risk-taking Behavior (Multivariate Analysis),147
Cholesteryl Ester Levels In Chylomicrons And Extremely Large VLDL,57
"Bilirubin Degradation Product, C17H18N2O4 (3) Levels",8
X-13684 Levels,6
Body Surface Area,317
Clinical LDL Cholesterol Levels,36
X-23756 Levels,5
Hernia,11
Nonsyndromic Orofacial Cleft X Sex Interaction,27
Skin Reflectance,16
Opioid Addiction,66
Linoleic Acid Levels,59
1-Palmitoyl-2-Docosahexaenoyl-Gpc (16:0/22:6) Levels,5
X-26109 Levels,5
Carnitine C4 Levels,5
Disruptive Behavior (Multivariate Analysis),27
Blood Pressure (Pleiotropy Model 1 DBP Adjusted For Estimated Causal Effects X SBP),305
Glycoprotein Acetyls Levels,59
Dietary Approaches To Stop Hypertension (DASH) Diet,5
Alcohol Dependence (Codominant Genetic Model),16
"COVID-19 (Severe Vs Tested, Not Severe)",44
BMI (Standard GWA),151
COVID-19 (Severe Vs Non-Severe With Positive Test),36
Migraine (MTAG),8
Anterior Thigh Muscle Fat Infiltration Percentage,8
Liver Proton Density Fat Fraction,7
Posterior Thigh Muscle Fat Infiltration Percentage,14
Hearing Loss,55
Body Composition (MOSTest),48
LDL (Standard GWA),86
LDL (Weighted GWA),27
Coffee Intake (Standard GWA),13
Age When Finished Full-Time Education (Standard GWA),142
Ease Of Sunburn,8
Ease Of Skin Tanning,9
Alpha Angle,8
COVID-19 (Severe Vs Population),47
Medication Use For T2D (Number Of Purchases),51
Suicidal Thoughts And Behaviors,11
COVID-19 Death (Death Vs Population),24
BMI (Weighted GWA),17
Cancer (Standard GWA),5
Diabetes (Standard GWA),23
Cervical Artery Dissection (MTAG),6
Small Vessel Stroke (MTAG),5
Large Artery Stroke (MTAG),13
COVID-19 Death (Death Vs Tested And Survived),24
Isovalerylcarnitine Levels,5
Glutaroyl Carnitine Levels,6
S-7-hydroxywarfarin Levels,44
COVID-19 (Severe Vs Population) X Multiple Deprivation Index Interaction (Joint Test),8
COVID-19 (Severe Vs Population) X Multiple Deprivation Index Interaction,5
COVID-19 (Severe Vs Population) X Cardiometabolic Health Status Interaction (Joint Test),10
COVID-19 (Severe Vs Population) X Sex Interaction (Joint Test),7
R-6-hydroxywarfarin To R-warfarin Ratio,39
S-6-hydroxywarfarin To S-warfarin Ratio,34
S-7-hydroxywarfarin To S-warfarin Ratio,30
X-11793--oxidized Bilirubin Levels,8
Isobutyrylcarnitine Levels,5
COVID-19 (Severe Vs Population) X Cardiometabolic Health Status Interaction,8
Severe COVID-19 Or Rheumatoid Arthritis (MTAG),15
Biliverdin Levels In Chronic Kidney Disease,9
Bilirubin Levels In Chronic Kidney Disease,8
"Malignant Lymphoma (Non-Hodgkin Lymphoma, Multiple Myeloma, Or Hodgkin Lymphoma)",7
Severe COVID-19 Infection,415
Age At Adiposity Rebound X Sex Interaction,5
BMI At Adiposity Rebound X Sex Interaction,6
Height (Standard GWA),392
Obstructive Sleep Apnea Trait (Minimum Oxyhemoglobin Saturation Across Sleep Episode),5
Endoxifen Levels In Tamoxifen-Treated Hormone-Receptor-Positive Breast Cancer,5
(Z)-4-hydroxytamoxifen To Tamoxifen Ratio In Tamoxifen-Treated Hormone-Receptor-Positive Breast Cancer,5
Acne Vulgaris,49
"Alzheimer's Disease, Proxy Alzheimer's Disease Or Related Dementias",12
"Alzheimer's Disease, Proxy Alzheimer's Disease Or Related Dementias (Adjusted For APOE E4 Dosage)",5
Ascending Aorta Strain,14
Descending Aorta Strain,11
Histone-lysine N-methyltransferase EHMT2 Levels,5
Skin Color (Fitzpatrick Scale),11
Skin Phototype Score,17
Age When Finished Full-Time Education (Weighted GWA),31
Age Of Onset Of Childhood Onset Asthma,52
Metachronous Colorectal Adenoma,6
Photoreceptor Cell Layer Thickness Phenotypes (MTAG),81
Methotrexate-induced Liver Injury In Rheumatoid Arthritis,11
Sleep Apnea (MTAG),17
Descending Aorta Diameter,33
High-density Lipoprotein Levels (MTAG),244
Skin Color,13
Age Of Onset Of Adult Onset Asthma,40
Fruit Intake (Standard GWA),9
Frontal QRS-T Angle,9
Spatial QRS-T Angle,56
Cryptic Phenotype That Captures Autosomal Dominant Polycystic Kidney Disease Severity,25
Genetically Independent Pain Phenotypes (GIP1),7
Endometriosis (Stage 3 Or 4),10
Surgical Knee Osteoarthritis,12
Non-surgical Knee Osteoarthritis,5
Surgical Hip Osteoarthritis,24
Non-surgical Hip Osteoarthritis,6
Ectonucleoside Triphosphate Diphosphohydrolase 1 Levels,6
Epididymal-specific Lipocalin-10 Levels,5
"Electron Transfer Flavoprotein Subunit Alpha, Mitochondrial Levels",6
Tinnitus-related Distress,31
Mannan-binding Lectin Serine Protease 1 Levels,7
Myeloid Cell Surface Antigen CD33 Levels,6
Mast Cell-Expressed Membrane Protein 1 Levels,6
Headache Or Migraine,44
Microfibrillar-associated Protein 2 Levels,6
MICAL-like Protein 2 Levels,5
"Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A Levels",5
Brain Shape (Segment 1),88
Abdominal Fat Cell Number,64
Endometriosis Or Depression (Pleiotropy),11
Biological Sex,98
Serum Levels Of Protein ADH5,5
Serum Levels Of Protein AHSA1,6
Serum Levels Of Protein HPSE,5
Serum Levels Of Protein F3,9
Haemorrhoidal Disease,69
Serum Levels Of Protein RBL2,5
Cervical Intraepithelial Neoplasia Grade 3 And Invasive Cervical Cancer,5
Serum Levels Of Protein NCMAP,5
Serum Levels Of Protein NDUFB4,5
Serum Levels Of Protein RAB5C,6
Noncognitive Aspects Of Educational Attainment,114
Serum Levels Of Protein NOG,9
Serum Levels Of Protein ADM,6
Serum Levels Of Protein ANGPTL3,6
Serum Levels Of Protein RAB26,5
Serum Levels Of Protein ETHE1,7
Serum Levels Of Protein EVA1C,5
Vitamin C Levels,10
Chronic Obstructive Pulmonary Disease X Ever Smoker Interaction (2Df),33
Chronic Obstructive Pulmonary Disease X Ever Smoker Interaction (Main Effect),23
Asthma With Severe Exacerbations,10
Well-being Spectrum (Multivariate Analysis),132
Endometrial Cancer (Endometrioid Histology),23
HDL Cholesterol And Triglyceride Levels (Pleiotropy),5
Falling Risk,10
Anthropometric Traits (Multi-Trait Analysis),24
Skin Pigmentation Traits,8
Hair Morphology Traits,8
Eudaimonic Well-Being,16
Velopharyngeal Dysfunction,43
Cognitive Empathy,52
Heart Rate In Heart Failure With Reduced Ejection Fraction,40
Depression In Smokers,30
Breast Cancer And/Or Colorectal Cancer,9
Metastasis In Stage I-III Microsatellite Instability Low/Stable Colorectal Cancer (Time To Event),15
Adult Onset Asthma And/Or Waist-To-Hip Ratio Adjusted For BMI,6
Nonatopic Asthma And/Or Waist-To-Hip Ratio Adjusted For BMI,6
Nonatopic Asthma Or Type 2 Diabetes,5
Adult Onset Asthma And/Or BMI,8
Nonatopic Asthma And/Or BMI,6
IDP dMRI ProbtrackX L1 Atr R,5
Forns Index In High Alcohol Intake,26
IDP dMRI TBSS ICVF Superior Cerebellar Peduncle L,5
IDP dMRI TBSS ICVF Cerebral Peduncle R,8
Beta Blocker Survival Benefit In Heart Failure With Reduced Ejection Fraction (Time To All Cause Mortality X Beta Blocker Interaction),8
IDP dMRI TBSS ICVF Superior Corona Radiata L,5
Adrenomedullin Levels,5
TNF-related Apoptosis-Inducing Ligand Levels,8
Tissue Factor Levels,13
Kallikrein-6 Levels,8
IDP dMRI TBSS ISOVF Anterior Corona Radiata L,5
Wg Lh Intensity-Contrast Fusiform,9
Wg Lh Intensity-Contrast Inferiorparietal,11
Type 2 Diabetes Or Prostate Cancer (Pleiotropy),41
IDP T1 FAST ROIs R Cerebellum Crus I,6
IDP T1 FAST ROIs R Cerebellum Crus II,5
IDP T1 FAST ROIs V Cerebellum VIIIa,5
Glucagon Levels,6
Insulin Levels In Lean Individuals,9
IDP dMRI ProbtrackX L2 Fmi,5
IDP dMRI ProbtrackX L3 Fmi,6
IDP dMRI TBSS ICVF Posterior Limb Of Internal Capsule L,5
IDP dMRI TBSS ICVF Retrolenticular Part Of Internal Capsule R,7
Alanine Transaminase Levels In High Alcohol Intake,10
Aspartate Transaminase Levels In High Alcohol Intake,5
Tumor Necrosis Factor Receptor 2 Levels,7
Tumor Necrosis Factor Ligand Superfamily Member 14 Levels,7
IDP dMRI TBSS ICVF Cingulum Cingulate Gyrus R,5
Cathepsin L1 Levels,10
IDP dMRI ProbtrackX ICVF Ptr L,5
Lectin-like Oxidized LDL Receptor 1 Levels,6
Tumor Necrosis Factor Receptor 1 Levels,5
Platelet-derived Growth Factor Subunit B Levels,9
IDP dMRI TBSS ICVF Posterior Thalamic Radiation R,5
IDP dMRI TBSS ICVF Sagittal Stratum R,6
IDP dMRI TBSS ICVF Sagittal Stratum L,9
IDP dMRI TBSS ICVF External Capsule R,6
Wg Lh Intensity-Contrast Lateraloccipital,7
Wg Lh Intensity-Contrast Lateralorbitofrontal,6
Wg Lh Intensity-Contrast Lingual,6
Wg Lh Intensity-Contrast Middletemporal,10
Wg Lh Intensity-Contrast Parstriangularis,6
Wg Lh Intensity-Contrast Posteriorcingulate,7
Wg Lh Intensity-Contrast Inferiortemporal,11
Wg Lh Intensity-Contrast Isthmuscingulate,8
Wg Lh Intensity-Contrast Parsopercularis,9
Wg Lh Intensity-Contrast Parsorbitalis,7
Episodic Memory (Pairs-Matching),7
Wg Rh Intensity-Contrast Inferiortemporal,8
Wg Rh Intensity-Contrast Isthmuscingulate,5
Wg Rh Intensity-Contrast Lateraloccipital,7
Wg Rh Intensity-Contrast Lateralorbitofrontal,7
Wg Rh Intensity-Contrast Lingual,6
Wg Rh Intensity-Contrast Fusiform,10
Wg Rh Intensity-Contrast Inferiorparietal,10
IDP dMRI TBSS ICVF Retrolenticular Part Of Internal Capsule L,6
IDP dMRI TBSS ICVF Superior Longitudinal Fasciculus L,7
IDP dMRI TBSS OD Cerebral Peduncle R,5
IDP dMRI TBSS OD Cerebral Peduncle L,5
IDP dMRI ProbtrackX ISOVF Ifo R,5
IDP dMRI ProbtrackX ISOVF Ilf L,5
IDP dMRI ProbtrackX ISOVF Slf R,5
Wg Rh Intensity-Contrast Parsopercularis,6
Wg Rh Intensity-Contrast Parsorbitalis,7
Wg Rh Intensity-Contrast Parstriangularis,8
Wg Rh Intensity-Contrast Medialorbitofrontal,6
Wg Rh Intensity-Contrast Middletemporal,7
Wg Rh Intensity-Contrast Parahippocampal,7
Insulin Levels In Overweight Individuals,7
Visfatin Levels In Type 2 Diabetes,5
Retinal Nerve Fibre Layer (RNFL) Thickness,25
Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness,22
Gut Microbiota Alpha Diversity (Inverse Simpson Index),8
Brain Shape (Segment 2),11
Neck Circumference,5
Retinal Nerve Fibre Layer Thickness Or Ganglion Cell Inner Plexiform Layer Thickness (MTAG),39
QT Dynamics During Exercise,13
Cerebrospinal Fluid Progranulin Levels,7
Vascular Endothelial Growth Factor A Levels,5
Early-onset Schizophrenia,11
Computer Vision Syndrome,6
Brain Shape (Segment 86),5
Gut Microbiota Alpha Diversity (Simpson Index),11
Gut Microbiota Abundance (Genus Bifidobacterium Id.436),9
Brain Shape (Segment 62),5
Brain Shape (Segment 40),5
Brain Shape (Segment 15),12
Brain Shape (Segment 7),16
Brain Shape (Segment 10),8
Brain Shape (Segment 117),7
Brain Shape (Segment 3),12
Brain Shape (Segment 5),11
Thymus And Reactivation Regulated Chemokine Levels,6
Gout Vs Asymptomatic Hyperuricemia,6
Chronic Obstructive Pulmonary Disease In Never Smokers,23
Chronic Obstructive Pulmonary Disease X Current Smoker Interaction (2Df),43
Bilateral Cleft Lip,44
Unilateral Cleft Lip,11
Serum Levels Of Protein PAXIP1,8
Chronic Obstructive Pulmonary Disease In Non-Current Smokers,40
Bilateral Cleft Lip And Palate,19
Unilateral Cleft Lip And Palate,19
Periodontitis (Stage III/IV Grade C),5
Cognitive Aspects Of Educational Attainment,157
Serum Levels Of Protein PFKFB3,5
Suicide Attempt Severity In Mood Disorders,7
Serum Levels Of Protein C4A;C4B,10
Serum Levels Of Protein CCL11,6
Serum Levels Of Protein CCL17,8
Serum Levels Of Protein CAPN1;CAPNS1,5
Spleen Iron Concentration,8
Asthma And Cardiovascular Disease,23
Bipolar Disorder Vs Major Depressive Disorder (Ordinary Least Squares (OLS)),5
Crohn's Disease Vs Rheumatoid Arthritis (Ordinary Least Squares (OLS)),20
Methazolamide-induced Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis,10
Major Depressive Disorder Vs ADHD (Ordinary Least Squares (OLS)),8
Crohn's Disease Vs Ulcerative Colitis (Ordinary Least Squares (OLS)),6
Major Depressive Disorder Vs Anorexia Nervosa (Ordinary Least Squares (OLS)),5
Schizophrenia Vs ADHD (Ordinary Least Squares (OLS)),34
Schizophrenia Vs Autism Spectrum Disorder (Ordinary Least Squares (OLS)),24
Schizophrenia Vs Bipolar Disorder (Ordinary Least Squares (OLS)),9
Schizophrenia Vs Anorexia Nervosa (Ordinary Least Squares (OLS)),32
Serum Levels Of Protein IL18R1,5
Schizophrenia Vs Tourette's Syndrome And Other Tic Disorders (Ordinary Least Squares (OLS)),13
Ulcerative Colitis Vs Rheumatoid Arthritis (Ordinary Least Squares (OLS)),9
Serum Levels Of Protein IL36A,6
SAPHO Syndrome,8
Serum Levels Of Protein NRXN3,7
Chronic Obstructive Pulmonary Disease X Current Smoker Interaction (Main Effect),40
Serum Levels Of Protein PCDHB14,5
Serum Levels Of Protein PCDHB4,6
Serum Levels Of Protein ATP13A1,5
Serum Levels Of Protein IL10RA,6
Serum Levels Of Protein AZGP1,6
Serum Levels Of Protein IGFL3,5
Psoriasis Or Type 2 Diabetes (Trans-Disease Meta-Analysis)(Opposite Effect),20
Chronic Obstructive Pulmonary Disease In Ever Smokers,23
Serum Levels Of Protein FAM3B,5
Chronic Obstructive Pulmonary Disease In Current Smokers,8
Serum Levels Of Protein APOL1,7
Serum Levels Of Protein IFNAR1,5
Psoriasis Or Type 2 Diabetes (Trans-Disease Meta-Analysis),15
Ultradistal Forearm Bone Mineral Density,14
Serum Levels Of Protein CDH15,5
Serum Levels Of Protein CDSN,5
Serum Levels Of Protein IL5RA,5
Childhood Aggressive Behavior,24
Serum Levels Of Protein ISG15,6
Serum Levels Of Protein CFB,6
Serum Levels Of Protein CLEC12B,6
Serum Levels Of Protein CKAP4,9
Serum Levels Of Protein COCH,5
Serum Levels Of Protein CMPK1,11
Serum Levels Of Protein KLRC3,6
"Tinnitus (Chronic, Bothersome)",14
Clinical Depression,13
Serum Levels Of Protein CREBBP,6
Childhood Gender Nonconformity,10
Acetoacetate Levels,5
Acetone Levels,11
P-cresol-glucuronide Levels,8
Succinimide Levels,9
Cholesteryl Ester Levels In Very Small VLDL,44
Cholesteryl Esters To Total Lipids Ratio In Very Small VLDL,69
Free Cholesterol Levels In Very Small VLDL,46
Free Cholesterol To Total Lipids Ratio In Very Small VLDL,43
1-Ribosyl-Imidazoleacetate (X-11334) Levels,5
Free Cholesterol Levels In Chylomicrons And Extremely Large VLDL,57
Free Cholesterol To Total Lipids Ratio In Chylomicrons And Extremely Large VLDL,19
Total Lipid Levels In Chylomicrons And Extremely Large VLDL,57
Andro Steroid Monosulfate (1) Levels,9
5-Bromotryptophan Levels,6
Phospholipid Levels In Chylomicrons And Extremely Large VLDL,49
Indoleacetate Levels,6
Hexadecenedioate (C16:1-Dc) (X-11905) Levels,6
Phospholipids To Total Lipids Ratio In Chylomicrons And Extremely Large VLDL,28
Metabolonic Lactone Sulfate (X-12063) Levels,8
1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3N3 Or 6) Levels,6
"4-Androsten-3Beta,17Beta-Diol Monosulfate (2) Levels",6
Concentration Of Chylomicrons And Extremely Large VLDL Particles,57
Refractive Error (Autorefraction Measured),13
"Bilirubin Degradation Product, C17H20N2O5 (2) Levels",8
"Bilirubin Degradation Product, C16H18N2O5 (4) Levels",8
"Bilirubin Degradation Product, C17H20N2O5 (1) Levels",9
"Bilirubin Degradation Product, C16H18N2O5 (3) Levels",8
"Bilirubin Degradation Product, C16H18N2O5 (2) Levels",8
"Bilirubin Degradation Product, C16H18N2O5 (1) Levels",8
Triglycerides To Total Lipids Ratio In Chylomicrons And Extremely Large VLDL,13
N-acetyl-isoputreanine (X-12688) Levels,7
Cholesterol Levels In Very Small VLDL,43
Urinary Microalbumin Levels,9
Cholesterol To Total Lipids Ratio In Very Small VLDL,63
Severe COVID-19 Or Systemic Lupus Erythematosus,9
Serum Glutamic-Oxaloacetic Transaminase Levels,11
Serum Glutamic-Pyruvic Transaminase Levels,6
AFP Levels,61
Fibromuscular Dysplasia,22
Concentration Of Very Small VLDL Particles,51
Bone Stiffness Index,42
Total Lipid Levels In Very Small VLDL,52
Common Executive Function,78
Phospholipids To Total Lipids Ratio In Very Small VLDL,45
Body Shape (Principal Component Analysis),6
Opioid Analgesic Dose Requirement In Cancer Pain Treatment,22
Methylsuccinoylcarnitine Levels,5
Cholesteryl Esters To Total Lipids Ratio In Chylomicrons And Extremely Large VLDL,14
Cholesterol Levels In Medium HDL,54
Basal Cell Carcinoma (MTAG),45
Squamous Cell Carcinoma (MTAG),21
Polyunsaturated Fatty Acid Levels,52
Total Esterified Cholesterol Levels,55
Blood Pressure (Pleiotropy Model 2 SBP Adjusted For Estimated Causal Effects X DBP),285
Triamcinolone Acetonide-Induced Ocular Hypertension,41
Phosphatidylcholine Diacyl C36:3 Levels,6
Phosphatidylcholine Diacyl C40:6 Levels,8
Phosphatidylcholine Diacyl C32:0 Levels,5
Triglyceride Levels In Type 2 Diabetes,15
Triglyceride Levels In Non-Type 2 Diabetes,228
Remission After Antidepressant Treatment In Major Depressive Disorder,13
Response To Antidepressants (Symptom Improvement) In Major Depressive Disorder,15
Time To Prostate-Specific Antigen Progression In Metastatic Castration-Resistant Prostate Cancer,5
Language Performance,11
Visceral Adipose Tissue Volumes (Adjusted For BMI And Height),12
Abdominal Adipose Tissue Volumes (Adjusted For BMI And Height),12
Gluteofemoral Adipose Tissue Volumes (Adjusted For BMI And Height),34
Hoarding Symptoms,12
S-warfarin Levels,41
Morbidity In COVID-19 (Deceased Vs Asymptomatic),10
R-warfarin Levels,98
Gluteofemoral Adipose Tissue Volumes,15
Opioid Use Disorder (Broad),6
Response To Dolutegravir In HIV Infection (Area Under The Concentration-Time Curve),5
Bilirubin Concentration In Dolutegravir-Treated HIV Infection,12
Response To Dolutegravir In HIV Infection (Clearance),13
Visceral Adipose Tissue Volumes To Gluteofemoral Adipose Tissue Volumes Ratio,19
Abdominal Adipose Tissue Volumes To Gluteofemoral Adipose Tissue Volumes Ratio,8
Visceral Adipose Tissue Volumes To Abdominal Adipose Tissue Volumes Ratio,19
Sleep Health Score,22
COVID-19 (Recovered Vs Asymptomatic),9
RS-warfarin Levels,54
Congenital Solitary Functioning Kidney,12
Colorectal Cancer X Menopausal Hormone Therapy Interaction (3Df Test),7
Colorectal Cancer X Estrogen-Progesterone Hormone Therapy Interaction,12
Colorectal Cancer X Estrogen-Progesterone Hormone Therapy Interaction (2Df Test),10
Colorectal Cancer X Estrogen Hormone Therapy Interaction (2Df Test),5
Colorectal Cancer X Estrogen-Progesterone Hormone Therapy Interaction (3Df Test),9
Dental Development,10
Cholesteryl Ester Levels In Large LDL,38
Cholesterol To Total Lipids Ratio In Large LDL,52
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) Levels In Elite Athletes,6
3-(4-Hydroxyphenyl)Lactate Levels In Elite Athletes,5
3-Aminoisobutyrate Levels In Elite Athletes,6
Plasma Manganese Levels,5
Plasma Nickel Levels,9
3-Hydroxyisobutyrate Levels In Elite Athletes,6
Plasma Selenium Levels,6
Cholesteryl Esters To Total Lipids Ratio In Large LDL,35
1-linoleoyl-GPE (18:2) Levels In Elite Athletes,5
Venous Thromboembolism In Pregnancy,6
1-oleoyl-GPC (18:1) Levels In Elite Athletes,7
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4N6) Levels In Elite Athletes,6
Asthma-COPD Overlap Syndrome,18
Free Cholesterol To Total Lipids Ratio In Large LDL,65
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) Levels In Elite Athletes,5
1-palmitoyl-2-oleoyl-GPC (16:0/18:1) Levels In Elite Athletes,7
1-palmitoyl-2-oleoyl-GPE (16:0/18:1) Levels In Elite Athletes,6
Total Lipid Levels In Large LDL,41
1-Palmitoylglycerol (16:0) Levels In Elite Athletes,5
Free Cholesterol To Total Lipids Ratio In Large HDL,53
Soluble E-selectin Levels (Adjusted For ABO Rs2519093 Genotypes),5
Coronary Artery Disease Or Factor VII Levels (Pleiotropy),66
Venous Thromboembolism Or Tissue Plasminogen Activator Levels (Pleiotropy),20
Venous Thromboembolism Or Plasminogen Activator Inhibitor 1 Levels (Pleiotropy),16
Concentration Of Large HDL Particles,68
Stearoylcarnitine (C18) Levels In Elite Athletes,8
Beta-guanidinopropanoate Levels In Elite Athletes,7
Coronary Artery Disease Or Von Willebrand Factor Levels (Pleiotropy),76
Gluconate Levels In Elite Athletes,9
Coronary Artery Disease Or Fibrinogen Levels (Pleiotropy),84
Coronary Artery Disease Or Factor XI Levels (Pleiotropy),66
Xanthosine Levels In Elite Athletes,6
Thioproline Levels In Elite Athletes,5
Methionine Sulfone Levels In Elite Athletes,7
Non(never)-lesional Skin FLG Expression Levels In Childhood Atopic Dermatitis,5
Coronary Artery Disease Or Plasminogen Activator Inhibitor 1 Levels (Pleiotropy),41
Ischemic Stroke Or Factor VII Levels (Pleiotropy),13
Triglycerides To Total Lipids Ratio In Large HDL,58
N-delta-acetylornithine Levels In Elite Athletes,6
N2-acetyllysine Levels In Elite Athletes,6
Cholesterol Levels In Large LDL,43
Serum Calcium Levels,10
Galactonate Levels In Elite Athletes,9
N6-carboxymethyllysine Levels In Elite Athletes,6
Treponema D Abundance In Stool,9
Fibrinogen Levels Or Factor VII Levels (Pleiotropy),28
Treponemataceae Abundance In Stool,7
Serum Chromium Levels,8
Serum Copper Levels,14
Serum Iron Levels,8
Serum Cobalt Levels,5
Triglyceride Levels In Large LDL,63
"3Beta,7Alpha-Dihydroxy-5-Cholestenoate Levels In Elite Athletes",5
Creatine Levels In Elite Athletes,7
Triglycerides To Total Lipids Ratio In Large LDL,56
Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 Levels,14
Dynein Light Chain Roadblock-Type 1 Levels,5
"5Alpha-Androstan-3Alpha,17Beta-Diol Monosulfate (1) Levels In Elite Athletes",6
Revision Surgery After Total Joint Arthroplasty,8
Revision Surgery Due To Aseptic Loosening After Total Hip Arthroplasty,14
"Gp41 C34 Peptide, HIV Levels",5
Revision Surgery Due To Aseptic Loosening After Total Knee Arthroplasty,10
Revision Surgery After Total Knee Arthroplasty,10
Cholesterol Levels In Large VLDL,57
"5Alpha-Pregnan-3Beta,20Alpha-Diol Monosulfate (2) Levels In Elite Athletes",17
"5Alpha-Pregnan-3Beta,20Beta-Diol Monosulfate (1) Levels In Elite Athletes",6
Dimethylglycine Levels In Elite Athletes,5
Adipoylcarnitine (C6-DC) Levels In Elite Athletes,5
Fasting Glucose Adjusted For BMI,13
Fasting Insulin Adjusted For BMI,9
Glycated Haemoglobin HbA1c Levels Adjusted For BMI,22
Granulocyte Telomere Length,7
Naive T-cell Telomere Length,5
Lymphocyte Telomere Length,5
B-cell Telomere Length,6
Neuropathic Pain,6
Angiopoietin-related Protein 1 Levels (ANGPTL1.9092.33.3),9
Ratio Of Apolipoprotein B To Apolipoprotein A1 Levels,58
Total Cholines Levels,51
Ratio Of Docosahexaenoic Acid To Total Fatty Acid Levels,22
Complement C4 Levels (C4A.C4B.4481.34.2),7
Free Cholesterol Levels In HDL,54
Carotid Intima-media Thickness (Mean Of The Maximum cIMT),124
Cigarette Consumption X Hours Spent Using Computers Interaction,34
Total Lipid Levels In HDL,58
Concentration Of HDL Particles,54
Alzheimer's Disease Or Educational Attainment (Pleiotropy),122
Alcohol Consumption X Playing Computer Games Interaction,11
Anxiety Severity X Hours Spent Watching Television Interaction,29
Neutrophil Collagenase Levels (MMP8.2954.56.2),5
Nuclear Receptor Subfamily 1 Group D Member 2 Levels (NR1D2.12885.42.3),5
Triglyceride Levels In HDL,46
Cholesterol To Total Lipids Ratio In IDL,64
Cholesteryl Ester Levels In IDL,47
Cholesteryl Ester Levels In HDL,60
Chronic Elevation Of Alanine Aminotransferase (cALT) Levels,63
Anxiety Severity X Playing Computer Games Interaction,30
Depression Severity X Playing Computer Games Interaction,13
Cigarette Consumption X Playing Computer Games Interaction,9
"Pediatric Dental Caries (Decayed, Missing And Filled Teeth >5)",6
Eotaxin Levels (CCL11.5301.7.3),5
Detectable Estradiol Levels In Postmenopausal Women,7
Soluble Urokinase Plasminogen Activator Receptor Levels,5
SLAM Family Member 7 Levels (SLAMF7.5487.7.3),5
Detectable Estradiol Levels In Premenopausal Women,6
Peripheral Artery Disease In Non Diabetes,7
Total Lipid Levels In Large HDL,65
2-Hydroxy-3-Methylvalerate Levels In Elite Athletes,6
4-Hydroxyglutamate Levels In Elite Athletes,7
4-Hydroxyphenylpyruvate Levels In Elite Athletes,8
Venous Thromboembolism Or Fibrinogen Levels (Pleiotropy),47
5-Acetylamino-6-Amino-3-Methyluracil Levels In Elite Athletes,6
Skeletal Age,5
Nonalcoholic Fatty Liver Disease (Imputed),51
Taurochenodeoxycholate Levels In Elite Athletes,5
N-(2-furoyl)glycine Levels In Elite Athletes,5
N-methylpipecolate Levels In Elite Athletes,8
Urate Levels In Elite Athletes,6
Whole Brain Free Water Diffusion (Multivariate Analysis),124
Coronary Artery Disease Or Tissue Plasminogen Activator Levels (Pleiotropy),43
N-acetylasparagine Levels In Elite Athletes,5
N-acetylcitrulline Levels In Elite Athletes,5
Total Bone Mineral Density X Gut Microbiota (ï»¿Genus Dialister) Interaction,7
Femur Total Bone Mineral Density X Gut Microbiota (ï»¿Genus Lactococcus) Interaction,20
N1-Methyl-2-pyridone-5-carboxamide Levels In Elite Athletes,6
Retinol (Vitamin A) Levels In Elite Athletes,5
Serum Tin Levels,7
Serum Zinc Levels,9
1-Methylurate Levels In Elite Athletes,5
Dopamine 3-O-sulfate Levels In Elite Athletes,5
1-Methylhistidine Levels In Elite Athletes,6
Cysteine Sulfinic Acid Levels In Elite Athletes,6
Glutarylcarnitine (C5-DC) Levels In Elite Athletes,5
Guanidinoacetate Levels In Elite Athletes,8
Venous Thromboembolism Or Von Willebrand Factor Levels (Pleiotropy),33
Venous Thromboembolism Or Factor XI Levels (Pleiotropy),20
Coronary Artery Disease Or Factor VIII Levels (Pleiotropy),71
Ischemic Stroke Or Fibrinogen Levels (Pleiotropy),31
Ischemic Stroke Or Tissue Plasminogen Activator Levels (Pleiotropy),7
Ischemic Stroke Or Plasminogen Activator Inhibitor 1 Levels (Pleiotropy),6
Factor VIII Levels Or Von Willebrand Factor Levels (Pleiotropy),12
Tiglylcarnitine (C5:1-DC) Levels In Elite Athletes,8
Trans-urocanate Levels In Elite Athletes,5
Fibrinogen Levels Or Plasminogen Activator Inhibitor 1 Levels (Pleiotropy),26
Fibrinogen Levels Or Factor VII Levels Or Factor XI Levels Or Tissue Plasminogen Activator Levels (Pleiotropy),33
Venous Thromboembolism Or Factor VII Levels (Pleiotropy),28
Plasma Copper Levels,8
1-arachidonoyl-GPC (20:4N6) Levels In Elite Athletes,6
Plasma Vanadium Levels,5
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4N6) Levels In Elite Athletes,5
1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) Levels In Elite Athletes,6
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) Levels In Elite Athletes,5
4-Vinylphenol Sulfate Levels In Elite Athletes,5
High-sensitivity Cardiac Troponin T Levels (MTAG),14
High-sensitivity Cardiac Troponin I Concentration (MTAG),14
1-palmitoyl-GPC (16:0) Levels In Elite Athletes,5
Alpha-L-iduronidase Levels (IDUA.3169.70.2),5
Carotid Intima Media Thickness (Minimum),24
Methotrexate-related Central Neurotoxicity In Children Treated For Acute Lymphoblastic Leukemia,10
Alcohol Consumption X Hours Spent Using Computers Interaction,13
Phospholipid Levels In HDL,53
Mitral Valve Prolapse After Mitral Valve Surgery,5
Beta-defensin 119 Levels (DEFB119.13455.10.3),5
C-C Motif Chemokine 17 Levels (CCL17.3519.3.2),7
C-C Motif Chemokine 21 Levels (CCL21.2516.57.3),6
Polycystic Ovary Syndrome (Adjusted For Age),6
Polycystic Ovary Syndrome (Adjusted For Age And BMI),5
Familial Combined Hyperlipidemia Defined By Mexico Criteria,30
Major Depressive Disorder Or Stroke (Pleiotropy),7
Depression Severity X Hours Spent Watching Television Interaction,24
Alcohol Consumption X Hours Spent Watching Television Interaction,29
PH And SEC7 Domain-Containing Protein 2 Levels (PSD2.9118.7.3),5
Cholesterol Levels In IDL,48
Familial Combined Hyperlipidemia Defined By Consensus Criteria,47
NK-cell Telomere Length,5
Apolipoprotein L1 Levels (APOL1.9506.10.3),5
MAP Kinase-Activated Protein Kinase 5 Levels (MAPKAPK5.8382.47.3),6
Protein Eva-1 Homolog C Levels (EVA1C.7008.13.3),5
Alzheimer's Disease (Age Of Onset) In APOE E4 Non-Carriers,10
Overall Survival In Advanced Colorectal Cancer,7
3-Hydroxyhippurate Levels In Elite Athletes,8
Imidazole Propionate Levels In Elite Athletes,5
Fibrinogen Levels Or Tissue Plasminogen Activator Levels (Pleiotropy),26
"Bilirubin (Z,Z) Levels In Elite Athletes",6
Serum Lead Levels,7
Serum Rubidium Levels,8
Serum Nickel Levels,12
Ubiquitin Carboxyl-Terminal Hydrolase 25 Levels (USP25.9215.117.3),5
UDP-glucuronosyltransferase 1-6 Levels (UGT1A6.7891.45.3),9
Beta-hydroxyisovalerate Levels In Elite Athletes,6
Betaine Levels In Elite Athletes,5
Alpha-hydroxyisovalerate Levels In Elite Athletes,8
Tryptophan Levels In Elite Athletes,9
N-acetyl-1-methylhistidine Levels In Elite Athletes,6
N-acetyl-aspartyl-glutamate (NAAG) Levels In Elite Athletes,6
Ischemic Stroke Or Von Willebrand Factor Levels (Pleiotropy),17
Ischemic Stroke Or Factor XI Levels (Pleiotropy),7
S-1-pyrroline-5-carboxylate Levels In Elite Athletes,5
"1,5-Anhydroglucitol (1,5-AG) Levels In Elite Athletes",17
Serum Manganese Levels,6
Serum Molybdenum Levels,15
Venous Thromboembolism Or Factor VIII Levels (Pleiotropy),30
Taurolithocholate 3-Sulfate Levels In Elite Athletes,5
Perfluorooctanesulfonic Acid (PFOS) Levels In Elite Athletes,5
Retinal Levels In Elite Athletes,5
Succinimide Levels In Elite Athletes,12
Ischemic Stroke Or Factor VIII Levels (Pleiotropy),11
"N2,N5-diacetylornithine Levels In Elite Athletes",5
"N6,N6,N6-trimethyllysine Levels In Elite Athletes",5
Urea Levels In Elite Athletes,5
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) Levels In Elite Athletes,7
Kininogen-1 Levels,5
Cholesterol To Total Lipids Ratio In Large VLDL,42
"Androstenediol (3Alpha, 17Alpha) Monosulfate (2) Levels In Elite Athletes",7
"Androstenediol (3Alpha, 17Alpha) Monosulfate (3) Levels In Elite Athletes",5
Cholesteryl Ester Levels In Large VLDL,55
Azelate (Nonanedioate) Levels In Elite Athletes,5
Gamma-glutamylglutamine Levels In Elite Athletes,8
Gamma-glutamylphenylalanine Levels In Elite Athletes,5
Phosphatidylglycerol (36:1) Levels,5
Phosphatidylglycerol (36:2) Levels,7
Phosphatidylinositol (16:0 16:1) Levels,5
Cholesteryl Esters To Total Lipids Ratio In Large VLDL,50
"Ceramide (D18:1/20:0, D16:1/22:0, D20:1/18:0) Levels In Elite Athletes",5
Glucuronate Levels In Elite Athletes,6
Andro Steroid Monosulfate C19H28O6S (1) Levels In Elite Athletes,5
Epiandrosterone Sulfate Levels In Elite Athletes,7
Ethylmalonate Levels In Elite Athletes,6
"Ceramide (D16:1/24:1, D18:1/22:1) Levels In Elite Athletes",5
Gamma-glutamyltyrosine Levels In Elite Athletes,8
Glycerate Levels In Elite Athletes,7
Neurexophilin-1 Levels,6
Neutral Ceramidase Levels,5
Repulsive Guidance Molecule A Levels,5
OCIA Domain-Containing Protein 1 Levels,9
Concentration Of Large LDL Particles,45
NKG2-D Type II Integral Membrane Protein Levels,5
"1,2-dipalmitoyl-GPE (16:0/16:0) Levels In Elite Athletes",8
Alpha-tocopherol Levels In Elite Athletes,8
Semaphorin-3A Levels,6
Phosphatidylcholine (18:1 18:2) Levels,6
Androsterone Sulfate Levels In Elite Athletes,8
Tryptase Beta-2 Levels,9
Phospholipids To Total Lipids Ratio In Large LDL,37
Carnitine Levels In Elite Athletes,5
Caffeine Levels In Elite Athletes,7
Number Of Clonal Hematopoiesis Mutations,29
Chenodeoxycholate Levels In Elite Athletes,7
Cholate Levels In Elite Athletes,5
alpha-Aminoadipic Acid Levels,13
Alanine Levels In Elite Athletes,8
Phosphatidylcholine (18:0 22:6) Levels,5
"12,13-DiHOME Levels In Elite Athletes",5
Tenascin Levels,6
Thioredoxin Domain-Containing Protein 12 Levels,22
13-HODE + 9-HODE Levels In Elite Athletes,6
14-HDoHE/17-HDoHE Levels In Elite Athletes,5
Methylglutarylcarnitine Levels,5
Octadecandienylcarnitine Levels,5
Octadecanoylcarnitine Levels,5
Alkylphosphatidylcholine (O-18:0/18:1) Levels,7
Arginine Levels In Elite Athletes,6
2-stearoyl-GPE (18:0) Levels In Elite Athletes,5
Biliverdin Levels In Elite Athletes,5
Calcium/calmodulin-dependent Protein Kinase Type 1 Levels,9
Calcium/calmodulin-dependent Protein Kinase Type 1D Levels,7
Phosphatidylcholine Acyl-Alkyl C42:2 Levels,5
Phosphatidylcholine Acyl-Alkyl C42:3 Levels,6
Complement C1s Subcomponent Levels,5
Free Cholesterol Levels In Large VLDL,56
Choline Phosphate Levels In Elite Athletes,9
Glycerophosphorylcholine (GPC) Levels In Elite Athletes,6
Glycine Levels In Elite Athletes,5
Cis-4-decenoylcarnitine (C10:1) Levels In Elite Athletes,8
Phosphatidylinositol (18:1 18:2) Levels,6
"Diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1]) Levels In Elite Athletes",5
Acylcarnitine (14:0) Levels,6
Free Cholesterol To Total Lipids Ratio In Large VLDL,36
Dihomo-linolenoylcarnitine (20:3N3 Or 6) Levels In Elite Athletes,5
Acylcarnitine (16:1) Levels,8
Etiocholanolone Glucuronide Levels In Elite Athletes,5
Glutarate (Pentanedioate) Levels In Elite Athletes,6
Glycerophosphoinositol Levels In Elite Athletes,5
Glycochenodeoxycholate Glucuronide (1) Levels In Elite Athletes,5
Homoarginine Levels In Elite Athletes,7
Triglycerides To Total Lipids Ratio In Small VLDL,58
Saturated Fatty Acid Levels,45
Mercuric Chloride-2 Levels,35
Methoxychlor Levels,35
Ratio Of Saturated Fatty Acids To Total Fatty Acids,21
Age-related Macular Degeneration Or COVID-19 Critical Illness (MTAG),30
Age-related Macular Degeneration Or COVID-19 Hospitalization (MTAG),30
Ratio Of Triglycerides To Phosphoglycerides,67
Total Concentration Of Branched-Chain Amino Acids (Leucine + Isoleucine + Valine),20
Total Fatty Acid Levels,58
Environmental Pollutants Exposure (POD Low),35
Systolic Blood Pressure X Depressive Symptoms Interaction (2Df Test),15
Diastolic Blood Pressure X Depressive Symptoms Interaction (2Df Test),16
Pulse Pressure X Low Social Support Interaction (2Df Test),6
Mean Arterial Pressure X Depressive Symptoms Interaction (2Df Test),13
Total Lipid Levels In Lipoprotein Particles,51
Potassium Chromate Levels,35
Environmental Pollutants Exposure (RfD High),35
Alzheimerâ€™s Disease Polygenic Risk Score (Upper Quantile Vs Lower Quantile),237
Cataract,6
VLDL Cholesterol Levels,51
Uterine Leiomyomata,46
Parathion Levels,35
Age-related Macular Degeneration Or COVID-19 Infection (MTAG),30
COVID-19 Critical Illness Or Age-Related Macular Degeneration (MTAG),8
COVID-19 Hospitalization Or Age-Related Macular Degeneration (MTAG),5
COVID-19 Infection Or Age-Related Macular Degeneration (MTAG),6
Environmental Pollutants Exposure (RfD Low),35
Cholesteryl Ester Levels In VLDL,49
Phospholipids To Total Lipids Ratio In Small VLDL,58
Total Omega-6 Fatty Acid Levels,46
Heptachlor Levels,35
Heptachlor Epoxide Levels,35
Juvenile Dermatomyositis,11
Mercuric Chloride Levels,35
Chronic Spontaneous Urticaria,6
Pentachlorophenol Levels,35
Environmental Pollutants Exposure (POD High),35
Accelerated Lung Function Decline (FVC) And Worsened/Persistent Change In Fatty Liver (Pleiotropy),5
BMI-adjusted Waist-Hip Ratio,12
Heterogeneous Nuclear Ribonucleoprotein Q Levels,5
Concentration Of Small LDL Particles,50
Phospholipid Levels In Small LDL,45
Metabolite Peak Levels (QI422),8
Metabolite Peak Levels (QI4307),8
"2,4,5-Trichlorophenol Levels",35
Triglycerides To Total Lipids Ratio In Small LDL,53
Environmental Pollutants Exposure (AC50 Low),35
Aldrin Levels,35
Cholesterol Levels In Small VLDL,53
Azinphos Methyl Levels,35
Cadmium Chloride Levels,35
Cholesterol To Total Lipids Ratio In Small VLDL,59
Chlorpyrifos Levels,35
Age Of Onset Of Parkinson Disease,6
Ankyrin-2 Levels,6
Cysteine-rich With EGF-like Domain Protein 1 Levels,19
Cholesteryl Ester Levels In Small VLDL,56
DDT Metabolite (DDD P-P') Levels,35
Ribavirin-induced Anemia In Chronic Hepatitis C,6
DDT Metabolite (DDT O-P') Levels,35
Metabolite Peak Levels (QI15805),9
Metabolite Peak Levels (QI2179),8
Metabolite Peak Levels (QI2180),8
Metabolite Peak Levels (QI2236),8
Metabolite Peak Levels (QI2240),8
Tyrosine-protein Kinase ZAP-70 Levels,8
Triglyceride Levels In Small LDL,62
Environmental Pollutants Exposure (AC50 High),35
"Vascular Endothelial Growth Factor A, Isoform 121 Levels",6
Coagulation Factor X Levels,5
Cholesteryl Esters To Total Lipids Ratio In Small VLDL,61
Low Affinity Immunoglobulin Gamma Fc Region Receptor II-a Levels,6
DDT Metabolite (DDT P-P') Levels,35
Serine/threonine-protein Kinase 16 Levels,8
Disulfoton Levels,35
Total Lipid Levels In Small VLDL,60
Endosulfan Levels,35
Concentration Of Small VLDL Particles,60
Lowest Magnesium Plasma Levels After Treatment With Platinum Based Chemotherapy,8
eGFR Decline After Treatment With Platinum Based Chemotherapy,12
Endrin Levels,35
Metabolite Peak Levels (QI1027),8
Metabolite Peak Levels (QI1071),8
Metabolite Peak Levels (QI10761),9
Metabolite Peak Levels (QI1087),9
Metabolite Peak Levels (QI11242),9
Time To Colon Cancer Recurrence,26
Colorectal Cancer Vs Inflammatory Bowel Disease,6
Metabolite Peak Levels (QI14931),9
Total Lipid Levels In Small LDL,45
Atrial Fibrillation (MTAG),89
Cardioembolic Stroke (MTAG),37
Metabolite Peak Levels (QI4952),9
"2,4,5-Trichlorophenol-2 Levels",35
"4,6-Dinitro-O-Cresol Levels",35
Interleukin-34 Levels,5
Lithium Clearance,5
Lithium Clearance (Adjusted For Clinical Predictors),6
Dickkopf-like Protein 1 Levels,7
Ethion Levels,35
Free Cholesterol Levels In VLDL,52
Total Lipid Levels In VLDL,59
Dietary Macronutrient Intake (Multi-Trait Analysis),21
Intrahepatic Cholestasis Of Pregnancy,8
Concentration Of VLDL Particles,53
Insomnia In Chronic Migraine,12
Insomnia In Migraine With Aura,12
Healthy Aging,12
Phospholipid Levels In VLDL,55
Written Spelling,5
Total Concentration Of Lipoprotein Particles,50
Total Phospholipid Levels In Lipoprotein Particles,44
Proteinuria In Preeclampsia,5
Average Diameter For VLDL Particles,59
Triglyceride Levels In VLDL,62
Opioid Use Disorder (MTAG),12
Right Ventricular Stroke Volume (MTAG),6
Pre-treatment Viral Load In HIV-1 Infection,66
Alzheimer's Disease With Visuospatial Domain Impairment,5
Bisphosphonate-associated Atypical Femoral Fracture,19
Atypical Femoral Fracture In Phosphonate Treatment,8
Cortical Amyloid Beta Load,10
Alzheimer's Disease Progression Score,11
Emotional Lability In Attention Deficit Hyperactivity Disorder,5
Self-reported Childhood Asthma In Adult Smokers,5
Glycemic Traits (Pleiotropy),16
Low Susceptibility To Hepatitis C Infection,8
Brain-derived Neurotrophic Factor Levels,5
Asthma (Age Of Onset),20
Medication Use (Anilides),7
Peginterferon Alfa-2A Treatment Response In Chronic Hepatitis B Infection,23
Lumbar Spine Bone Mineral Density (Trabecular),7
Lumbar Spine Bone Mineral Density (Integral),10
Asthma Onset (Childhood Vs Adult),28
Anti-thyroid Peroxidase (TPOAb) And Anti-Thyroglobulin (TgAb) Levels In Hashimoto's Thyroiditis,6
Resting-state Electroencephalogram Vigilance,18
Response To TNF Inhibitor In Rheumatoid Arthritis (Change In Swollen 28-Joint Count),7
Extremely High Intelligence,15
Depression (Broad),50
Disrupted Circadian Rhythm (Low Relative Amplitude Of Rest-Activity Cycles),8
Initial Alcohol Sensitivity,17
Diverticulitis,7
Serum CC16 Levels,5
Urinary Albumin Excretion (No Hypertensive Medication),13
Latent Autoimmune Diabetes Vs. Type 2 Diabetes,5
Seasonality And Depression,6
Sleep Duration (Short Sleep),17
Sleep Duration (Long Sleep),6
Digit Length Ratio (Right Hand),5
Digit Length Ratio (Left Hand),5
Metabolic Syndrome (Multivariate Analysis),5
High IL-1beta Levels In Gingival Crevicular Fluid,10
Nicotine Dependence And Major Depression (Severity Of Comorbidity),29
Total Hippocampal Volume,6
Strabismus,16
"Anorexia Nervosa, Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder, Major Depression, Obsessive-Compulsive Disorder, Schizophrenia, Or Tourette Syndrome (Pleiotropy)",96
Arterial Stiffness Index,28
Health Literacy,21
Autoimmune Traits (Pleiotropy),25
T-Cell Immunoglobulin And Mucin Domain 1 Levels,7
Chronic Obstructive Pulmonary Disease Or High Blood Pressure (Pleiotropy),17
Chronic Obstructive Pulmonary Disease Or Resting Heart Rate (Pleiotropy),17
Carotid Plaque Maximum Area,9
Mean Area Of Carotid Plaque,6
Sum Of Carotid Plaque Area,9
Maximum Stenosis,11
Metabolite Peak Levels (QI1459),8
Metabolite Peak Levels (QI14717),8
Metabolite Peak Levels (QI14719),8
Metabolite Peak Levels (QI14741),8
Metabolite Peak Levels (QI14769),8
Alpha-L-iduronidase Levels,12
Metabolite Peak Levels (QI1631),8
Metabolite Peak Levels (QI961),8
Metabolite Peak Levels (QI9680),5
Metabolite Peak Levels (QI1565),8
Metabolite Peak Levels (QI1568),8
Metabolite Peak Levels (QI15739),8
Metabolite Peak Levels (QI1234),8
Metabolite Peak Levels (QI1249),9
Chromobox Protein Homolog 5 Levels,6
RAC-beta Serine/Threonine-Protein Kinase Levels,7
Metabolite Peak Levels (QI14216),8
Metabolite Peak Levels (QI14569),8
Metabolite Peak Levels (QI14010),9
Metabolite Peak Levels (QI14012),8
Metabolite Peak Levels (QI14032),8
Metabolite Peak Levels (QI14045),8
Metabolite Peak Levels (QI14055),9
Metabolite Peak Levels (QI1379),9
Metabolite Peak Levels (QI13938),8
Metabolite Peak Levels (QI13939),8
Metabolite Peak Levels (QI14798),8
Metabolite Peak Levels (QI1480),8
Metabolite Peak Levels (QI1481),9
Metabolite Peak Levels (QI1483),9
Right Colon Cancer,13
Hazardous Alcohol Drinking,7
Ideal Cardiovascular Health Score (Clinical And Behavioral),10
Di-n-butyl Phthalate Levels,35
Survival In Coronary Artery Disease,8
Diazinon Levels,35
Free Cholesterol To Total Lipids Ratio In Small VLDL,64
Dicofol Levels,35
Perinatal Depression,14
Dieldrin Levels,35
Stabilin-2 Levels,5
Cyclin-dependent Kinase 5:Cyclin-dependent Kinase 5 Activator 1 Complex Levels,5
Cathepsin L2 Levels,6
Alanine Aminotransferase Levels In Low Dose Methotrexate Treatment,5
Aspartate Aminotransferase Levels In Low Dose Methotrexate Treatment,6
Ubiquitin Carboxyl-Terminal Hydrolase 25 Levels,5
Age Of Onset Of Depression X Felt Loved As A Child Interaction,10
Vaginal Microbiome Relative Abundance (F Aerococcaceae),5
Vaginal Microbiome Relative Abundance (F Bifidobacteriaceae),8
Vaginal Microbiome Relative Abundance (S Finegoldia Magna),12
Vaginal Microbiome Relative Abundance (S Lactobacillus Reuteri),6
F-coffee/alcohol Liking (Derived Food-Liking Factor),9
F-cooking Flavour Liking (Derived Food-Liking Factor),6
F-cooking Vegetables Liking (Derived Food-Liking Factor),8
Vaginal Microbiome MetaCyc Pathway (TCA-GLYOX-BYPASS|superpathway Of Glyoxylate Bypass And TCA),6
Thrombin Levels,5
Vaginal Microbiome Relative Abundance (F Peptostreptococcales-Tissierellales),7
Hormone-sensitive Cancer,10
Incident Hormone-Sensitive Cancer,7
Tumor Necrosis Factor Receptor Superfamily Member 3 Levels,6
Angiopoietin-related Protein 4 Levels,5
Environmental Pollutants Exposure (Expo High),35
"Advanced Glycosylation End Product-Specific Receptor, Soluble Levels",9
Circulating Docosahexaenoic Acid Levels,31
Total Omega-3 Fatty Acid Levels,32
Environmental Pollutants Exposure (Expo Low),35
Vaginal Microbiome MetaCyc Pathway (RUMP-PWY|formaldehyde Oxidation I),5
Vaginal Microbiome MetaCyc Pathway (PYRIDNUCSAL-PWY|NAD Salvage Pathway I),6
Vaginal Microbiome MetaCyc Pathway (RHAMCAT-PWY|L-rhamnose Degradation I),5
F-chocolate/coffee Liking (Derived Food-Liking Factor),7
F-cheese Liking (Derived Food-Liking Factor),8
Mitogen-activated Protein Kinase 8 Levels,5
Vaginal Microbiome Relative Abundance (S Gardnerella Vaginalis),6
Hexokinase-1 Levels,5
Sodium-coupled Monocarboxylate Transporter 1 Levels,8
Body Mass Index (MTAG),807
Serine Protease Inhibitor Kazal-type 4 Levels,5
RNA Polymerase II Elongation Factor ELL Levels,6
40S Ribosomal Protein S3 Levels,5
"40S Ribosomal Protein S4, X Isoform Levels",5
Protein Sel-1 Homolog 2 Levels,7
Killer Cell Immunoglobulin-Like Receptor 2DL1 Levels,5
"Adenylate Kinase 4, Mitochondrial Levels",6
RNA-binding Protein 24 Levels,5
Ribosome Biogenesis Protein TSR3 Homolog Levels,5
Retinoic Acid Early Transcript 1G Protein Levels,6
E3 Ubiquitin-Protein Ligase RNF128 Levels,5
E3 Ubiquitin-Protein Ligase RNF13 Levels,5
RING Finger Protein 24 Levels,5
Somatoliberin Levels,5
S-methyl-5-thioadenosine Phosphorylase Levels,5
Folate Receptor Beta Levels,6
Low-density Lipoprotein Levels (MTAG),218
ADP-ribosylation Factor GTPase-activating Protein 1 Levels,6
Apolipoprotein C-III Levels,7
"Procollagen-lysine,2-oxoglutarate 5-Dioxygenase 2 Levels",5
Patatin-like Phospholipase Domain-Containing Protein 2 Levels,5
Melanocyte Protein PMEL Levels,6
Triglyceride Levels (MTAG),236
Proteasome Subunit Alpha Type-1 Levels,5
PH And SEC7 Domain-Containing Protein 1 Levels,8
PH And SEC7 Domain-Containing Protein 2 Levels,6
GDH/6PGL Endoplasmic Bifunctional Protein Levels,7
"HLA Class I Histocompatibility Antigen, Alpha Chain G Levels",5
Holo-Transcobalamin-2 Levels,5
Heat Shock 70 kDa Protein 1-Like Levels,5
High Affinity Immunoglobulin Epsilon Receptor Subunit Alpha Levels,5
Hemoglobin Subunit Delta Levels,5
Probable E3 Ubiquitin-Protein Ligase HERC4 Levels,5
Histatin-3 Levels,5
Heparin-binding EGF-like Growth Factor Levels,5
Hemoglobin Subunit Zeta Levels,5
DNA-directed RNA Polymerases I And III Subunit RPAC1 Levels,6
DNA-directed RNA Polymerase III Subunit RPC9 Levels,6
Kidney-associated Antigen 1 Levels,5
Integral Membrane Protein 2B Levels,5
SAM Pointed Domain-Containing Ets Transcription Factor Levels,5
Sodium/potassium-transporting ATPase Subunit Beta-1 Levels,5
Inosine-5-monophosphate Dehydrogenase 1 Levels,5
Inosine-5-monophosphate Dehydrogenase 2 Levels,5
Inter-alpha-trypsin Inhibitor Heavy Chain H1 Levels,5
DNA-binding Protein SATB2 Levels,5
Klotho Levels,5
Interleukin-36 Receptor Antagonist Protein Levels,5
Single Ig IL-1-related Receptor Levels,5
Receptor-interacting Serine/Threonine-Protein Kinase 2 Levels,8
Insulin Growth Factor-Like Family Member 3 Levels,5
Inactive Gamma-Glutamyltranspeptidase 2 Levels,6
Immunoglobulin Lambda-Like Polypeptide 1 Levels,6
"Alpha-N-acetylgalactosaminide Alpha-2,6-Sialyltransferase 2 Levels",5
Hexokinase-3 Levels,7
Heat Shock 70 kDa Protein 6 Levels,5
HSP 70 Levels,6
Interleukin-12 Subunit Beta Levels,5
Immunoglobulin M Levels,5
Secretoglobin Family 3A Member 1 Levels,7
Sulfotransferase Family Cytosolic 2B Member 1 Levels,5
Kv Channel-Interacting Protein 1 Levels,6
Lactosylceramide 4-Alpha-Galactosyltransferase Levels,5
3-Hydroxybutyrate Levels,16
X-24748 Levels,8
X-24870 Levels,5
Nonsyndromic Orofacial Cleft X Sex Interaction (2Df),33
Migraine Or Type 2 Diabetes,28
Headache Or Type 2 Diabetes,15
Dihydroorotate Levels,6
Hypertension Complicating Pregnancy,5
Hernia (Any Subtypes),15
Histidine Betaine (Hercynine) Levels,11
Decadienedioic Acid (C10:2-Dc) (X-21792) Levels,5
Acetate Levels,10
Visuospatial Ability,9
Type 2 Diabetes Or Schizophrenia (Pleiotropy),13
Maximum Habitual Alcohol Consumption (MTAG),21
Asthma In Any Disease,54
IgG Antibody Levels In Response To SARS-CoV-2 Vaccination,7
Total Antibody Levels In Response To SARS-CoV-2 Vaccination,8
Neutral Antibody Levels In Response To SARS-CoV-2 Vaccination,12
Dyslexia,71
Asthma In Gastrointestinal Disease,5
Paralemmin-1 Levels,5
Complement C1q-like Protein 2 Levels,5
Complement C1q Tumor Necrosis Factor-Related Protein 1 Levels,5
Resistance To COVID-19 Infection (Exposed Negative Vs Positive),375
V-set And Transmembrane Domain-Containing Protein 4 Levels,6
Von Willebrand Factor A Domain-Containing Protein 2 Levels,6
Protein Wnt-5a Levels,5
Vacuolar Protein Sorting-Associated Protein 28 Homolog Levels,5
WAP Four-Disulfide Core Domain Protein 1 Levels,6
Glycerol-3-phosphate Dehydrogenase 1-Like Protein Levels,5
Oxysterols Receptor LXR-beta Levels,6
Cellular Retinoic Acid-Binding Protein 1 Levels,5
DNA Repair Protein RAD51 Homolog 4 Levels,6
Ras-related Protein Rab-17 Levels,5
Ras-related Protein Rab-35 Levels,6
Rab9 Effector Protein With Kelch Motifs Levels,5
rRNA 2-O-methyltransferase Fibrillarin Levels,5
Adhesion G-protein Coupled Receptor G1 Levels,5
Glutathione S-transferase A4 Levels,5
Growth Factor Receptor-Bound Protein 7 Levels,7
Potassium Voltage-Gated Channel Subfamily A Member 10 Levels,5
"Poly(A) RNA Polymerase, Mitochondrial Levels",6
Poly(U)-specific Endoribonuclease Levels,5
Inactive Peptidyl-Prolyl Cis-Trans Isomerase FKBP6 Levels,6
"Beta-1,4-galactosyltransferase 2 Levels",6
GDNF Family Receptor Alpha-Like Levels,6
Protein Zwilch Homolog Levels,5
Inhibin Beta B Chain (Mixed) Levels,5
Protein FAM69C Levels,6
Cytochrome P450 3A4 Levels,6
Pyridoxine-5-phosphate Oxidase Levels,5
Cellular Tumor Antigen P53 R175H Mutant Levels,5
Peptidyl-prolyl Cis-Trans Isomerase G Levels,5
PR Domain Zinc Finger Protein 1 Levels,5
Pre-mRNA-processing Factor 6 Levels,5
F-box/LRR-repeat Protein 4 Levels,6
Aldo-keto Reductase Family 1 Member B10 Levels,7
Cyclic AMP-dependent Transcription Factor ATF-6 Alpha Levels,5
Augurin Levels,5
Beta-defensin 1 Levels,5
Beta-defensin 132 Levels,5
Beta-hexosaminidase Subunit Beta Levels,5
S-methylmethionine--homocysteine S-methyltransferase BHMT2 Levels,6
Baculoviral IAP Repeat-Containing Protein 5 Levels,6
Beta-glucuronidase Levels,6
Prenylcysteine Oxidase 1 Levels,5
Protein Kinase C And Casein Kinase Substrate In Neurons Protein 1 Levels,6
Extracellular Tyrosine-Protein Kinase PKDCC Levels,6
Pleckstrin Homology Domain-Containing Family A Member 1 Levels,5
Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-11 Levels,5
Guanylate-binding Protein 6 Levels,7
Galactosylceramide Sulfotransferase Levels,6
Gastrokine-2 Levels,5
EF-hand Domain-Containing Protein D1 Levels,5
Dynactin Subunit 2 Levels,6
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 3 Levels,5
Lymphocyte Antigen 75 Levels,5
Epidermal Growth Factor-Like Protein 6 Levels,5
Lymphokine-activated Killer T-cell-originated Protein Kinase Levels,7
Isoform L-VEGF165 Levels,6
Microtubule-associated Proteins 1A/1B Light Chain 3B Levels,6
O-acetyl-ADP-ribose Deacetylase MACROD1 Levels,5
Microtubule-associated Proteins 1A/1B Light Chain 3A Levels,7
Melanoma-associated Antigen 5 Levels,5
Melanoma-associated Antigen 6 Levels,5
Drinks Per Week,426
Membrane-associated Progesterone Receptor Component 1 Levels,8
Probable ATP-dependent RNA Helicase DDX23 Levels,5
Probable ATP-dependent RNA Helicase DDX46 Levels,7
Diamine Acetyltransferase 2 Levels,5
D-dopachrome Decarboxylase Levels,5
Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 3 Levels,5
Liver Carboxylesterase 1 Levels,5
Cadherin-11 Levels,7
Ceroid-lipofuscinosis Neuronal Protein 5 Levels,5
Clusterin Levels,7
Disks Large Homolog 3 Levels,7
Leucine-rich Repeat-Containing Protein 74A Levels,5
Leucine-rich Repeat And Fibronectin Type III Domain-Containing Protein 1 Levels,5
Leucine-rich Repeat And Fibronectin type-III Domain-Containing Protein 5 Levels,5
Lactase-phlorizin Hydrolase Levels,5
Leucine-rich Repeat-Containing Protein 15 Levels,5
Chitinase-3-like Protein 2 Levels,6
Cholinesterase Levels,11
Complement Receptor Type 1 Levels,6
Cochlin Levels,9
Protein CREG1 Levels,5
CREB-binding Protein Levels,5
Cigarettes Smoked Per Day,133
Cathelicidin Antimicrobial Peptide Levels,5
Calcineurin Subunit B Type 2 Levels,8
Protein CASC4 Levels,6
CCAAT/enhancer-binding Protein Beta Levels,5
Ceruloplasmin Levels,5
Catenin Beta-1 Levels,5
Myeloid Leukemia Factor 1 Levels,6
RBC Levels Of Fumarate,10
Adenylyltransferase And Sulfurtransferase MOCS3 Levels,5
Left Ventricular Mass Indexed By Body Surface Area,21
RBC Levels Of Pyruvate (uM),61
Vascular Endothelial Function,32
RBC Levels Of 11-HETE.1,9
RBC Levels Of 15-HETE,9
Myelin Protein Zero-Like Protein 2 Levels,6
RBC Levels Of Sphingosine 1-Phosphate,7
RBC Levels Of UDP-N-acetyl-D-glucosamine,5
Cervical Dysplasia,5
Synaptotagmin-11 Levels,5
Transmembrane Protein 106A Levels,5
Tumor Protein P53-Inducible Protein 11 Levels,6
N-acetylated-alpha-linked Acidic Dipeptidase-Like Protein Levels,6
"NAD-dependent Protein Deacetylase Sirtuin-3, Mitochondrial Levels",5
Stromal Interaction Molecule 1 Levels,6
Serine/threonine-protein Kinase DCLK1 Levels,5
RBC Levels Of Urate (uM),7
Surfeit Locus Protein 1 Levels,5
TNF Receptor-Associated Factor 1 Levels,7
Transcription Regulator Protein BACH1 Levels,5
tRNA (guanine-N(7)-)-methyltransferase Levels,7
U6 snRNA-associated Sm-like Protein LSm4 Levels,5
C-C Motif Chemokine 28 Levels,6
Calponin-1 Levels,10
C-type Lectin Domain Family 4 Member D Levels,5
"Cytochrome C Oxidase Subunit 4 Isoform 2, Mitochondrial Levels",5
Desmin Levels,5
17-Beta-Hydroxysteroid Dehydrogenase 14 Levels,5
Probable ATP-dependent RNA Helicase DHX58 Levels,5
Defensin-5 Levels,6
Desmocollin-1 Levels,5
Dipeptidase 2 Levels,6
Opticin Levels,6
Oral Cancer-Overexpressed Protein 1 Levels,6
Activin Receptor type-2A Levels,5
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 3 Levels,5
Serine/threonine-protein Kinase ULK3 Levels,6
Stathmin Levels,5
T-cell Surface Glycoprotein CD3 Epsilon Chain Levels,10
T-cell Surface Glycoprotein CD5 Levels,5
T-complex Protein 11 Homolog Levels,5
Protein NDRG4 Levels,5
Neuroendocrine Protein 7B2 Levels,5
"Neuregulin-1, Sensory And Motor Neuron-Derived Factor Isoform Levels",5
Protein Disulfide-Isomerase TMX3 Levels,5
Tripeptidyl-peptidase 1 Levels,6
Thioredoxin-interacting Protein Levels,5
5-Formyltetrahydrofolate Cyclo-Ligase Levels,6
Myotubularin-related Protein 1 Levels,6
Mucin-16 Levels,5
TOM1-like Protein 2 Levels,7
Trypsin-3 Levels,6
Tryptase Beta-1 Levels,5
Transcription Factor AP-1 Levels,6
Tuftelin-interacting Protein 11 Levels,5
Transcription Factor IIIB 90 kDa Subunit Levels,5
Thrombospondin Type-1 Domain-Containing Protein 1 Levels,5
Height (Weighted GWA),95
"Thymidine Kinase, Cytosolic Levels",5
TLR4 Interactor With Leucine Rich Repeats Levels,7
UDP-glucuronic Acid Decarboxylase 1 Levels,5
Valine--tRNA Ligase Levels,5
Voltage-dependent Calcium Channel Subunit Alpha-2/Delta-3 Levels,5
Systolic Blood Pressure (Weighted GWA),23
NKG2-E Type II Integral Membrane Protein Levels,6
Transcription Factor RelB Levels,5
Transmembrane Protein 87B Levels,6
Transmembrane And Coiled-Coil Domains Protein 3 Levels,6
Transmembrane Protein 185A Levels,6
Insomnia (Standard GWA),13
Number Of Non-Cancer Illnesses (Standard GWA),11
UDP-glucuronosyltransferase 1-1 Levels,12
UDP-glucuronosyltransferase 1-6 Levels,10
Reaction Time (Standard GWA),6
Risk Taking (Standard GWA),5
Alcohol Frequency Weekly (Standard GWA),18
Smoking Status (Standard GWA),27
Uncharacterized Protein C20orf173 Levels,6
Systolic Blood Pressure (Standard GWA),90
Smoking Status (Weighted GWA),6
Uncharacterized Protein C3orf18 Levels,5
Urotensin-2 Levels,5
Noelin-3 Levels,5
Noggin Levels,8
Nuclear Pore Complex-Interacting Protein Family Member B3 Levels,5
